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Summary 
Pharmacoepidemiology is the science of the use and the effects of drugs in large 
human populations. Although its original role was confined to post-marketing 
surveillance of rare or long-latency adverse drug events, the science is gaining 
increasing importance across different stages of drug development, where it has 
been applied to assess drug utilization patterns and cost-effectiveness, to 
characterize target populations of drugs in development, to evaluate undiscovered 
beneficial or detrimental drug effects, or to provide evidence of effectiveness when 
randomized controlled trials face ethical or practical barriers.   
Rosacea is a common but under-investigated inflammatory skin disease, 
characterized by relapses and remissions. The exact pathomechanism of the skin 
disease remains to be elucidated, but recent findings indicate a key etiologic role of 
the innate immune system. Evidence-based treatment options for the skin disease 
are sparse and greatly needed.  
The aim of the comprehensive rosacea project presented within this thesis was to 
contribute to the general understanding of the skin disease, thereby focusing on the 
impact of different drugs and diseases on incident rosacea. The project comprises six 
individual studies, set up in a case-control study design, using data from the General 
Practice Research Database (GPRD). This United Kingdom (UK)-based database 
contains longitudinal primary-care records of millions of patients, representative of 
the UK population. Information is recorded by general practitioners including 
demographics, lifestyle factors, medical diagnoses, referrals to secondary care, 
laboratory and diagnostic results, and a complete history of drug prescriptions.  
The study population consisted of 53,927 patients with an incident rosacea diagnosis 
between 1995 and 2009 and the same number of rosacea-free controls, matched on 
age, sex, index date, general practice, and history in the database. Study 3.1 builds 
the basis of the project, and describes the study population in terms of 
demographics, lifestyle characteristics, and ocular symptoms. An overall incidence 
rate of diagnosed rosacea in the UK of 1.65 / 1,000 person-years was calculated, 
and stratified by age, gender, calendar time, and geographic region. While cigarette 
smoking seemed to prevent patients from developing rosacea, alcohol consumption 
yielded a marginal risk increase.  
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Studies 3.2 and Study 3.5 fathom the insufficiently supported notion regarding the 
association of rosacea with migraine (Study 3.2) and with psychiatric diseases 
(Study 3.5). Drug effects of triptans (Study 3.2) and of psychotropic drugs (Study 3.5) 
on incident rosacea were also studied. In contrast to previous findings, pre-existing 
migraine was not generally associated with incident rosacea, but post-menopausal 
women with severe migraine may be at a slightly increased risk of rosacea. Although 
mechanistically conceivable, triptans did not alter the risk of developing rosacea. 
Neither depression nor other affective disorders affected the relative risk of rosacea, 
but patients with diagnosed schizophrenia were diagnosed with rosacea less 
frequently. Although the latter finding is intriguing, it requires further investigation, as 
diagnostic bias cannot be ruled out. Of all psychotropic drugs, current lithium 
exposure may protect patients from developing the skin disease. Topical lithium has 
been proven to be effective in seborrheic dermatitis, and might be an interesting 
approach for rosacea therapy.  
Two further studies evaluate the effect of diuretics (focus spironolactone, Study 3.3) 
and of other antihypertensive drugs (including β-blockers and calcium channel 
blockers, Study 3.6) on incident rosacea. In line with one previous study, 
spironolactone yielded a significantly decreased rosacea risk, whereas no other 
diuretic drug class showed an effect. Despite a generally assumed detrimental effect 
of calcium channel blockers on rosacea, Study 3.6 did not reveal an increased risk of 
rosacea for users of this drug class. β-blockers, which have been suggested as an 
off-label treatment for erythematotelangiectatic rosacea, revealed a small risk 
decrease, which is probably larger in erythematotelangiectatic rosacea patients 
alone. Especially with abundantly used therapeutics, such as antihypertensive drugs, 
sound evidence is required in order for healthcare professionals to make the right 
decisions in clinical practice.   
Finally, Study 3.4 reports a previously uninvestigated decreased rosacea risk for 
patients with diabetes at an advanced disease stage, potentially due to impaired 
vasodilation. It remains to be clarified whether insulin enhances this effect. 
In summary, these large population-based studies contribute to the understanding of 
rosacea yielding important evidence and raising new hypotheses. While some results 
may directly support clinicians in their daily decisions on rosacea treatment, yet 
others might spark follow-up projects on potential new treatment approaches for 
rosacea as well as on pathomechanistic aspects of the skin disease. 
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1 Introduction 
1.1  Pharmacoepidemiology 
1.1.1  Development of a young science 
Pharmacoepidemiology is a relatively young science that applies epidemiologic 
methods to study adverse drug events (ADEs), drug use patterns, and drug 
effectiveness in large human populations. This discipline mainly evolved in answer to 
the need to monitor drugs with regard to rare or long-latency side effects beyond their 
market introduction. This demand for post-marketing drug surveillance mainly roots in 
the 1950’s, when the ‘thalidomide disaster’ caused several thousand children to be 
born with phocomelia (a congenital limb deformation), due to in-utero exposure to the 
hypnotic thalidomide. In consequence, spontaneous reporting systems were 
implemented in the United States (US) and Europe, in which health care 
professionals could report suspected ADEs to local authorities. Although 
spontaneous reports of ADEs have led to market withdrawal of several drugs (e.g. 
practolol due to oculomucocutaneous symptoms) their efficacy is severely 
compromised by underreporting and insurmountable bias. Whereas long-latency 
drug reactions (e.g. carcinogenicity) are rarely reported, media attention can 
stimulate over-reporting of others. Furthermore, reporting rates generally decline over 
time upon marketing of a drug, and reporting levels correlate with the likeliness of 
diagnostic suspicion; diagnoses, such as agranulocytosis, which are 
pharmacologically induced in 60-70% of cases, are reported much more frequently 
than acute myocardial infarction for instance. These limitations, combined with the 
limited capability of spontaneous reporting systems to quantitatively assess observed 
effects, prompted the demand for more efficient methods allowing also the 
quantitative assessment of drug hazards in post-marketing drug surveillance.  
Pharmacoepidemiology originated in the mid 1960’s in the United States (US), when 
the Boston Collaborative Drug Surveillance Program (BCDSP) and the Johns 
Hopkins Hospital started monitoring in-hospital drug use and related risks in cohort 
studies.3 The original focus of pharmacoepidemiology lay on the assessment of drug 
effects that are insufficiently captured in pre-marketing randomized controlled trials 
(RCT), due to their limited size, their relatively short duration, as well as their strictly 
selected volunteering study population. Such drug effects mainly comprise rare 
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and/or long-latency ADEs, or drug hazards in untested patient groups, such as 
children, pregnant or lactating women, or elderly patients. However, due to ever-
increasing regulatory requirements, pharmacoepidemiology has developed into a 
discipline involved across the entire process of drug development (Figure 1.1-1). 
Today’s risk management in drug safety requires a continuous risk-benefit evaluation 
across the entire life cycle of a drug. Pharmacoepidemiologic studies have been 
used, for instance, to evaluate background incidence rates (IRs) of serious ADEs in 
the non-exposed general population to appraise serious ADEs encountered during 
clinical trials, or to identify risk factors for specific observed ADEs in retrospective 
analyses of clinical trial data. Furthermore, epidemiologic studies on the natural 
history of a certain disease to be treated by a new drug performed early in the drug 
development process can provide a characterization of the target population (e.g. 
drug use and comorbidities).3-7 
 
 
1.1.2 Observational research and particularities of pharmacoepidemiology 
Clinical research is categorized into experimental and observational research. 
Experimental research includes randomized and non-randomized clinical trials, in 
which a patient’s exposure status is actively assigned. Observational research 
observes usual clinical practice and falls into two general categories; analytical and 
descriptive research. While descriptive studies (i.e. case series and case reports) 
describe clinical observations, analytical observational studies (i.e. case-control 
Figure 1.1-1: Pre- and post-marketing phases of drug development and the role of pharmacoepidemiology. 
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studies, cohort studies, and cross-sectional studies) feature a control group allowing 
the quantification of associations. Such analytical observational study designs are the 
basis for pharmacoepidemiologic research.  
In terms of evidence based medicine (EBM), studies on the evaluation of intended 
therapy effects are classified according to grades of evidence on the basis of their 
research design, using internal validity as the criterion for hierarchical ranking. The 
quality of individual studies may sometimes be rated within each grade. According to 
this hierarchy, RCTs are evidence of the highest grade, and as the only study design 
allow causal inference due to minimized selection bias and confounding, whereas 
observational studies fall into an intermediate level of evidence (Table 1.1-1).7-11  
 
  
               Table 1.1-1: Hierarchy of clinical evidence according to the US Preventive Services Task Force (USPSTF). Table adapted from9  
Quality of evidence according to the US preventive services task force9 
 
I Evidence from one or more properly randomized controlled trials 
II-1 Evidence from well-designed non-randomized controlled trials 
II-2 Evidence from methodologically sound cohort or case-control studies, if possible from several 
independent research centers 
II-3 Evidence from multiple time series (with or without interventions), or of important / dramatic 
results in uncontrolled experiments 
III Expert opinions based on clinical experience, descriptive studies, and expert committee reports 
 
Significance of observational research in medicine 
The lack of randomization makes observational studies prone to bias and 
confounding, since prognoses naturally differ between the exposed and the 
unexposed group. However, the corollary that causal inference cannot be drawn from 
observational studies has often been based on results from poorly designed example 
studies, while recent evidence shows that results between RCTs and observational 
studies do not need to show substantial differences.12, 13 Hernan et al.14 and Danaei 
et al.15, 16 demonstrated that previously disputed discrepant findings between 
observational studies and RCTs were attributable to differences in the study 
question; after the observational study designs were changed so they would emulate 
the RCT of interest in design and analysis (only difference was adjustment for 
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baseline non-time-varying confounders) results of the cohort studies and the RCTs 
were congruent.  
Furthermore, although RCTs are the gold standard to demonstrate drug efficacy, in 
practice they face different practical and ethical barriers, which is when epidemiologic 
studies are the method of choice to tackle a research question. 1) First, deliberately 
exposing patients to potentially harmful drugs is unethical. Putatively harmful effects 
can thus never be tested in an RCT. It was pharmacoepidemiologic research that led 
to the withdrawal of appetite suppressant drugs due to cardiac-valve regurgitation, or 
that uncovered the association between prescription drug use and the risk of motor 
vehicle accidents. 2) Second, due to less restrictive eligibility criteria, external validity 
/ generalizability is increased in observational studies when compared to RCTs 
(selected volunteers). Thus, results of observational studies more accurately 
represent the heterogeneous target population of a certain drug, often including 
children and elderly poly-morbid people. 3) Third, RCTs do not accurately capture 
rare and long-latency ADEs. The fact that rare ADEs are not foreseen by the GP 
minimizes confounding by indication, which makes observational studies especially 
suitable for evaluating such effects. 4) Fourth, when it comes to ranking study types 
that give the best chance of discovery, the hierarchical order of study designs in 
medical research needs to be inversed either way.17 It is the natural path in research 
that descriptive studies (e.g. case reports) or results from basic science spark 
analytical observational studies which may be followed-up by RCTs. Several 
important hypotheses such as the association between aspirin and myocardial 
infarction were raised by means of observational research, based on basic scientific 
considerations and clinical observations. 5) Finally, the greater timeliness and lower 
costs make observational research designs a desirable tool to achieve quick and 
affordable answers to urgent study questions. Thus, it is the interplay between 
different types of research for different types of questions that advances modern 
medicine. 4, 5, 7, 18-21 
Particularities of drugs as an exposure variable 
Analytical epidemiology is the science that is concerned with uncovering associations 
between exposures and outcomes using specifically developed methods. The 
particular nature of the assessed exposure variable in pharmacoepidemiology (i.e. 
drug exposure) introduces some additional unique methodologic needs to the 
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science of pharmacoepidemiology. First, drug exposure is a time-varying factor, 
demanding for an exact exposure definition in terms of timing and duration of drug 
use. Second, ADEs are often rare disorders with a complex association to the 
causing agent, with different mechanisms behind most disorders. This requires a 
deeper understanding of the relation between the outcome and exposure, as well as 
accurate and complete information on drug exposure and covariates to adequately 
address potential confounding and biases.4, 19 Finally, all drugs are prescribed for a 
medical reason, which raises complexion to another level as a putative causal drug 
effect needs to be distinguished from a disease effect. Thus, meticulous attention has 
to be paid to methodologic aspects, such as changes in prescription habits over time, 
potential confounding by indication, prevailing contraindications for the drug in the 
study population, disease severity, the natural course of the disease, the changing 
risk of an adverse drug reaction across treatment period, or simply compliance of 
people, some of which are discussed in detail below (section 1.1.4).4 However, 
despite a sound methodology, observational studies are always subject to a certain 
degree of residual confounding and chance, which has to be considered for all 
results and causal inference should be drawn considerately.3, 5, 19  
 
1.1.3 Causality 
‘Who knows, asked Robert Browning, but the world may end tonight? True, but on 
available evidence most of us make ready to commute on the 8.30 next day.’ 22 
 
Pharmacoepidemiology, like clinical epidemiology, is an empirical science mainly 
aimed at uncovering relationships between exposures and outcomes. However, 
determining whether a given relation is causal may be complex, since empirical 
sciences involve naturalistic observations that are inherently fallible and incomplete. 
In 1965, Sir Austin Bradford Hill published a checklist of 9 criteria, known as the ‘Hill 
criteria’, as a means to support inference upon causality in medical research.22 
However, as helpful and desirable as such checklists may be, they will always fail to 
deliver a clear verdict of causation (Table 1.1-2). The same is true for complex 
statistical / methodologic approaches that may be used to address causality 
questions; a statistical test may give us a measure for the role of chance within our 
findings as well as an idea about the size of the effect. This can guide causal 
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inference, but even the most elaborate tool will never ‘prove’ or ‘dismiss’ a 
hypothesis. It is and always will be the way that such tools are applied in combination 
with scientists’ critical scrutiny of a hypothesis by conjecture and refutation that will 
evaluate causality over time.10, 11, 13, 22 In essence, decisions are made on the best 
evidence available applying critical thinking combined with a profound understanding 
of the matter under question on behalf of the decision maker. And nobody has 
expressed this more accurately than Sir Austin Bradford Hill himself:  
 
‘All scientific work is incomplete – whether it be observational or experimental. All 
scientific work is liable to be upset or modified by advancing knowledge. That does 
not confer upon us a freedom to ignore the knowledge we already have, or to 
postpone the action that it appears to demand at a given time.’22  
 
Table 1.1-2: ‚Hill criteria‘ on causality in medical research with their inherent problems. Table adapted from 10  
Criterion Problems 
1. Strength Other causes that might confound the association. ADEs rarely reveal high risk 
estimates. 
2. Consistency / Repeatability Exceptions might only be understood with hindsight / errors may be carried over 
across experiments. 
3. Specificity One cause can have several effects. 
4. Temporality Not always easy to establish. 
5. Biologic gradient / dose-
response curve Could be confounded / threshold phenomena do not show progressive relation. 
6. Plausibility Subjective – might be understood with hindsight. 
7. Coherence Same as consistency or plausibility?  
8. Experimental evidence Not always available. 
9. Analogy Analogies are abundant and may guide or mislead. 
 
 
1.1.4 Study designs, bias, and confounding 
The special nature of drug exposure and the continuous advancements in 
methodology, statistical methods, data availability, and computer software have 
introduced new challenges as well as preferred solutions to estimate risk and benefit 
in pharmacoepidemiology. Some of the most important study designs and 
methodologic aspects are discussed below. 3, 5, 19 
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Case-control studies 
A case-control study design captures patients (cases) with a certain outcome of 
interest (e.g. a certain disease) and then looks backwards in time for an exposure of 
interest. Along with the cases, a group of control patients is defined without the 
specific outcome. The proportion of individuals exposed to this specific exposure 
variable in both the cases and the controls then allows the calculation of a measure 
of association, defined as the odds ratio (OR). Although case-control studies do not 
yield relative risks, an OR is a good approximation of the true relative risk, especially 
when the IR of the outcome of interest is low (<5%) in the general population. While 
an OR greater than 1 indicates a potentially increased risk for the outcome in 
exposed patients, an OR below 1 suggests a protective effect. An equal distribution 
of the exposure variable between cases and controls yields an OR of 1. Case control 
studies are increasingly popular, as they are relatively cheap and allow a fast and 
efficient approach to a study question. The study design is especially useful for rare 
outcomes (e.g. autism), and for outcomes with a long latency (e.g. cancer). However, 
a meticulously sound methodology is required to ensure valid results, as case-control 
studies are more vulnerable to bias and confounding. The selection of an appropriate 
control group is crucial; controls should be free of the outcome of interest, but 
otherwise represent the population at risk of becoming cases as closely as possible. 
Furthermore, sufficient exposure information is essential to account for bias and 
confounding during the study design stage or with analytical techniques.4, 18, 23 
Cohort studies 
Cohort studies trace people forward in time from exposure to outcome. Two groups 
are identified at the beginning of a cohort study: one group exposed to some factor of 
interest (e.g. use of antihypertensives) and a control group without the respective 
exposure. Both groups are then followed forward in time to assess for the outcome of 
interest (e.g. myocardial infarction). While a higher incidence of the outcome within 
the exposed group than in the unexposed group indicates an increased risk for the 
outcome in exposed patients, the exposure has protective properties otherwise. Risk 
estimates used in cohort studies are IRs, relative risks, survival curves and hazard 
ratios.18, 24 Cohort studies can be performed prospectively, by moving forward in time 
from the present, but they may as well be conducted retrospectively, thereby 
comprising the cohort in the past and following them up into the present. Thus, while 
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in either case the study moves in the same direction, data collection may already be 
completed by the time of patient selection in the case of a retrospective study. Cohort 
studies are especially useful to study rare exposures, and allow investigation of 
multiple outcomes after a single exposure (e.g. cigarette smoking and the 
development of stroke, emphysema, oral cancer, and heart disease). Cohort studies 
do however also have important limitations. Firstly, the choice of an accurate control 
group is important because selection bias (discussed below) often imposes a major 
challenge, and secondly, especially in cohort studies that continue for decades, 
differential losses of follow-up between exposed and unexposed individuals or a 
time-varying factors such as change in exposure status may cause bias in the 
results.4, 20, 24, 25  
Nested case-control studies 
The nested case-control study depicts a case-control study embedded within a 
cohort study, and is especially important in epidemiologic research on drug effects. 
Analogously to a cohort study, a cohort of individuals is assembled and followed 
forward in time to assess the occurrence of an outcome of interest. But instead of 
analyzing data for everyone in the cohort, the analysis is conducted as a case-control 
study in individuals who developed the outcome of interest (cases) only, to each of 
which a defined number of controls (i.e. individuals who did not develop the outcome 
of interest) is selected from the initial cohort. The number of selected controls per 
case usually ranges between 4 and 10, depending on the statistical power of the 
study. Nested case-control studies combine strengths of cohort studies and of case-
control studies. Their main advantage is a better control for potential bias such as 
age, calendar time, or disease duration through matching, thereby avoiding complex 
statistical techniques such as propensity scores. This matching of cases and controls 
on time (i.e. on the date of outcome diagnosis) also minimizes bias which can be 
introduced by time-dependent variables such as drug exposure, allowing a relatively 
straight-forward time-stratified analysis of drug exposure by duration of use. Such 
time varying factors would have to be addressed by elaborate time-dependent Cox 
proportional hazard models (an advanced version of the traditional time-independent 
Cox model) in a regular cohort study. Additionally, data collection and analysis is less 
expensive and less time-consuming, especially compared to large cohorts that are 
followed over a long period of time. 4, 24, 26, 27 
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Particular pharmacoepidemiologic study designs 
Study designs such as the case-crossover and the case-time-control design are 
more recent refinements of the original case-control and cohort study designs, aiming 
to overcome specific confounding, inherent to pharmacoepidemiologic research. The 
case-crossover study design allows the study of the association of acute transient 
effects (e.g. myocardial infarction) with intermittent drug exposure (e.g. short acting 
nifedipine), using the exposure history of each case as his, or her, own control. This 
mitigates between-person time-invariant confounding (e.g. by chronic co-morbidities). 
Several further methods have been suggested to overcome suspected time trend 
bias (e.g. healthy-user / sick-stopper or protopathic bias), which are introduced by 
changes in prescribing patterns or disease severity within patients over time. Such 
methods include the case-time-control design, in which results of a case-crossover 
study are adjusted by means of the exposure history of a conventional control group, 
or the case-case time control design, where use of concomitantly used non-causal 
but prognosis-related drugs within patients, or pre-event time of future cases is used 
to adjust results of the drug of interest. However, inconsiderate use of such methods 
can also introduce additional bias by over-adjustment due to selection bias, or it may 
unnecessarily reduce statistical power due to reduction of eligible cases. Thus 
application of such methods has to be considered carefully. 4, 28-30  
Bias 
Bias is the lack of internal validity, i.e. if a systematic error causes the statistic 
estimate of a certain association not to represent the true value. Roughly three broad 
categories of bias can be distinguished. Namely, selection bias, information bias, and 
confounding.31 
Selection bias 
Selection bias occurs when the study population does not accurately represent the 
target population, and can be introduced at several stages of research conduction; 
poorly defined eligibility criteria, inaccurate sampling frame, and uneven diagnostic 
procedures in the target population. Various selection biases have been defined in 
the literature, such as the ‘healthcare access bias’, the ‘Neyman bias / selective 
survival bias’, the ‘healthy patient bias’, ‘detection bias’, or bias introduced by the 
‘healthy worker effect’ that may occur in occupational studies. As the association 
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between exposure and outcome among those who are not included in the study is 
usually unknown, the presence of selection bias must usually be inferred rather than 
observed.32 Thus, bias should be addressed at the stage of study design by matching 
of the study population. However, matching itself may introduce bias by 
overmatching, when matching is performed on non-confounding variables that might 
produce an underestimation of an association. 31, 33 
Information bias 
Information bias usually arises during data collection. The three main types of 
information bias are misclassification bias, ecological fallacy, and regression to the 
mean. Misclassification bias is highly relevant in database research and originates if 
a patient is placed in the wrong category due to a lack of sensitivity and / or 
specificity of the procedure in detecting exposure. Misclassification of study subjects 
is either differential or non-differential. Differential misclassification bias is present 
when misclassification differs in the groups being compared, whereas non-differential 
misclassification bias is present when the misclassification is the same across the 
groups being compared.  Misclassification can be introduced by several biases, 
including detection bias, recall bias, or reporting bias. Ecological fallacy occurs when 
results achieved at group level are inadequately used to make inferences at the 
individual level. Another type of information bias that is relevant to 
pharmacoepidemiology is ‘protopathic bias’, which is often mistaken as confounding 
by indication, whereby a drug is inadvertently prescribed for an early manifestation of 
a disease that has not yet been diagnosed. When the disease is later discovered, a 
causal association between the drug and the disease may be incorrectly inferred.31-35  
Further biases in pharmacoepidemiology 
One bias particular to the epidemiologic study of drug effects is the immortal time 
bias in cohort studies, which arises from an improper exposure definition ascribing a 
survival advantage to exposed patients as compared to unexposed patients; e.g. if a 
study aims to analyze overall mortality, thereby defining exposure as being 
prescribed a certain drug within a certain time period upon cohort entry. Exposed 
patients are then per definition ‘immortal’ during this time lag whereas unexposed 
patients could die any time after cohort entry. Such imbalances may cause an 
underestimation of the outcome rate among exposed patients. To avoid such bias in 
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the analysis of complex time-varying drug exposure data, the application of time-
dependent Cox proportional hazard analyses or nested case-control designs are 
indicated.4 Furthermore, publication bias plays a greater role in observational 
research as compared to RCTs, as results showing an effect tend to be published 
more often than null-results.36   
Confounding 
Confounding occurs when a variable is a risk factor for an effect among non-exposed 
persons and is at the same time associated with the exposure of interest in the 
population from which the effect derives, without being an intermediate step in the 
causal pathway. Confounding can substantially distort the risk estimate, and is a 
central issue in analytical observational research. 32, 33 Confounding can be 
neutralized at the design stage of a study by matching or restriction of the study 
population (i.e. in observational studies) or randomization (i.e. in RCTs), and/or at the 
analysis-level by stratifying results at the level of the potential confounder or by 
performing multivariate analysis, given that sufficient and accurate information on 
potential confounders is available.31, 32 A particular type of confounding frequently 
encountered in pharmacoepidemiology is ‘confounding by indication’. This type of 
confounding bias is present if the indication for the prescription of a drug of interest is 
related to the outcome of interest. For example, confounding by indication could be 
present in a study of the association of L-tryptophan with myalgia syndrome, because 
L-tryptophan is indicated to treat insomnia and depression, both of which are 
commonly associated with myalgia. Confounding by indication may also be present 
as ‘confounding by disease severity – channeling bias’. In case of confounding by 
indication, results may simulate a lack of effectiveness of the drug under study, as 
exposed patients reveal higher IRs of the outcome when compared to unexposed 
patients. Confounding by indication is often difficult to control, especially in large 
database studies, as the precise drug indication is rarely explicitly labeled. Thus, 
control of confounding by indication has to be implemented as far as possible by 
eligibility restrictions at the design level of a study, and needs to be discussed 
critically when discussing results.4, 33, 35, 37 
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Propensity scores in pharmacoepidemiology  
The lack of randomization in observational research introduces systematic 
differences between patients in terms of measured and unmeasured confounders. 
Propensity scores are a relatively new method in mitigating such confounding (mainly 
addressing confounding by indication). The propensity score represents the 
probability of a patient receiving a certain drug with a defined set of covariates. It 
depicts a single summary variable, made up of several variables that are associated 
with treatment allocation, and may also represent a proxy for variables that were not 
captured in the data. Study subjects may be matched or stratified on their propensity 
scores, or scores can be integrated into the multivariate regression analysis. 
Although propensity scores are increasingly popular, incomplete data / incomplete 
variable inclusion into the score may distort findings just as much. Propensity scores 
are mainly useful in the case of a limited study size that does not allow matching or 
adjusting for all individual factors, whereby sufficient information on relevant 
covariates needs be available. Since our study encompassed some 50’000 cases 
and 50’000 controls, the application of such scores was not indicated. After all, 
missing data on residual confounders such as nutrition, ethnicity, sun light exposure, 
and other life-style factors could not have been augmented by the use of propensity 
scores. 4, 38 
 
1.1.5 Data sources 
Before the mid-1980’s, most data for pharmacoepidemiologic studies were hospital-
based, and information was specifically retrieved to answer the study question via 
patient interviews. However, over the last two decades, utilization of existing data 
sources, such as multipurpose cohorts or large health databases have become 
increasingly popular, as this allows approaching a research question with more 
efficiency.4, 19 
Multipurpose cohorts 
Multipurpose cohorts are study cohorts that consist of a defined population which is 
followed over time and which is not assembled by a specific exposure. Such cohorts 
allow studying a variety of research hypotheses. Exposure variability is usually 
sufficient to allow the evaluation of the association between specific drug exposures 
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and a disease, as long as the outcome, as well as sufficient information on potential 
confounders, has been captured. One of the most frequently used multipurpose 
cohorts for pharmacoepidemiologic research is the US Nurses’ Health Study, in 
which female nurses within the US were followed prospectively from 1976 by 
biannually mailed follow-up questionnaires inquiring about different exposures 
(particularly hormone use), lifestyle factors (e.g. smoking status, exercise habits), 
and the development of chronic conditions (e.g. cancer, cardiovascular diseases). 
Later, questions about dietary habits and issues related to quality of life were added. 
Although the study was initially designed to investigate the association between oral 
contraceptive use and the risk of breast cancer, it has also been extensively used to 
study other pharmacoepidemiologic research questions.4 
Health Databases 
Over the last decades, large computerized health databases have become an 
increasingly important source for pharmacoepidemiologic research, as they offer an 
efficient approach in assessing the hundreds of marketed drugs. Currently, there are 
two main types of such databases; i.e. administrative databases and physician-based 
databases. Administrative claims databases have mainly emerged in the US and 
Canada with the main purpose of health care reimbursement administration. These 
databases usually contain patient-level data from several files (population registry, 
pharmacy dispensation file, hospitalization file, ambulatory physician visits file), 
linked via a unique anonymized identification number (usually the social security 
number). Longitudinal patient files can be tailored to the research question by linking 
several files of interest. Some databases additionally allow linkage to registries, such 
as cancer registries or birth malformation registries. Other examples of administrative 
databases include the US Group Health Cooperative databases, the Kaiser 
Permanente databases, or the Medicaid databases, with the main differences 
between them arising from the health care system in the respective country. 
The United Kingdom (UK), Scotland and some other countries built up large primary 
care based databases, where enrolled general practitioners (GPs) electronically 
enter patient data. Of these, the General Practice Research Database (GPRD) is 
probably the best-known example, which is also the database used for the rosacea 
project presented in this thesis. Because the UK offers a unique medical environment 
with the GP operating as the gatekeeper and as the central health care provider, the 
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GPRD was initiated in 1987 in the UK under the name Value Added Medical 
Products (VAMP) research databank. VAMP provided GPs with practice computers 
and the corresponding software and in turn GPs agreed to undertake data quality 
training and to provide anonymized data to the centralized database. After several 
organizational and managerial changes, the database was donated to the 
UK Department of Health and at the same time VAMP was renamed as GPRD.  
In April 2012 the GPRD was transferred into the Clinical Practice Research Datalink 
(CPRD), the new English National Health Service (NHS) observational data and 
interventional research service, jointly funded by the NHS National Institute for Health 
Research (NIHR) and the Medicines and Healthcare products Regulatory Agency 
(MHRA). Since data collection of the studies presented within this thesis has been 
conducted before the GPRD was transferred into the CPRD, the database will be 
referred to as the GPRD throughout this thesis. A more detailed description of the 
characteristics of the GPRD is found in the methods section of the studies in this 
thesis. Other examples of physician-based databases include The Health 
Improvement Network (THIN) database, which also uses medical records from UK 
patients, or the Intercontinental Marketing Services (IMS) disease analyzer 
(previously known as MediPlus) databases, which contains 
patient records from the UK, Germany, and France.3, 4, 7 
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1.2 Rosacea 
1.2.1 History of rosacea 
Some of the first evidence of a general perception of rosacea in the society dates 
back to the late 14th century, when Geoffrey Chaucer, a preeminent English poet, 
drew a vivid picture of the skin condition within his Canterbury Pilgrims, suggesting 
its etiology in a sanguine constitution and alcoholic habits. Shakespeare also 
described men with red faces and enlarged noses in his Henry V.  
 
A somnour was ther with us in that place, 
That hadde a fyr-reed chrubbines face, 
For sawcefleema he was, with eyen narwe. 
As hoot he was and lecherous as a sparwe, 
With scalled browes blake and piled berd; 
Of his visage children were afred. 
Ther nas quik-silver, litharge ne brimstoon, 
Boras, ceruce, ne oille of tarter noon, 
Ne oynement that wolde clense and byte, 
That him highte helpen of his whelks whyte, 
Nor of the knobbes sittinge on his chekes. 
Wel loved he garllk, oynons and eek lekes, 
And for to drinken strong wyn red as blood. 
 Canterbury pilgrims, Prologue, 623-635.39 
 
 
Further artistic tribute to rosacea can be found throughout the centuries, such as in 
the painting in the Louvre "The Old Man and His Grandson" by the Italian painter 
Domenico Ghirlandaio from around the year 1480 (see title page). The first medical 
description of rosacea appeared in the 14th century, when Dr. Guy de Chauliac, a 
French surgeon, described "red lesions in the face, particularly on the nose and 
cheeks," and named the condition ‘goutterose’ (French for ‘pink droplet’) or 
‘couperose’. Dr. Thomas Bateman introduced the term ‘acne rosacea’ in 1812, when 
he wrote: "The perfect cure of acne rosacea is, in fact, never accomplished." While 
many 19th century references listed rosacea as a sub-type of acne, in 1891, Dr. Henri 
G. Piffard, a professor of dermatology in New York, called for distinctions among 
different forms of acne.39, 40 
 
 
 
 
                                                 
a
 afflicted with pimples, supposed to be caused by too much salt phlegm. 
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1.2.2 Epidemiology 
Although rosacea appears to be rather common, it remains sparsely investigated. 
Previously reported prevalence rates span over a wide range. A Swedish 
observational study from 1989 screened 809 office employees and reported a 
rosacea prevalence of 10%,41 whereas a German study (48,665 employees) and an 
Estonian study reported prevalences of 2.2% and 22%, respectively.42, 43 Differences 
might be attributable to a lacking official disease definition, to potential 
misclassification of actinic damage, but also to varying disease susceptibility across 
geographic regions. Since fair-skinned people of Celtic origin seem to be at a greater 
rosacea risk than people with darker skin, demographic data of rosacea cannot 
invariably be extrapolated onto other ethnic groups.44Rosacea is more frequent in 
women and is usually diagnosed after the age of 30 years.45 A more detailed 
background on the epidemiology of facial and ocular rosacea is given in Study 3.1.46  
 
1.2.3 Clinical manifestation, classification, and diagnosis 
Rosacea is a chronic skin disease of the facial convexities (chin, cheeks, nose, 
forehead), characterized by remissions and relapses.47 It can manifest with a broad 
diversity of clinical features such as prolonged flushing (especially at early disease 
stages), burning, stinging, erythema, papules, pustules, edema, telangiectasia, 
ocular leasions, or phymatous changes,48 whereby  specific symptoms usually 
appear in defined clusters in any given patients. In 2002, an expert committee 
assembled by the National Rosacea Society (NRSEC) introduced a provisinoal 
classification system that categorized rosacea into 4 clinical sub-types and one 
variant form (granulomatous rosacea), differentiated by the appearance of certain 
conglomerates of symptoms.48 Symptoms of different sub-types often overlap, but 
usually manifestation of one sub-type dominates the clinical picture.45, 47 In 2004 the 
NRSEC further released a standard grading system for assessing the relative 
severity of the disease.48, 49 Both tools are aimed to homogenize disease 
classification in clinical practice and in the communication of research findings on 
rosacea.49 The following four rosacea sub-types were introduced, defined by the 
minimum of symptoms sufficient for diagnosis.  
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Erythematotelangiectatic rosacea (ETR) is probably the most frequent rosacea sub-
type and is characterized by prolonged flushing with persistent central facial 
erythema, often accompanied by telangienctasia. Edema, stinging burning, rougness 
or scaling of the skin may coexist.47, 48 This rosacea sub-type may be difficult to 
distinguish from chronic actinic damage.47 Although flushing is a central main feature 
of rosacea, flushing symptoms alone do not qualify for a rosacea diagnosis, as many 
patients with flushing symptoms never develop the skin disease.45, 47 
 
Papulopustular rosacea (PPR) presents with persistent central facial erythema with 
transient papules and/or pustules. Plaques can form from inflammatory lesions in 
severe forms of the disease, and burning and stinging sensations may be reported. 
This sub-type resembles acne vulgaris, does not prevent with comedones. 
Additionally, patients with acne are usually younger and have less erythema but oilier 
skin. However, acne vulgaris and rosacea may also coexist. Papulopustular rosacea 
often overlaps with an erythematotelangiectatic manifestation of rosacea presenting 
with telangiectasia.47, 48 
 
Phymatous rosacea includes thickening of the sebaceous glands and the connective 
tissue, resulting in nodular changes and enlargement of the skin surface, most 
frequently presenting as rhinophyma (phymatous thickening of the nose). Phymatous 
changes may also occur on the chin, forehead, cheeks and ears. Other subtypes 
often, but not always, coexist (PPR > ETR).47, 48 The rhinophyma can be socially 
stigmatizing since it is arbitrarily referred to as a ‘whiskey nose’ or a ‘rum blossom’.47 
While other rosacea sub-types show a strong female preponderance, the rhinophyma 
appears about 20 times more often in men than in women.45, 47 
 
Ocular rosacea is defined by the presence of one of the following symptoms; watery 
or bloodshot eyes, foreign body sensation, burning or stinging, dryness, itching, light 
sensitivity, blurred vision, telangiectases of the conjunctiva or the lid-margin, or lid-
edema. Blepharitis, conjunctivitis, irregularities of the lid-margins, and hordeola and 
chalazia also occur. Ocular rosacea most often, but not always, coexists with 
cutaneous rosacea.2, 48 Symptoms are usually mild to moderate and nonspecific, but 
severe cases of keratitis, which can even lead to visual loss, have been reported.45, 47 
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Diagnosis 
In the absence of confirmatory histologic or serologic markers, rosacea is diagnosed 
based on the clinical picture and the exclusion of differential diagnoses, such as acne 
vulgaris, perioral dermatitis, seborrheic dermatitis, or lupus erythematosus, which 
may differ between rosacea sub-types. Biopsies may be warranted at most to rule 
out alternative diagnoses.2, 47 
 
1.2.4 Triggers and risk factors of rosacea 
The predominant presumption that rosacea, and especially rhinophyma, originates in 
alcoholic indulgence is drawn through the early medical literature and even led to an 
early reference to the disease as ‘pustule de vin’ (‘French for ‘pimples of wine’).39, 40 
Although this belief has never been proven, it is still widespread in present general 
thinking, making rosacea a socially stigmatizing disease.47 Among experts, however, 
it is now accepted that alcohol may aggravate the condition, but that the symptoms 
are just as frequently observed in teetotalers. 
 
Over the last decades, an abundance of further pathomechanistic hypotheses of 
environmental and genetic origins have been raised, albeit mostly with inconclusive 
findings. The incomplete understanding of the pathology of the skin disease also 
caused the distinction between suggested etiologic and aggravating / triggering 
factors to often remain unclear.  
Rosacea flare-ups seem to be triggered by environmental or lifestyle factors, mostly 
related to flushing. Among the most commonly referred to rosacea triggers are sun 
exposure, emotional stress, temperature extremes, wind, exercise, alcohol 
consumption, spicy foods, humidity, certain skin care products / cosmetics, and hot 
beverages.50, 51 Factors that have been discussed in the etiology of the skin disease 
are abundant and frequently based on inconclusive results, such as gastrointestinal 
disorders (mainly Helicobacter Pylori), psychogenic factors such as traumatic events 
or stress, skin mite infestation (Demodex folliculorum, Bacillus oleronius), UV 
radiation, menopause, reactive oxygen species, certain proteases and other 
‚Sauf, dass dir die Nase glüht, rot wie ein Karfunkel, damit du eine Leuchte hast, 
in des Daseins Dunkel.‘ 
Philosophie einer Eckkneipe, Author and Date unknown  
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neuropeptides, epidermal barrier defects, small blood vessel abnormalities, and 
childhood styes.47, 48, 52-55  
 
1.2.5 Pathomechanism 
Although the exact pathomechanism of rosacea remains to be elucidated, recent 
evidence points toward a key role of the innate immune system in the skin disease 
causing neurovascular dysregulation and neurogenic inflammation.1 This hypothesis 
is especially interesting, as it links most of the previously postulated etiologic and / or 
triggering factors (Section 1.2.4) in a plausible model (Figure 1.2-1). According to this 
hypothesis, a genetically predisposed hypersensitive skin activates the innate 
immune system upon contact with certain trigger factors (e.g. UV radiation, skin 
mites, emotional stress, temperature extremes etc.) via a mechanism that is not yet 
completely understood. This leads to hyper-stimulation of cutaneous sensory 
neurons and to a consequent release of vasoactive and inflammatory neuropeptides, 
resulting in vasodilation (flushing, telangiectasia, edema and burning-stinging 
sensation), and chronic neurogenic inflammation. Chronic neurogenic stimulation 
may further lead to persistent erythema and ultimately to a rearrangement of the 
extracellular matrix, resulting in fibrosis (i.e. rhinophyma). The exact link between the 
neuronal and the innate immune component remains to be clarified.  Various 
inflammatory mediators, such as cytokines, antimicrobial peptides, or radical oxygen 
species, seem to additionally aggravate the inflammatory response. For instance, an 
abundance of aberrantly processed cathelicidines (LL37, vasoactive and 
inflammatory antimicrobial peptide) was observed in rosacea-affected skin, which 
induced rosacea like pathologic changes in mice when injected under the skin. 
However, a systematic profiling and the exact role of such compounds is not yet 
available.1, 55-57  
In summary, rosacea seems to be an inflammatory skin disease characterized by 
neuroimmune dysfunction and neurovascular dysregulation. Meanwhile, an 
abundance of open questions remain to be answered; Can this neuroinfalmmatory / 
neurovascular hypothesis be proven over the years? What are the exact 
mechanisms and their interaction among each other? What is their relevance in the 
entire complex process? And may these mechanisms have potential as drug targets 
for rosacea treatment? 
INTRODUCTION   ROSACEA   
22 
 
 
1.2.6 Treatment 
Historically, rosacea was treated by means of bloodlettings and application of 
leeches on rosacea-affected skin.40 Although rosacea therapy has advanced since 
this time, a curative treatment approach has not yet been developed, and the main 
substances used in rosacea treatment are relatively old. Because official treatment 
guidelines are yet lacking, treatment methods have to be applied more or less in a 
trial and error strategy. The main focus of rosacea therapy is on patients’ quality of 
life, aiming to alleviate the prevailing symptoms, to improve appearance, as well as to 
prevent progression or sustain remission. An abundance of drug therapies and 
physical treatments (e.g. surgical or laser procedures) have been suggested, but only 
few are backed up by clinical evidence. 2, 47, 51  
Topical treatments are the mainstay in the therapy of mild to moderate rosacea. The 
three primary drugs that are approved and supported by efficacy data are azelaic 
acid, metronidazole, and sodium sulfacetamide-sulphur. Metronidazole was first 
used, based on the belief in a microbial origin of the skin disease, but it is now known 
Figure 1.2-1: Suggested pathomechanism of rosacea. Reprinted by permission from Macmillan Publishers Ltd: [Journal of Investigative 
Dermatology. Symposium proceedings]1 copyright (2011) 
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to exert an antiinflammatory effect, as do the other two substances. Various other 
topical therapies are used as off-label treatments, such as clindamycin, erythromycin 
(+/- zinc), topical retinoids, permethrin 5% cream and others, often based on 
anecdotal evidence. 2, 47, 52, 58  
Systemic therapy mainly includes oral tetracycline and its second-generation 
derivatives minocycline and doxycycline, which hold antiinflammatory properties. A 
sub-antimicrobial dosage of doxycycline allows long-term application without causing 
pathogen resistances. Macrolide antibiotics (i.e. erythromycin, clarithromycin, and 
azithromycin), metronidazole, and isotretinoin have also been used to a lesser 
degree. Suggested off-label treatments, mainly to control flushing symptoms, include 
β-blockers (BBs), spironolactone, naloxone, ondansetron, aspirin, and clonidine, but 
clinical evidence for the use of such substances is extremely scarce. 2, 58, 59 
Daily sunscreen application may slow progression of the disease, and decorative 
cosmetics and education on avoidance of flushing triggering factors can mitigate the 
psychosocial impact of the skin disease.2, 47, 51, 58 
Although sub-type-specific rosacea treatment has been described,59 the frequent 
overlap of sub-types within patients requires a symptom oriented approach either 
way, whereby topical and systemic treatments may be combined. Most topical 
treatments and oral antibiotics are mainly effective against inflammatory symptoms 
such as papules and pustules, whereas laser therapy is used to remove 
telangiectases or persistent erythema.2 Oral isotretinoin or laser interventions may be 
applied to treat rhinophyma. Mild ocular rosacea can usually be treated by lid 
hygiene, and lubricating eye drops, and in more severe cases with topical or 
systemic antibiotics or cyclosporine. More detailed information on sub-type or 
symptom specific rosacea treatment is found in recent literature.2, 47-49, 51, 52, 59  
Within the UK, only topical metronidazole and azelaic acid, as well as oral 
oxytetracycline and doxycycline are officially indicated for the treatment of rosacea.60   
Figure 1.2-2 shows a therapy guideline, suggested by the ROSIE Group (ROSacea 
International Expert Group) in 2011, in an attempt to introduce a rational, evidence-
based, symptom oriented treatment approach for the skin disease.2  Whether such 
schemes are applied in daily non-dermatologic clinical practice remains uncertain. 
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Figure 1.2-2: Suggested symptom-based treatment algorhythm for rosacea. From Elewski et al.2 Rosacea – global diversity and optimized outcome: proposed international consensus from the Rosacea International 
Expert Group. Journal of the European Academy of Dermatology and Venereology. Copyright © 2011 by John Wiley & Sons, Inc. Reprinted by permission of John Wiley & Sons, Inc. 
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2 Aims of the thesis 
The aim of this thesis was to contribute to the general understanding of rosacea in a 
comprehensive observational case-control study, using data from the GPRD, a large 
and well-established physician-based primary care database from the UK. Rosacea 
is a yet under-investigated field of research, haunted by an abundance of 
inconclusive hypotheses regarding its etiology, pathomechanism, and comorbidities. 
Rosacea has not been studied on the GPRD before. Study 3.1 is the basis of the 
project and aims at describing the study population in terms of demographics, and 
lifestyle characteristics, including ocular symptoms and first-ever IRs. 
Study 3.2 and 3.5 fathom some insufficiently supported notions regarding the 
association of rosacea with certain comorbidities.  An association of migraine and 
rosacea has been discussed over years, based on inconclusive findings.41, 61-63 Study 
3.2 assesses the risk of incident rosacea in patients with migraine, stratified by age 
and gender. Within this context the impact of triptans on the risk of developing 
rosacea is assessed, which could be interesting from a mechanistic point of view. 
The rumor of a psychogenic origin of the skin disease has sustained over decades, 
but could neither be entirely established nor dismissed.53, 54, 64, 65 Study 3.5 assessed 
the risk for rosacea in patients with depression, other affective disorders, or 
schizophrenia, stratified by use of antidepressant and antipsychotic drugs. 
Based on weak evidence, spironolactone and BBs have been recommended as off-
label treatments for rosacea, whereas a general advice not to apply calcium channel 
blockers (CCBs) in rosacea patients prevails in the literature.47, 66-69 The objective of 
Studies 3.3 and 3.6 was to evaluate the effect of diuretics (focus spironolactone, 
Study 3.3), and of antihypertensive drugs (including BBs and CCBs, Study 3.6) on 
the risk of rosacea. Especially with abundantly used therapeutics (e.g. 
antihypertensive drugs) a basis of sound evidence is needed in order for healthcare 
professionals to make adequate decisions in clinical practice.   
Finally, Study 3.4 introduces a novel aspect to rosacea research; i.e. the association 
of rosacea and diabetes mellitus (DM) / antidiabetic drugs (insulin and oral 
antidiabetic drugs [OADs]). The momentarily most credible pathomechanistic 
hypothesis on rosacea involves neurogenic vasodilation, whereas DM is known to 
inhibit vasodilation especially at an advanced disease stage and upon insulin 
exposure.1, 56, 70, 71 
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3.1.1 Abstract 
Background: Rosacea is a chronic facial skin disease of unclear origin. 
Epidemiological data are scarce and controversial, with reported prevalences ranging 
from 0.09% to 22%. To our knowledge, incidence rates have not been quantified 
before.  
Objectives: In this observational study we quantified incidence rates of diagnosed 
rosacea in the UK and described demographic characteristics and the prevalence of 
ocular symptoms in patients with rosacea. We compared lifestyle factors such as 
smoking and alcohol consumption between rosacea patients and controls. 
Methods: Using the UK-based General Practice Research Database, we identified 
patients with an incident diagnosis of rosacea between 1995 and 2009 and matched 
them (1:1) to rosacea-free control patients. We assessed person-time of all patients 
at risk and assessed incidence rates of rosacea, stratified by age, sex, year of the 
diagnosis, and region. 
Results: We identified 60,042 rosacea cases and 60,042 controls (61.5% women). 
The overall incidence rate for diagnosed rosacea in the UK was 1.65 / 1,000 
person-years. Rosacea was diagnosed in some 80% of cases after the age of 30 
years. Ocular symptoms were recorded in 20.8% of cases at the index date. We 
observed a significantly reduced relative risk of developing rosacea among current 
smokers (odds ratio 0.64, 95% CI 0.62-0.67). Alcohol consumption was associated 
with a marginal risk increase.  
Conclusions: We quantified incidence rates and characteristics of patients with 
rosacea diagnosed in clinical practice in a large epidemiological study using primary 
care data from the UK. Smoking was associated with a substantially reduced risk of 
developing rosacea.  
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3.1.2 Introduction 
Rosacea is a chronic inflammatory facial skin disease characterised by flushing 
episodes, erythema, papules, pustules, and telangiectasia. Phymatous changes 
mostly of the nose, the rhinophyma, as well as inflammation of the eye and the eyelid 
can also be manifestations of the disease.48, 52, 72, 73 Rosacea is not life-threatening, 
but affects quality of life.52, 72-75 Official diagnostic guidelines do not exist, due to 
lacking measurable parameters and an official clinical definition of rosacea.47, 52, 72, 73, 
76, 77
 In 2002, the American National Rosacea Society Expert Committee introduced a 
classification system which divides the disease into four subtypes: 
‘erythematotelangiectatic’, ‘papulopustular’, ‘phymatous’, and ‘ocular’ rosacea.48, 52  
The pathogenesis of rosacea remains unclear. Among various other factors, an 
altered innate immune response, neurogenic inflammation, neurovascular 
dysregulation, or sun damage have been hypothesised as possible causes.1, 41, 47, 52, 
55, 56, 72, 78-80 
Epidemiological data on rosacea are scarce, with reported prevalences between 
0.09% and 22%.41, 42, 44, 81-85 A study from Sweden screened 809 office employees 
and revealed a rosacea prevalence of 10%,41 while a German and an Estonian study 
reported prevalences of 2.2% and 22%, respectively.42, 43 Incidence rates (IRs) of 
rosacea, to our knowledge, have not been studied before. Rosacea is usually 
diagnosed after the third decade of life. Most studies reported the disease to be more 
common in women, but to develop into phymatous stages more frequently in men.41-
43, 72, 78, 82, 83, 86, 87
 Rosacea seems to be diagnosed more often in fair-skinned people 
of Celtic origin. However, it is unclear whether pigmentation simply obscures 
detection of typical skin symptoms in darker skin.41, 43, 44, 52, 72, 73, 76, 78, 85  
Ocular rosacea is most likely to be of inflammatory nature, but the exact aetiology 
remains unclear. Blepharitis, conjunctivitis, hordeola/chalazia, tear film insufficiency 
and foreign body sensation have been described as frequent ophthalmic symptoms, 
while sight-threatening corneal involvement may occur in rare cases.72, 73, 88-91 
Ophthalmic involvement in patients with rosacea has been observed in 6% - 72% of 
cases, depending on diagnostic methods and the population under study.48, 52, 73, 88-93 
The association between cigarette smoking and the risk of developing rosacea has 
been explored in three studies: while one study found patients with rosacea to smoke 
less frequently than the general population,94 two other studies associated cessation 
of smoking with an increased risk of developing this skin disease.80, 95 Despite sparse 
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evidence, rosacea and in particular rhinophyma have been linked to excessive 
alcohol consumption.47, 72, 78, 96 Alcohol can trigger flushing episodes, but previous 
studies did not find evidence for a materially altered rosacea risk associated with 
alcohol consumption.47, 80, 96-98 
We conducted a large observational study to establish IRs of diagnosed rosacea in 
the UK, to characterise demographics of patients with rosacea, to quantify the 
prevalence of diagnosed ocular involvement, and to explore the impact of various 
lifestyle factors on the risk of developing the disease.  
 
3.1.3 Materials and Methods 
Study Design and Data Source 
We conducted a retrospective case-control study using the UK-based General 
Practice Research Database (GPRD). This database is a large source of 
anonymised primary-care data comprising approximately 7 million active patients 
who are enrolled with selected general practitioners (GPs). Those GPs have been 
trained to provide clinical data in a standardised format. Participating practices 
provide information on patient demographics and characteristics (e.g. age, sex, 
height, weight, smoking status), symptoms or medical diagnoses, laboratory test 
results, referrals to secondary care and drug prescriptions, which are directly 
generated by the computer. The Medicines and Healthcare Products Regulatory 
Agency (MHRA) anonymises the raw data before release and performs quality 
control checks, to ensure that the standards are followed. The patients enrolled in the 
GPRD are representative of the UK population with regard to age, sex, geographical 
distribution, and annual turnover rate. Extensive validation of the GPRD 99, 100 has 
documented high case validity, especially for chronic conditions.99 The database has 
been the source for numerous pharmacoepidemiological studies and for public health 
and disease epidemiology studies.101 The study protocol was approved by the 
Independent Scientific Advisory Committee (ISAC) for MHRA database research. 
Study Population 
The study population consisted of all patients in the GPRD with a first-time recorded 
READ-code for rosacea99 at a date between January 1995 and September 2009 
(subsequently referred to as index date [ID]). We excluded patients with <3 years of 
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recorded active history on the database prior to their first-time rosacea diagnosis to 
increase the likelihood of including only incident cases. Patients with a diagnosis for 
rhinophyma only or ocular rosacea only were not included.  
For the case-control analysis we randomly identified a rosacea-free control group of 
the same size and applied the same exclusion criteria as to cases. In addition, 
control patients were not eligible for inclusion if they had rhinophyma (without facial 
rosacea) or flushing symptoms recorded at any time. Controls were matched 1:1 to 
case patients on age (year of birth), sex, general practice, calendar time (ID), and 
number of years of recorded history in the database prior to the ID.  
We assessed ocular symptoms in cases and controls within 1 year prior to and within 
90 days after the ID. We further evaluated whether differential diagnoses of rosacea 
were recorded in cases and controls, in particular acne, perioral dermatitis, lupus 
erythematosus, atopic dermatitis, and seborrhoeic dermatitis.  
We assessed the smoking status (non, current, ex, unknown), body mass index 
(BMI; <18.5, 18.5-24.9, 25.0-29.9, or 30+ kg m-2), and alcohol consumption (0, 1-4, 
5-9, 10-14, 15-24, or 25+ units per week, or unknown) for cases and controls, as well 
as the number of GP visits over a 1-year period prior to the ID as a marker for 
medical attention. Furthermore, we assessed the number of rosacea cases who had 
been referred to a dermatologist or an ophthalmologist within 1 year prior to or after 
the ID. 
Statistical Analysis 
We estimated IRs of diagnosed rosacea for all patients in the GPRD between 1995 
and 2008, overall and stratified by age, sex and index year. Rates were calculated as 
the number of new cases divided by the total number of person-years (py) at risk. For 
rosacea-free patients, the number of py at risk was calculated by adding up 
person-time of all patients at risk in the GPRD between 1 January 1995 and the end 
of follow-up, which was the earliest of the following: a rosacea diagnosis, death, 
leaving the practice, or the end of the study period. In an additional analysis, we 
established IRs stratified into three geographical regions, i.e. the North (Scotland, 
Northern Ireland, North East England, North West England, and Yorkshire and the 
Humber), the Centre (Wales, East Midlands, West Midlands, East of England), or the 
South (South West, South Central, London, South East Coast) of the UK. We 
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age-standardised IRs stratified by geographical regions and by index year applying 
the direct method, using the European standard population as reference. 
For the case-control analysis, we conducted conditional logistic regression analyses 
using SAS statistical software (version 9.2, SAS Institute, Inc., Cary, NC, US). 
Relative risk estimates were calculated as odds ratios (ORs) with 95% confidence 
intervals (CIs). 
 
3.1.4 Results 
The study population encompassed 60,042 rosacea cases and 60,042 controls, of 
whom 61.5% were female. The vast majority (80%) of patients with rosacea were at 
or above the age of 30 years at the ID (Table 3.1-1). Only 7.3% of the rosacea cases 
were referred to a dermatologist, and 4.1% saw an ophthalmologist within 1 year 
before or after the ID. A rhinophyma diagnosis was recorded in 422 (0.7%) of the 
cases, of whom 80.3% were male.  
Incidence Rates 
The overall IR of diagnosed rosacea in the GPRD population was 1.65 / 1,000 py 
(95% CI 1.63-1.66). It was higher in women (IR 1.92 / 1,000 py [95% CI 1.90-1.94]) 
than in men (IR 1.34 / 1,000 py [95% CI 1.32-1.36]), and peaked between the age of 
40 and 59 years (Figure 3.1-1). The crude rate increased between 1995 and 2002 
and then levelled off; the same was the case for the European-standardised rates 
over time, although slightly lower (Table 3.1-1). The crude IR was higher in the North 
with an IR of 1.93 / 1,000 py (95% CI 1.90-1.95) than in the South of the UK 
(IR 1.46 / 1,000 py [95% CI 1.44-1.48]). The age-standardised IR was 1.71 / 1,000 py 
(95% CI 1.69-1.73) in the North and 1.29 / 1,000 py (95% CI 1.27-1.31) in the South 
of the UK. 
Demographics and Life-Style Characteristics 
Current smokers had a significantly reduced relative risk of developing rosacea when 
compared with nonsmokers, yielding an OR of 0.64 (95% CI 0.62-0.67). The OR for 
ex-smokers, when compared with nonsmokers, was slightly increased (OR 1.14, 
95% CI 1.10-1.18). The OR for rosacea increased slightly with increasing number of 
alcohol units consumed per week, with the highest OR of 1.51 (95% CI 1.41-1.63) for 
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patients consuming more than 25 units per week, as compared to those not drinking 
alcohol. Neither high nor low BMI was associated with an altered risk.  
Rosacea cases had more GP visits in the year prior to the ID than controls, with the 
highest OR of 2.33 (95% CI 2.25-2.41) for those with 10 or more GP visits when 
compared with patients with 0-2 GP visits (Table 3.1-2). 
Ocular Symptoms and Differential Diagnoses 
In total, 12,480 (20.8%) of 60,042 rosacea cases had at least one ocular symptom 
recorded within a 1-year period prior to or up to 90 days after the ID, compared with 
7,737 (12.9%) controls. Thus, the relative risk for cases to be diagnosed with ocular 
symptoms was 1.82 (95% CI 1.76-1.88). The prevalence of ocular symptoms was 
similar in men (19.8%) and women (21.4%). The most frequent ocular symptoms 
were hordeola / chalazia, followed by conjunctivitis and dry or watery eyes. The 
largest difference between cases and controls was seen for blepharitis, where the 
OR was 3.57 (95% CI 3.17-4.02).  
We identified 23.2% of cases and 6.3% of controls with a recorded acne diagnosis 
prior to or up to 90 days after the ID, with most co-diagnoses in the age-group of <20 
years. Seborrhoeic dermatitis was found in 10.9% of the cases and in 3.7% of the 
controls. The distribution of differential diagnoses of rosacea in cases 
and controls is displayed in Table 3.1-3.   
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 Table 3.1-1: Incidence rates of diagnosed rosacea in the UK between 1995 and 2008 
 
Person-years 
at risk 
Rosacea 
cases 
IR per 1,000 person-years 
(95% CI) 
IR per 1,000 person-years 
(95% CI) 
IR per 1,000 person-years 
(95% CI) 
         
Overall 34,136,657 56,253 1.65 (1.63-1.66)     
         
By Sex                 
Men 16,141,632 21,645 1.34 (1.32 - 1.36)         
Women 17,995,025 34,608 1.92 (1.90 - 1.94)         
     
    
By Age   Men and Women Men Women 
<20 7,179,962 6,367 0.89 (0.87 - 0.91) 0.83 (0.80 - 0.86) 0.95 (0.92 - 0.98) 
20-29 3,948,312 5,147 1.30 (1.27 - 1.34) 0.91 (0.87 - 0.95) 1.68 (1.63 - 1.74) 
30-39 4,776,305 8,657 1.81 (1.77 - 1.85) 1.05 (1.01 - 1.10) 2.47 (2.41 - 2.53) 
40-49 5020,453 11,734 2.34 (2.30 - 2.38) 1.54 (1.49 - 1.59) 3.06 (3.00 - 3.13) 
50-59 4,685,054 10,164 2.17 (2.13 - 2.21) 1.86 (1.81 - 1.92) 2.46 (2.39 - 2.52) 
60-69 3,747,948 7,608 2.03 (1.98 - 2.08) 2.03 (1.97 - 2.10) 2.03 (1.96 - 2.09) 
70+ 4,778,621 6,576 1.38 (1.34 - 1.41) 1.59 (1.54 - 1.65) 1.23 (1.19 - 1.27) 
    
 
    
By Year of 
Diagnosis         Age-Standardised Rates*      
1995 1,734,936 2,428 1.40 (1.34 - 1.46) 1.29 (1.24-1.34)   
1996 1,934,725 2,929 1.51 (1.46 - 1.57) 1.42 (1.37-1.47)   
1997 2,081,764 3,123 1.50 (1.45 - 1.55) 1.41 (1.36-1.46)   
1998 2,200,167 3,467 1.58 (1.52 - 1.63) 1.48 (1.43-1.53)   
1999 2,315,649 3,504 1.51 (1.46 - 1.56) 1.41 (1.36-1.46)   
2000 2,429,796 4,139 1.70 (1.65 - 1.76) 1.58 (1.53-1.63)   
2001 2,502,051 4,408 1.76 (1.71 - 1.81) 1.61 (1.56-1.66)   
2002 2,564,020 4,591 1.79 (1.74 - 1.84) 1.63 (1.58-1.68)   
2003 2,622,215 4,276 1.63 (1.58 - 1.68) 1.48 (1.44-1.52)   
2004 2,686,549 4,716 1.76 (1.71 - 1.81) 1.58 (1.54-1.62)   
2005 2,722,527 4,581 1.68 (1.63 - 1.73) 1.50 (1.46-1.54)   
2006 2,760,846 4,568 1.65 (1.61 - 1.70) 1.46 (1.42-1.50)   
2007 2,779,225 4,625 1.66 (1.62 - 1.71) 1.46 (1.42-1.50)   
2008 2,802,186 4,898 1.75 (1.70 - 1.80) 1.54 (1.50-1.58)     
 
Abbreviations: IR, incidence rate; CI, confidence interval. 
*Rates were age-standardised using the European standard population as reference. 
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Table 3.1-2: Distribution of patient characteristics and lifestyle factors in patients with rosacea and controls in the UK 
  
Rosacea cases,  
No (%) (n=60,042) 
Rosacea-free controls, 
No (%) (n=60,042) OR crude (95% CI) OR adjusted* (95% CI) 
Age (years)         
<20 6,673 (11.1) 6,680 (11.1) NA NA NA NA 
20-29 5,425 (9.0) 5,420 (9.0) NA NA NA NA 
30-39 9,172 (15.3) 9,184 (15.3) NA NA NA NA 
40-49 12,576 (21.0) 12,550 (20.9) NA NA NA NA 
50-59 10,851 (18.1) 10,855 (18.1) NA NA NA NA 
60-69 8,246 (13.7) 8,250 (13.7) NA NA NA NA 
70+ 7,099 (11.8) 7,103 (11.8) NA NA NA NA 
Sex 
        
male 23,118 (38.5) 23,118 (38.5) NA NA NA NA 
female 36,924 (61.5) 36,924 (61.5) NA NA NA NA 
Alcohol 
Consumption 
(units/week) 
        
none/ex 7,622 (12.7) 7,874 (13.1) 1.00 (ref.) 1.00 (ref.) 
current (units ?) 10,929 (18.2) 10,957 (18.3) 1.04 (0.99-1.08) 1.03 (0.99-1.08) 
1-4 10,455 (17.4) 10,150 (16.9) 1.09 (1.04-1.13) 1.06 (1.02-1.11) 
5-9 5,764 (9.6) 5,462 (9.1) 1.12 (1.06-1.18) 1.10 (1.05-1.16) 
10-14 5,087 (8.5) 4,516 (7.5) 1.20 (1.14-1.27) 1.20 (1.14-1.26) 
15-24 3,299 (5.5) 2,859 (4.8) 1.25 (1.17-1.33) 1.26 (1.19-1.35) 
25+ 2,668 (4.4) 2,032 (3.4) 1.43 (1.33-1.53) 1.51 (1.41-1.63) 
unknown 14,218 (23.7) 16,192 (27.0) 0.81 (0.76-0.85) 0.95 (0.90-1.00) 
Smoking Status 
        
Non 30,105 (50.1) 27,681 (46.1) 1.00 (ref.) 1.00 (ref.) 
Current 8,972 (14.9) 12,274 (20.4) 0.66 (0.64-0.68) 0.64 (0.62-0.67) 
Ex 11,863 (19.8) 9,657 (16.1) 1.17 (1.13-1.21) 1.14 (1.10-1.18) 
Unknown 9,102 (15.2) 10,430 (17.4) 0.68 (0.65-0.71) 0.82 (0.77-0.86) 
BMI (kg/m2) 
        
12.0-18.4 995 (1.7) 1,070 (1.8) 0.85 (0.77-0.92) 0.90 (0.82-0.98) 
18.5-24.9 21,038 (35.0) 19,556 (32.6) 1.00 (ref.) 1.00 (ref.) 
25.0-29.9 15,116 (25.2) 14,233 (23.7) 0.99 (0.96-1.02) 0.97 (0.94-1.00) 
30.0-60.0 8,020 (13.4) 8,235 (13.7) 0.91 (0.88-0.94) 0.89 (0.86-0.93) 
Unknown 14,873 (24.8) 16,948 (28.2) 0.72 (0.70-0.75) 0.82 (0.78-0.86) 
GP Visits                
  (1 y prior to ID)         
0-2 10,290 (17.1) 16,888 (28.1) 1.00 (ref.) NA NA 
3-4 7,332 (12.2) 7,440 (12.4) 1.67 (1.60-1.74) NA NA 
5-9 14,834 (24.7) 12,922 (21.5) 2.03 (1.96-2.10) NA NA 
10+ 27,586 (45.9) 22,792 (38.0) 2.33 (2.25-2.41) NA NA 
 
Abbreviatoins: BMI, body mass index; CI, confidence interval; GP, general practitioner; ID, index date; NA, not applicable; OR, odds ratio.  
* Adjusted for BMI, smoking, alcohol consumption. 
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Table 3.1-3: Distribution of ocular symptoms and differential diagnoses in rosacea cases and controls in the UK 
  
Rosacea cases,  
No (%) (n=60,042) 
Rosacea-free controls, 
No (%) (n=60,042) OR crude (95% CI) 
Ocular Symptoms (1 year prior to and up to 90 days after the ID) 
Blepharitis 1,250 (2.1) 360 (0.6) 3.57 (3.17-4.02) 
Hordeolum / chalazion 4,573 (7.6) 2,240 (3.7) 2.15 (2.04-2.26) 
Conjunctivitis 2,471 (4.1) 1,443 (2.4) 1.75 (1.64-1.87) 
Other inflammation 262 (0.4) 130 (0.2) 2.02 (1.63-2.49) 
Other conjunctival disorders 193 (0.3) 144 (0.2) 1.34 (1.08-1.66) 
Corneal disorders 416 (0.7) 308 (0.5) 1.35 (1.17-1.57) 
Red eyes 1,358 (2.3) 958 (1.6) 1.43 (1.32-1.56) 
Watery or dry eye 2,149 (3.6) 1,259 (2.1) 1.78 (1.66-1.92) 
Itchy eye 1,157 (1.9) 709 (1.2) 1.67 (1.51-1.83) 
Eye irritation / pain 1,928 (3.2) 1,320 (2.2) 1.49 (1.39-1.60) 
Blurred vision 620 (1.0) 512 (0.9) 1.21 (1.08-1.37) 
Eye involvement total 12,480 (20.8) 7,737 (12.9) 1.82 (1.76-1.88) 
men 4,585 (19.8) 2,630 (11.4) 1.97 (1.87-2.08) 
women 7,895 (21.4) 5,107 (13.8) 1.74 (1.67-1.81) 
Differential Diagnoses (prior to or up to 90 days after the ID) 
Acne 13,921 (23.2) 3,772 (6.3) 6.13 (5.85-6.43) 
<20 years 3,842 (6.4) 834 (1.4) 11.88 (10.50-13.44) 
20-29 years 3,052 (5.1) 1,141 (1.9) 5.27 (4.76-5.83) 
30-39 years 3,065 (5.1) 879 (1.5) 5.20 (4.73-5.71) 
40-49 years 2,411 (4.0) 606 (1.0) 5.03 (4.54-5.57) 
50-59 years 1,013 (1.7) 219 (0.4) 4.94 (4.24-5.76) 
60-69 years 367 (0.6) 71 (0.1) 5.68 (4.35-7.42) 
70+ years 171 (0.3) 22 (0.0) 7.68 (4.93-11.98) 
Seborrhoea / seborrhoeic dermatitis 6,528 (10.9) 2,199 (3.7) 3.25 (3.09-3.42) 
Perioral dermatitis 974 (1.6) 172 (0.3) 5.92 (5.01-6.99) 
Lupus erythematosus 173 (0.3) 85 (0.1) 2.04 (1.57-2.64) 
Atopic dermatitis 4,125 (6.9) 2,922 (4.9) 1.48 (1.40-1.55) 
 
   Abbreviations: CI, confidence interval; ID, index date; OR, odds ratio. 
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Figure3.1-1: Incidence rates of rosacea diagnosed in the UK between 1995 and 2008. py,  person-years. 
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3.1.5 Discussion 
In this large observational study we quantified IRs and assessed the demographic 
distribution of patients with rosacea in a primary care setting in the UK. Overall, the 
IR of GP-diagnosed rosacea in the UK was 1.65 / 1,000 py (95% CI 1.63-1.66), with 
higher IRs in females. Rosacea also tended to be diagnosed earlier in women than in 
men, a finding consistent with other studies, and usually developed after the age of 
30 years.41, 52, 72, 77, 78, 82, 86, 87 We further observed a slight increase in the crude and 
age-standardised IRs over the course of the study period until 2002, as was reported 
by the authors of a US-based publication from 2002.79 A possible explanation for this 
rise is increased awareness of rosacea among GPs. In our study population, IRs 
were higher in the North than in the South of the UK. This observation was not 
changed after age standardisation. The Irish population has been reported to be 
predominantly fair-skinned,102 so our findings may reflect an increased risk of 
rosacea with more fair-skinned populations.41, 43, 44, 52, 78, 85  
We observed a significantly decreased OR for current smokers when compared with 
nonsmokers. Ex-smokers, on the other hand, yielded a slightly increased OR. It has 
been suggested that there is an immunosuppressive effect of cigarette smoking 
leading to potential beneficial effects in certain inflammatory diseases, such as 
ulcerative colitis and sarcoidosis.103, 104 However, a negative impact on other 
inflammatory diseases, such as Crohn’s disease or rheumatoid arthritis, has also 
been reported.103 Further, neurovascular dysfunction causing vasodilatation has 
been implicated in the pathogenesis of rosacea.1, 56 Cigarette smoking impairs 
peripheral microvascular relaxation and might thus decrease the risk of incident 
rosacea.105 Three small studies of no more than 172 rosacea cases previously 
addressed the association between cigarette smoking and rosacea. One study found 
patients with rosacea to smoke less frequently than the general population,94 and the 
other two found that cessation of smoking was associated with an increased risk of 
developing rosacea when compared to current or nonsmokers. The latter two 
hypothesised an immunosuppressive effect of cigarette smoking on rosacea, exerting 
a triggering or aggravating effect upon withdrawal, as has been described for 
ulcerative colitis.80, 94, 95, 104 All three studies were based on self-reported smoking 
status. Current smoking status has been shown to be more reliably recorded than 
former skoking in the GPRD, with about 30% of ‘ex-smokers’ actually being current 
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smokers.106 Thus, the risk of developing rosacea for ex-smokers may be somewhat 
higher than observed due to misclassification of smoking status. Regardless of some 
possible misclassification, our data suggest that cigarette smoking reduces the risk of 
developing rosacea.  
A potential causal role of alcohol in the pathogenesis of rosacea has been discussed 
controversially for decades.47, 97 However, most previous studies found a 
nonsignificant association between alcohol and the skin disease.80, 96-98 In our study, 
ORs increased marginally with increasing number of alcohol units consumed per 
week, yielding an OR of 1.51 for patients drinking more than 25 units per week (4.4% 
of cases and 3.4% of controls). These data do not suggest that alcohol consumption 
plays a major role in the pathophysiology of rosacea.  
 
We observed ocular symptoms in 20.8% of the cases within a year prior to or up to 
90 days after the ID, implying an almost two-fold increased likelihood that patients 
with rosacea would be affected by ocular disorders when compared with controls. A 
study from 1953 reported that ocular symptoms preceded dermatologic findings in up 
to 20% of rosacea patients, whereas 27% of patients were diagnosed 
concomitantly.48, 72, 107 We observed men and women to be similarly at risk, while 
previously reported male/female ratios were not consistent.89, 90, 92, 107 
Hordeola / chalazia were the most prevalent ocular symptoms in our study 
population, followed by conjunctivitis and dry or watery eyes. Although the reported 
frequencies of ocular symptoms of rosacea varied in the literature the overall 
distribution of observed symptoms in our study was consistent with most 
publications.72, 73, 88-90 However, blepharitis was recorded in only 2.1% of rosacea 
cases in this study, while it has previously been among the most frequently reported 
ocular symptoms.88, 91 It is possible that blepharitis usually occurs at a later stage of 
the disease and was therefore not yet present at the time of the diagnosis in our 
study population. Most ocular findings in our study were GP-diagnosed, with only 
4.1% of cases referred to an ophthalmologist within the year prior to or after the ID. 
Diagnostic bias has been implicated before, suggesting that ocular rosacea may 
often go undetected in clinical practice.48, 52, 73, 88-92  
As there are no strict guidelines for diagnosing rosacea, differential diagnostic criteria 
may have led to some misdiagnoses. Of all rosacea cases, 23.2% also had an acne 
diagnosis recorded before or up to 90 days after the ID, most of them in the age 
ROSACEA PROJECT  STUDY 3.1 
 
44 
 
group of <20 years. Rosacea is a common disease and can, just by coincidence, 
coexist with acne vulgaris.86, 108 However, as rosacea does not typically manifest 
before the age of 20,41, 78, 82, 87 it is unclear whether these results represent diagnostic 
uncertainty by the GP, or whether these two diseases actually coexisted in our 
sample. A study from the 1950’s found acne to be present in about 7% of rosacea 
cases and controls.98 On the other hand, young patients with rosacea were 
mentioned to often have a history of acne, although statistical evidence to back up 
this hypothesis was not found.78, 108 The magnitude of the increase of co-diagnoses, 
however, suggests that diagnostic bias may play a certain role which needs to be 
considered when interpreting our results. 
Seborrhoeic dermatitis has been referred to as a common feature of rosacea,78, 86, 98, 
109
 although an increased sebum excretion in rosacea-affected skin was not 
observed.110 We observed a three-fold increased OR of seborrhoeic dermatitis in 
patients with rosacea compared with controls. Again, we cannot establish whether 
these patients had seborrhoeic dermatitis as a feature of their rosacea, or whether 
they had been misdiagnosed. The results on atopic dermatitis (marginally elevated 
OR) as well as on lupus erythematosus or perioral dermatitis (low prevalence) do not 
imply major diagnostic bias within our study.  
This study has several limitations that should be considered in interpreting our 
findings. First, mild rosacea may not necessarily cause patients to seek medical help; 
thus, a certain portion of cases may remain undetected, and our rates may be lower 
than the true rates in the UK population. Also, there is possible detection bias present 
since women might seek medical care more often than men.76 Second, the likelihood 
of being diagnosed with rosacea may increase with increasing medical attention. To 
address this issue, we quantified the number of GP visits, and observed that patients 
with rosacea tended to see the GP more often prior to the diagnosis than controls. 
Thus, a certain degree of diagnostic bias cannot be ruled out. Third, due to lacking 
diagnostic guidelines or clinically measurable parameters, rosacea is diagnosed 
based on visible symptoms and by exclusion of other diseases. Such GP-diagnosed 
diseases are difficult to validate because most usual options for a case validation are 
not available, such as sending for referral letters, hospital discharge letters, or 
questionnaires. The observed overlap of rosacea and acne diagnoses around the ID 
might represent some degree of diagnostic uncertainty or misclassification of 
disease. However, a cross-sectional study analysing dermatology patient data from 
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South-East Scotland revealed a concordance of rosacea diagnoses of dermatologists 
and the referring GPs of 74%.111 The fact that only 7.3% of all patients with rosacea 
were referred to a dermatologist, most probably those with an uncertain or more 
complicated diagnosis, allows us to assume an overall high validity of rosacea 
diagnoses in the GPRD. Finally, we could not control for ethnic background, skin 
pigmentation, socioeconomic status (e.g. income, education), or lifestyle factors such 
as sun exposure, profession or nutrition as these parameters are not recorded in the 
GPRD.41, 47, 52, 72, 78-80 We were also not in a position to distinguish between 
erythematotelangiectatic and papulopustular rosacea, which may cause 
overdiagnosis of the disease as chronic actinic damage such as heliodermatitis is not 
always distinguishable from erythematotelangiectatic rosacea, in the absence of 
inflammatory lesions.47, 85 Despite these limitations, this is - to our knowledge - the 
first epidemiological study on rosacea using UK-based primary care data, and by far 
the largest study to focus on the characteristics of patients with rosacea, including an 
analysis on the impact of alcohol consumption and cigarette smoking on the risk of 
incident rosacea. 
In summary, this large observational study describes the epidemiology of rosacea in 
a large sample of the UK population and quantifies the presence of ocular 
involvement in this skin disease. Our findings suggest that smoking may substantially 
reduce the risk of developing rosacea, whereas alcohol consumption is associated 
with only a small increase in risk.  
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3.2.1 Abstract 
Background: Rosacea is a common skin disease, involving neurogenic inflammation 
and neurovascular dysregulation. Migraine has been associated with vascular 
changes and sterile inflammation. The 2 diseases have been associated over 
decades, but evidence is scarce. Triptans have vasoconstricting and 
antiinflammatory properties, but a potential impact of this drug class on rosacea 
remains uninvestigated.  
Objective: We sought to analyze the association between migraine or triptan 
exposure and the risk of developing rosacea within the UK.  
Methods: We conducted a case-control study using the UK-based General Practice 
Research Database (GPRD). We identified patients with incident rosacea between 
1995 and 2009 (cases), and matched one rosacea-free control subject to each case. 
We compared the prevalence of diagnosed migraine and exposure to triptans before 
the first-time rosacea diagnosis between cases and controls using multivariate 
conditional logistic regression.  
Results: Among 53,927 cases and 53,927 controls, we observed a small overall 
association between rosacea and migraine in women (adjusted OR 1.22, 95% CI 
1.16-1.29), but not in men. This effect was somewhat more distinct in female 
migraineurs aged 50 to 59 years (OR of 1.36, 95% CI 1.21-1.53). Female triptan 
users also revealed slightly increasing risk estimates with increasing age, with the 
highest OR of 1.66 (95% CI 1.30-2.10) in women of ≥60 years. 
Limitations: This is a retrospective case-control study, for which a certain degree of 
bias and confounding cannot be ruled out.  
Conclusions: We observed a slightly increased risk for female migraineurs to develop 
rosacea, particularly in women with severe migraine aged 50 years or older.  
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3.2.2 Introduction 
Rosacea is a chronic facial skin disease, with neurovascular dysregulation and 
neurogenic inflammation as presumed pathophysiologic key components.1, 47, 56, 70 
Like rosacea, migraine is thought to involve neurovascular dysregulation and 
neurogenic inflammation.112-114 Despite scarce evidence, the 2 diseases have been 
associated over decades,41, 47 but previous results range from an overall strong 
association between rosacea and migraine to an association confined to 
postmenopausal women.41, 61- 63, 115 Triptans, selective serotonin agonists, are 
indicated for treatment of acute migraine headache. Besides cerebral 
vasoconstriction, triptans are supposed to inhibit neurogenic inflammation, and 
transmission of nociceptive impulses.112, 116-120 We were interested in assessing 
whether triptans or ergot derivatives may have a beneficial effect on the risk of 
developing rosacea by either mechanism, an association which, to our knowledge, 
has not been reported yet. We conducted a large population-based case-control 
study to explore the association between migraine, use of triptans and ergot 
derivatives, and the risk of developing rosacea within the UK.  
 
3.2.3 Materials and Methods 
Study design and data source 
We conducted a matched case-control analysis using data from the UK-based 
GPRD. The GPRD was established in 1987 and is a large source of primary-care 
data comprising approximately 7 million patients who are enrolled with selected 
general practitioners (GPs) across the UK. In the UK, GPs hold a gatekeeper role 
within the National Health System (NHS). After referrals, consultants are required to 
send information on outpatient diagnoses and treatments to the GP who enters this 
information into the database and takes over long-term care. The GPs have been 
trained to provide clinical data in a standardized format. Participating practices 
provide information on patient demographics and characteristics (e.g. age, sex, 
height, weight, smoking status), symptoms or medical diagnoses, laboratory test 
results, referrals to secondary care, and drug prescriptions, which are directly 
generated by the computer, ensuring a complete and anonymous drug history. The 
Medicines and Healthcare Products Regulatory Agency (MHRA) checks the raw data 
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before release and performs quality-control checks on the comprehensiveness and 
validity of data recording by GPs. The patients enrolled in the GPRD are 
representative of the UK population with regard to age, sex, geographic distribution, 
and annual turnover rate. Extensive validation of the GPRD99, 100 has documented its 
high validity, especially for chronic conditions.99, 121 The database has been the 
source of numerous pharmacoepidemiologic studies and of public health and disease 
epidemiology studies.101, 121 The study protocol was approved by the Independent 
Scientific Advisory Committee for MHRA database research. 
Cases and controls  
Cases were all patients with a first-time recorded medical Read-code for rosacea99 at 
any age between January 1995 and September 2009. We excluded patients with 
less than 3 years of recorded active history in the database before the date of their 
first-time rosacea diagnosis (subsequently referred to as index date) to increase the 
likelihood of only including incident cases. Patients with a diagnosis for rhinophyma 
only or ocular rosacea only were not included. We also excluded all patients with a 
recorded specific Read-code for alcohol addiction or alcohol abuse, cancer (except 
nonmelanoma skin cancer), or HIV / AIDS before the index date. The same exclusion 
criteria were applied to rosacea-free controls as to cases. In addition, control patients 
were not eligible if they had rhinophyma (without facial rosacea) or flushing 
symptoms recorded at any time.  
We randomly identified 1 control for each case patient matched on age (year of 
birth), sex, general practice, calendar time (index date), and number of years of 
recorded history in the database prior to the index date.  
Exposure 
Exposure was defined as a diagnosis of migraine (using Read-codes consistent with 
International Statistical Classification of Diseases, 10th Revision codes for migraine) 
at any time before the index date. The validity of migraine diagnoses in the GPRD 
has been shown to be more than 72% with diagnosed migraineurs presenting 1 or 
more symptoms mentioned in the International Classification of Headache Disorders 
of the International Headache Society.122 Exposure to triptans was assessed 
irrespective of an underlying migraine diagnosis. Triptans are indicated in the UK for 
migraine exclusively, except for the subcutaneous application of sumatriptan, which 
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is also indicated for cluster headache. Only 84 of 1,590 triptan users had a record for 
cluster headache, of which 69 also had a migraine diagnosis. Drug exposure was 
defined as a minimum of one prescription for a triptan prior to the index date. The 
same was done to assess exposure to ergot derivatives.  
Case-control analysis 
We conducted 2 separate analyses using 2 different models. In 1 analysis we 
compared the likelihood of having a recorded diagnosis of migraine, and in the other 
we compared exposure to triptans as well as to ergot derivatives before the index 
date between cases and controls. Results are presented according to sex and 
different age groups. We further stratified use of triptans or ergot derivatives 
according to exposure duration, categorizing patients by the number of drug 
prescriptions into groups of 0, 1 to 3, or greater than or equal to 4 prescriptions. 
Because triptans are prescribed as stand-by drugs, timing of drug exposure could not 
be assessed, as the date of prescription rarely represents the actual date of drug 
intake. Finally, we compared the prevalence of tension-type headache, cluster 
headache, and unspecified headache between cases and controls before the index 
date.  
Statistical analysis 
We conducted multivariate conditional logistic regression analyses using SAS 
statistical software (version 9.2, SAS Institute, Inc., Cary, NC, US). Relative risk 
estimates were calculated as odds ratios (ORs) with 95% confidence intervals (CIs). 
We implemented several measures to account for potential confounding, bias, and 
effect modification. Our study population was matched on age, sex, general practice, 
calendar time (index date), and number of years on the database before the index 
date. To assess potential interactions we stratified drug use according to timing and 
duration of drug exposure. In the multivariate model, we adjusted all ORs for smoking 
(non, current, ex, unknown), alcohol consumption (0, 1-4, 5-9, 10-14, 15-24, or 25+ 
U/wk, or unknown), and for body mass index (<18.5, 18.5-24.9, 25.0-29.9, 30+ kg/m2, 
or unknown). We further tested for potential confounding by drugs used in acute 
migraine (i.e. acetylsalicylic acid [except platelet aggregation inhibition dosage], 
paracetamol, nonsteroidal antiinflammatory drugs) or for migraine prophylaxis in the 
UK (i.e. CCBs, valproate, BBs, monoamine reuptake inhibitors, oral contraception, or 
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hormone replacement therapy [HRT]),123 as well as for diseases previously 
associated with migraine (i.e. ischemic stroke / transient ischemic attack, myocardial 
infarction, diabetes mellitus, hypertension, depression, other affective disorders, 
epilepsy, or asthma).112, 122, 124-127 Because none of these variables changed the 
relative risk estimates for the association between migraine and rosacea by more 
than 10%, we did not include them in the final multivariate model. As an exception, 
we also adjusted all female strata above the age of 50 years for exposure to HRT 
before the index date.  
 
3.2.4 Results 
We identified a total of 53,927 rosacea cases and the same number of matched 
controls. Of those, 62.8% were female, and 54.4% were diagnosed between 30 and 
59 years of age. Table 3.2-1 provides the distribution of characteristics, lifestyle 
factors (smoking, body mass index, and alcohol consumption), comorbidities, and 
comedications of the study population.  
We observed a significantly decreased OR of 0.63 (95% CI 0.61-0.66) for rosacea in 
current smokers, whereas neither alcohol consumption nor body mass index were 
associated with rosacea. We recently published a detailed description of the study 
population including lifestyle factors.46 ORs for rosacea were slightly decreased in 
those with prior myocardial infarction (OR 0.88, 95% CI 0.80-0.97) and diabetes 
mellitus (OR 0.81, 95% CI 0.76-0.87), while opposed and unopposed HRT yielded 
ORs of 1.64 (95% CI 1.55-1.73) and of 1.48 (95% CI 1.39-1.57), respectively 
(females only).  
The distribution of diagnosed migraine in cases and controls is displayed in Table 
3.2-2, presented according to sex and age groups. In total, 4,803 patients with 
rosacea (8.9%) and 4,137 control subjects (7.7%) were given a diagnosis of 
migraine, resulting in an adjusted OR of 1.18 (95% CI 1.13-1.24). Of all identified 
migraineurs, 81.6% of cases were female. We calculated risk estimates for men and 
women within various age groups and observed ORs around 1 for men across all 
ages, and a marginal trend towards increasing ORs in women with increasing age, 
with the highest OR in women between 50 and 59 years of age (OR of 1.36, 95% CI 
1.21-1.53). 
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Exposure to triptans was recorded in 1,590 cases (3.0%) and in 1,246 controls 
(2.3%), revealing an adjusted OR of 1.30 (95% OR 1.20-1.40). Stratification 
according to exposure duration did not change the effect, with an OR of 1.28 (95% CI 
1.17-1.41) for patients with 1 to 3 prescriptions and of 1.31 (95% CI 1.16-1.49) for 
patients with 4 or more prescriptions. Again, we found ORs around unity for male 
patients across all ages, whereas ORs increased with increasing age in women, with 
the highest adjusted OR of 1.66 (95% CI 1.30-2.10) for women aged 60 years or 
older (Table 3.3-3). Further adjustment for use of HRT resulted in an OR of 1.51 
(95% CI 1.19-1.93). Overall, use of ergot derivatives was associated with a small risk 
increase of developing rosacea (adjusted OR 1.26, 95% CI 1.04-1.52). Stratification 
according to duration of drug use (0, 1-3, ≥4 prescriptions) did not change this 
observation (data not shown). In total, some 250 cases received ergot derivatives, 
which did not allow extensive stratification as with triptans.  
Finally, we observed 1,329 cases and 1,015 controls with a diagnosis for tension-
type headache before the index date (adjusted OR 1.33, 95% CI 1.22-1.44). Cluster 
headache was diagnosed in 284 cases and 256 controls before the index date 
(adjusted OR 1.12, 95% CI 0.94-1.32), and 9,893 cases and 8,441 controls had ever 
been given a diagnosis of unspecified headache at any time before the index date 
(adjusted OR 1.23, 95% CI 1.19-1.27). 
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Table 3.2-1: Distribution of demographics, life-style factors, co-morbidities, and co-medications in rosacea cases and controls in the UK 
  
Rosacea cases,  
No (%) (n=53,927) 
Rosacea-free controls,  
No (%) (n=53,927) OR crude (95%CI) OR adjusted* (95% CI) 
Sex 
        
male 20,048 (37.2) 20,048 (37.2)     
female 33,879 (62.8) 33,879 (62.8)  
Age (years) 
        
<20 6,630 (12.3) 6,626 (12.3)     
20-29 5,202 (9.7) 5,213 (9.7)     
30-39 8,586 (15.9) 8,576 (15.9)     
40-49 11,338 (21.0) 11,343 (21.0)     
50-59 9,410 (17.5) 9,403 (17.4)     
60-69 6,955 (12.9) 6,960 (12.9)     
70+ 5,806 (10.8) 5,806 (10.8)     
Alcohol consumption (units/week) 
    
  
non/ex 6,918 (12.8) 7,162 (13.3) 1.00 (ref.) 1.00 (ref.) 
current (units NA) 9,512 (17.6) 9,628 (17.9) 1.03 (0.98-1.07) 1.02 (0.98-1.07) 
1-4 9,641 (17.9) 9,168 (17.0) 1.12 (1.07-1.17) 1.10 (1.05-1.15) 
5-9 5,205 (9.7) 4,756 (8.8) 1.16 (1.10-1.23) 1.16 (1.10-1.22) 
10-14 4,477 (8.3) 3,906 (7.2) 1.22 (1.15-1.29) 1.23 (1.16-1.30) 
15-19 1,041 (1.9) 883 (1.6) 1.26 (1.15-1.39) 1.29 (1.17-1.42) 
20+ 3,421 (6.3) 3,123 (5.8) 1.17 (1.10-1.25) 1.22 (1.14-1.30) 
unknown 13,712 (25.4) 15,301 (28.4) 0.84 (0.80-0.88) 0.96 (0.91-1.02) 
Smoking status 
        
Non 27,475 (51.0) 25,031 (46.4) 1.00 (ref.) 1.00 (ref.) 
Current 7,635 (14.2) 10,660 (19.8) 0.64 (0.62-0.66) 0.63 (0.61-0.66) 
Ex 9,981 (18.5) 8,277 (15.4) 1.13 (1.09-1.17) 1.11 (1.07-1.15) 
Unknown 8,836 (16.4) 9,959 (18.5) 0.69 (0.66-0.72) 0.80 (0.76-0.85) 
BMI (kg/m2) 
        
12.0-18.5 905 (1.7) 953 (1.8) 0.88 (0.80-0.97) 0.94 (0.85-1.03) 
18.5-24.9 18,839 (34.9) 17,808 (33.0) 1.00 (ref.) 1.00 (ref.) 
25.0-29.9 13,146 (24.4) 12,291 (22.8) 1.01 (0.98-1.05) 1.00 (0.97-1.03) 
30.0-60.0 6,942 (12.9) 7,184 (13.3) 0.92 (0.88-0.95) 0.91 (0.87-0.94) 
Unknown 14,095 (26.1) 15,691 (29.1) 0.76 (0.73-0.79) 0.86 (0.83-0.91) 
Co-morbidities 
        
Myocardial infarction 824 (1.5) 923 (1.7) 0.88 (0.80-0.97)   
Ischemic stroke / TIA 897 (1.7) 973 (1.8) 0.92 (0.83-1.01)   
Diabetes mellitus 1,686 (3.1) 2,042 (3.8) 0.81 (0.76-0.87)   
Hypertension 7,235 (13.4) 7,411 (13.7) 0.97 (0.93-1.00)   
Depression 8,883 (16.5) 7,907 (14.7) 1.16 (1.12-1.20)   
Other affective disorders 1,624 (3.0) 1,424 (2.6) 1.15 (1.07-1.24)   
Epilepsy 1,102 (2.0) 1,152 (2.1) 0.96 (0.88-1.04)   
Asthma 8,264 (15.3) 7,722 (14.3) 1.09 (1.05-1.13)   
Co-medication 
        
CCB 4,409 (8.2) 4,427 (8.2) 1.00 (0.95-1.04)   
BB 8,978 (16.7) 8,319 (15.4) 1.11 (1.07-1.15)   
Acetylsalicylic acid 1,457 (2.7) 1,334 (2.5) 1.10 (1.02-1.19)   
Paracetamol 25,791 (47.8) 24,588 (45.6) 1.11 (1.09-1.14)   
NSAID 30,168 (55.9) 28,044 (52.0) 1.20 (1.17-1.23)   
Valproic acid 412 (0.8) 403 (0.8) 1.02 (0.89-1.17)   
Monoamine reauptake inhibitors 9,165 (17.0) 7,887 (14.6) 1.22 (1.18-1.26)   
COC (females only) 11,440 (33.8) 10,793 (31.9) 1.18 (1.13-1.23)   
HRT opposed (females only) 4,357 (12.9) 3,094 (9.1) 1.64 (1.55-1.73)   
HRT unopposed (females only) 3,193 (9.4) 2,341 (6.9) 1.48 (1.39-1.57)   
 
Abbreviations: BB, β-blocker; BMI, body mass indes; CCB, calicum channel blocker; CI, confidence interval; COC, comined oral contraception; HRT, hormone 
replacement therapy; NA, no answer; NSAID, nonsteroidal antiinflammaotry drugs; OR, odds ratio; TIA, transient ischemic attack 
* adjusted for smoking, BMI, alcohol consumption 
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Table 3.2-2: Distribution of diagnosed migraine stratified by age and gender in rosacea cases and controls in the UK 
  
Rosacea cases, 
No (%) (n=53,927) 
Rosacea-free controls, 
No (%) (n=53,927) OR crude (95%CI) OR adjusted* (95% CI) 
No Migraine 49,124 ( 91.1) 49,790 (92.3) 1.00 (ref.) 1.00 (ref.) 
Migraine 4,803 (8.9) 4,137 (7.7) 1.18 (1.13-1.24) 1.18 (1.13-1.24) 
By age (y)    
<40 1,868 (3.5) 1,665 (3.1) 1.14 (1.06-1.22) 1.14 (1.06-1.22) 
40-49 1,214 (2.3) 1,046 (1.9) 1.19 (1.09-1.30) 1.20 (1.09-1.31) 
50-59 951 (1.8) 757 (1.4) 1.29 (1.17-1.43) 1.29 (1.16-1.43) 
≥60 770 (1.4) 669 (1.2) 1.17 (1.05-1.30) 1.15 (1.03-1.29) 
Men by age (y) 886 (0.2) 861 (0.2) 1.03 (0.94-1.14) 1.04 (0.94-1.14) 
<40 378 (0.1) 380 (0.1) 0.99 (0.86-1.15) 0.99 (0.85-1.14) 
40-49 156 (0.0) 142 (0.0) 1.09 (0.86-1.38) 1.14 (0.89-1.45) 
50-59 166 (0.0) 158 (0.0) 1.05 (0.84-1.32) 1.06 (0.84-1.33) 
≥60 186 (0.0) 181 (0.0) 1.03 (0.84-1.27) 1.03 (0.83-1.27) 
Women by age (y) 3,917 (0.7) 3,276 (0.6) 1.23 (1.17-1.29) 1.22 (1.16-1.29) 
<40 1,490 (0.3) 1,285 (0.2) 1.18 (1.09-1.28) 1.19 (1.10-1.29) 
40-49 1,058 (0.2) 904 (0.2) 1.20 (1.09-1.33) 1.21 (1.09-1.33) 
50-59 785 (0.1) 599 (0.1) 1.36 (1.22-1.53) 1.36 (1.21-1.53) 
≥60 584 (0.1) 488 (0.1) 1.22 (1.07-1.38) 1.20 (1.05-1.36) 
 
Abbreviations: CI, confidence interval; OR= odds ratio. 
* adjusted for smoking, body mass index, alcohol consumption. 
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Table 3.2-3: Distribution of triptan exposure stratified by age, gender, and exposure duration (number of prescriptions) in rosacea cases and 
controls in the UK 
  
Rosacea cases,                
No (%) (n=53,927) 
Rosacea-free controls,  
No (%) (n=53,927) OR crude (95% CI) OR adjusted* (95% CI) 
No triptan Rxs  52,337 (97.1) 52,681 (97.7) 1.00 (ref.) 1.00 (ref.) 
Triptan Rxs 1,590 (3.0) 1,246 (2.3) 1.29 (1.20-1.40) 1.30 (1.20-1.40) 
By number of triptan 
Rxs 
        
1-3 980 (1.8) 776 (1.4) 1.28 (1.16-1.41) 1.28 (1.17-1.41) 
4+ 610 (1.1) 470 (0.9) 1.32 (1.17-1.49) 1.31 (1.16-1.49) 
 
By age (y) and by 
number of triptan Rxs     
<40 471 (0.9) 392 (0.7) 1.22 (1.06-1.40) 1.25 (1.09-1.43) 
1-3 356 (0.7) 311 (0.6) 1.17 (1.00-1.36) 1.20 (1.02-1.40) 
4+ 115 (0.2) 81 (0.2) 1.44 (1.08-1.91) 1.44 (1.08-1.92) 
40-49 491 (0.9) 404 (0.7) 1.24 (1.08-1.42) 1.24 (1.08-1.42) 
1-3 295 (0.5) 228 (0.4) 1.31 (1.10-1.56) 1.31 (1.09-1.56) 
4+ 196 (0.4) 176 (0.3) 1.14 (0.93-1.40) 1.14 (0.93-1.41) 
50-59 392 (0.7) 291 (0.5) 1.37 (1.17-1.61) 1.36 (1.16-1.59) 
1-3 206 (0.4) 156 (0.3) 1.33 (1.08-1.65) 1.31 (1.06-1.63) 
4+ 186 (0.3) 135 (0.3) 1.42 (1.13-1.78) 1.41 (1.12-1.77) 
≥60 236 (0.4) 159 (0.3) 1.49 (1.22-1.83) 1.51 (1.23-1.86) 
1-3 123 (0.2) 81 (0.2) 1.53 (1.15-2.02) 1.53 (1.15-2.04) 
4+ 113 (0.2) 78 (0.1) 1.46 (1.09-1.95) 1.48 (1.10-1.99) 
Men by age (y) and by 
number of triptan Rxs  202 (0.4) 191 (0.4) 
 
 
1.06 
 
 
(0.87-1.29) 
 
 
1.08 
 
 
(0.88-1.32) 
<40 65 (0.1) 44 (0.1) 1.48 (1.01-2.17) 1.50 (1.02-2.21) 
1-3 50 (0.1) 37 (0.1) 1.35 (0.88-2.07) 1.38 (0.90-2.13) 
4+ 15 (0.0) 7 (0.0) 2.14 (0.87-5.25) 2.13 (0.86-5.27) 
40-49 48 (0.1) 53 (0.1) 0.90 (0.61-1.34) 0.88 (0.59-1.33) 
1-3 34 (0.1) 38 (0.1) 0.89 (0.56-1.43) 0.87 (0.54-1.41) 
4+ 14 (0.0) 15 (0.0) 0.93 (0.45-1.93) 0.91 (0.43-1.92) 
50-59 47 (0.1) 52 (0.1) 0.90 (0.60-1.35) 0.94 (0.62-1.42) 
1-3 27 (0.1) 35 (0.1) 0.77 (0.47-1.27) 0.80 (0.48-1.34) 
4+ 20 (0.0) 17 (0.0) 1.20 (0.61-2.38) 1.26 (0.63-2.52) 
≥60 42 (0.1) 42 (0.1) 1.00 (0.65-1.53) 1.07 (0.69-1.65) 
1-3 27 (0.1) 22 (0.0) 1.23 (0.70-2.15) 1.28 (0.72-2.27) 
4+ 15 (0.0) 20 (0.0) 0.75 (0.39-1.47) 0.83 (0.42-1.64) 
Women by age (y) 
and by number of 
triptan Rxs 
 
 
1,388 (2.6) 1,055 (2.0) 
 
1.34 
 
 
(1.23-1.45) 
 
 
1.33 
 
 
(1.23-1.45) 
<40 406 (0.8) 348 (0.6) 1.19 (1.02-1.38) 1.21 (1.05-1.41) 
1-3 306 (0.6) 274 (0.5) 1.14 (0.96-1.35) 1.17 (0.99-1.39) 
4+ 100 (0.2) 74 (0.1) 1.37 (1.01-1.84) 1.37 (1.01-1.86) 
40-49 443 (0.8) 351 (0.7) 1.29 (1.12-1.49) 1.28 (1.11-1.49) 
1-3 261 (0.5) 190 (0.4) 1.39 (1.15-1.68) 1.39 (1.15-1.68) 
4+ 182 (0.3) 161 (0.3) 1.16 (0.94-1.45) 1.16 (0.93-1.44) 
50-59 345 (0.6) 239 (0.4) 1.48 (1.25-1.76) 1.44 (1.21-1.72) 
1-3 179 (0.3) 121 (0.2) 1.51 (1.19-1.91) 1.46 (1.15-1.86) 
4+ 166 (0.3) 118 (0.2) 1.46 (1.15-1.85) 1.42 (1.11-1.82) 
≥60 194 (0.4) 117 (0.2) 1.68 (1.33-2.12) 1.66 (1.30-2.10) 
1-3 96 (0.2) 59 (0.1) 1.65 (1.19-2.28) 1.62 (1.16-2.25) 
4+ 98 (0.2) 58 (0.1) 1.71 (1.23-2.39) 1.70 (1.21-2.37) 
 
Abbreviations: CI, confidence interval; OR, odds ratio; Rx, prescription.    
* adjusted for smoking, BMI, alcohol consumption 
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3.2.5 Discussion 
In this large case-control analysis we observed slightly increased ORs for incident 
rosacea among patients with diagnosed migraine, and in patients with previous 
exposure to triptans or ergot derivatives. We found ORs around unity across all age 
groups for men, whereas women, particularly those with exposure to triptans, were at 
a slightly increased relative risk of developing rosacea at older ages. Duration of 
triptan or ergot derivative exposure did not change the risk estimates. 
Tan and Cunliffe62 first described a strong overall association between migraine and 
rosacea in 1976 (44% in cases vs. 13% in controls) in a study including 137 cases. In 
1994, Ramelet61  reported an association of rosacea and migraine in women only in 
48 patients with papulopustular rosacea (44% in women vs. 10% in men). Although 
we also observed slightly increased ORs among female migraineurs, the effect size 
was too small to suggest a clinically relevant association. Furthermore, we could not 
distinguish between papulopustular and erythematotelangiectatic rosacea on the 
GPRD. Female migraine patients aged 50 years or older, mainly those with exposure 
to triptans, yielded a somewhat increased rosacea risk. This finding is consistent with 
results of a cross-sectional study (809 office employees) by Berg and Liden, which 
described a significantly increased co-occurrence of rosacea and migraine in 
postemenopausal female rosacea patients only.41, 63 The fact that the risk increase 
was stronger in female triptan users aged 50 years or older than in migraineurs of the 
same age overall, could either reflect an actual drug effect, or the severity of the 
underlying migraine (>80% of triptan users were previously diagnosed with migraine). 
Considering that patients with migraine using prescription medication tend to have 
more severe migraines, and that a previous GPRD study suggested triptan use as 
proxy for migraine recency and severity, such channelling bias seems likely.128-130 In 
addition, a dose-response effect of triptans, a potential indicator for a drug effect, was 
not observed. Nevertheless, we cannot explain why ORs were increased in female 
triptan users aged 60 years or older, whereas female migraineurs overall yielded a 
slight trend in 50- to 59-year-old women only. The migraine subtype with aura has 
been associated with certain comorbidities (i.e. cardiovascular / psychiatric) and with 
all-cause mortality. Furthermore, migraine with aura has been shown to be 
overrepresented among patients with diagnosed migraine and to be more prevalent 
in women (10%) than in men (5%).113, 125, 127, 131-133 Thus, although we could not 
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differenciate between the 2 migraine subtypes (>90% of migraine records fell on 1 
unspecific Read-code), the aura subtype might contribute to the increased ORs in 
women. However, it does not explain why the effect was only observed at age50 
years or older; while hormonal and vascular changes or some other factors might 
play a role,134 we are also aware that such a small risk increase could be explained 
by chance, uncontrolled bias, confounding, or multiple comparisons in the analyses.  
Use of ergot derivatives overall was associated with a slight risk increase, but 
causality remains uncertain considering potential residual confounding. In addition, it 
seems that ergot derivatives are not often used in the UK anymore, as about 80% of 
prescriptions dated back more than 2 years. 
Although this observational study is based in a large and high quality primary-care 
database, several limitations have to be considered. First, we may be missing some 
migraine and rosacea patients due to underdiagnosis. Based on a study from the US, 
approximately half of all migraine patients remain without a diagnosis.129, 131, 135 
However, although we most likely included the more severe cases and still no effect 
was found, material bias is unlikely.111, 113, 126, 129 While we may have missed some 
rosacea cases, a 74% concordance of rosacea diagnoses between dermatologists 
and the referring GPs has been shown in a study from South-East Scotland,111 
providing reassurance that the validity of rosacea diagnoses for included cases in the 
GPRD is sufficient. Second, we previously showed an overlap of rosacea and acne 
diagnoses around the index date among patients younger than 20 years, which might 
indicate diagnostic uncertainty.46 Migraine has been reported to be underdiagnosed 
in children and adolescents.136 This potential diagnostic bias has to be considered 
when interpreting our results. Third, the likelihood of being diagnosed with rosacea 
may increase with increasing medical attention. Previous GPRD studies showed that 
migraine patients saw the GP significantly more often than patients without 
migraine,122 and that rosacea cases have a higher number of GP visits before the 
index date than control subjects.46 However, as we only observed a weak association 
of rosacea and migraine, diagnostic bias seems unlikely to play a substantial role. 
Finally, we could not control for ethnic background, socioeconomic status (e.g. 
income, education), skin pigmentation, or lifestyle factors such as sun exposure, 
profession, or nutrition, as these parameters are not routinely recorded in the GPRD. 
We also were not in a position to account for severity of rosacea, or to distinguish 
between erythematotelangiectatic and papulopustular rosacea. The latter may cause 
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an overdiagnosis of rosacea, as chronic actinic damage such as heliodermatitis is not 
always distinguishable from the erythematotelangiectatic subtype in the absence of 
inflammatory lesions.47, 85 Despite these limitations, this is – to our knowledge – by 
far the largest study on the association of rosacea and migraine, and the first study to 
assess a potential impact of triptans and ergot derivatives on the risk of developing 
rosacea.  
In summary, this large case–control study provides evidence that the overall risk of 
developing rosacea is not materially increased in patients with migraine, an 
association which has been controversially discussed over decades. However, while 
ORs for men remained around 1.0 across all age groups, female migraineurs older 
than 50 years, particularly those with more severe migraine, had a slightly, but 
statistically significantly increased risk for incident rosacea. Exposure to triptans 
seems to represent a proxy for disease severity.  
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3.3.1 Abridged report 
Rosacea is a chronic facial skin disease, with neurovascular dysregulation and 
neurogenic inflammation as presumed pathogenic key factors.1 Spironolactone is 
recommended as an off-label treatment for rosacea, despite scarce evidence of 
efficacy 47, 137 (http://www.cks.nhs.uk/rosacea/management/scenario_rosacea#335 
449004, accessed 04 March 2013) Using the UK-based General Practice Research 
Database (GPRD99), we conducted a large population-based case-control analysis, 
including patients with a first-time diagnosis of rosacea (index date) between 
January 1995 and September 2009. We excluded patients with recorded alcoholism, 
cancer, or HIV, and patients with <3 years of recorded active history before the index 
date. Patients with diagnosed rhinophyma or ocular rosacea only were excluded. We 
randomly matched one control to each case on age, sex, general practice, calendar 
time, and number of previous years of recorded history in the database, and applied 
the same exclusion criteria to controls as to cases. The study protocol was approved 
by the Independent Scientific Advisory Committee (ISAC) for MHRA database 
research. We assessed use of diuretics (including combined products) before the 
index date, classified according to the WHO ATC index (http://www.whocc.no/atc_ 
ddd_index/?code=C03, accessed 27 December 2012) into low-ceiling diuretics, high-
ceiling diuretics, and potassium sparing agents (spironolactone vs. 
amiloride/triamterene). We stratified drug use by timing (last prescription ≤ or >180 
days before the index date) and duration of use (number of prescriptions before the 
index date). To account for confounding by indication, we performed two sensitivity 
analyses; in the first model, we classified spironolactone users into those with or 
without a previous diagnosis of acne, seborrhea, hirsutism, or androgenic alopecia 
(dermatologic off-label indications for spironolactone), overall and stratified by 
exposure duration (further stratified by gender).137 In the second model, we classified 
current spironolactone users into patients with or without concomitantly (≤180 days) 
prescribed cardiovascular drugs, such as ACE inhibitors, angiotensin receptor 
blockers, BBs, CCBs, thiazide- or loop diuretics, and nitrates (i.e. likely 
cardiovascular indication vs. likely dermatologic indication). We conducted 
multivariate conditional logistic regression analyses using SAS statistical software 
(version 9.3, SAS Institute, Inc., Cary, NC, US), and calculated odds ratios (ORs) 
with 95% confidence intervals (CIs). We adjusted all ORs for smoking (non, current, 
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ex, unknown), alcohol consumption (0, 1-4, 5-9, 10-14, 15-24, or 25+ units per week, 
or unknown), and body mass index (<18.5, 18.5-24.9, 25.0-29.9, 30+ kg m-2, or 
unknown). Each diuretic drug class was adjusted for other diuretics and for drug 
classes contained in combined products, if applicable. Because other potential 
confounders, i.e. cardiovascular drugs (ACE inhibitors, angiotensin receptor 
blockers, CCBs, BBs and statins), anti-androgenic drugs, HRT, or cardiovascular 
comorbidities (hypertension, myocardial infarction, heart failure, ischemic stroke / 
transient ischemic attack, ischemic heart disease, diabetes mellitus, and 
hyperlipidemia) did not alter the relative risk estimates for the association between 
use of diuretics or spironolactone and rosacea by ≥10%, we did not include them in 
the final model.  
The study population’s demographics and methodology including limitations have 
been described in detail elsewhere.46 Among 53,927 rosacea cases and the same 
number of controls, 8372 (15.5%) cases and 7926 (14.7%) controls had ≥1 recorded 
prescription for a diuretic drug before the index date (Table 3.3-1). While high-ceiling 
diuretics, low-ceiling diuretics, and amiloride/triamterene yielded ORs around 1.0 
across all strata, spironolactone use (281 cases, 327 controls) revealed an overall 
adjusted OR of 0.83 (95% CI 0.70-0.98), which dropped to an OR of 0.47 (95% CI 
0.35-0.63) in current users at the index date. At an α-level of 0.05 and a current 
spironolactone exposure prevalence of 0.5% among cases, the statistical power to 
detect an OR of 0.5 is 99%. We observed an OR of 0.39 (95 % CI 0.27-0.54) in 
current spironolactone users without a previous diagnosis for an androgenic skin 
disease (Table 3.3-2). This finding was consistent in men and women (Table 3.3-3, 
supplementary). We further observed an OR of 0.39 (95% CI 0.24-0.64) in current 
long-term spironolactone users with concomitant cardiovascular medication, 
whereas patients without such medication revealed an overall OR of 0.68 (95% CI 
0.35-1.32). 
While the decreased relative risks suggest that rosacea develops at a substantially 
decreased rate during spironolactone exposure, the mechanism remains unclear. As 
no other class of diuretics affected the risk estimate, a diuretic drug effect is an 
unlikely cause for the observed effect. Spironolactone is an aldosterone receptor 
antagonist with anti-androgenic properties (inhibition of androgen production and 
antagonism at the androgen receptor). Oral spironolactone has been proposed as 
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rosacea treatment, based on beneficial results of a small uncontrolled clinical trial in 
Japanese men. The authors hypothesized an inhibition of skin specific cytochromes 
underlying the observed effect.66 Androgenic sebaceous stimulation has been 
discussed controversially with regard to rosacea.47, 138, 139 Besides sebaceous 
activities, the androgen receptor has been linked to delayed wound repair, enhanced 
epidermal hyperplasia and collagen formation, pro-inflammatory properties, and an 
inhibitory effect on immune functions.140, 141 Furthermore, activation of the 
aldosterone receptor (expressed in human skin) promotes inflammation, which is 
blocked by spironolactone.142, 143 Evidence also emerged for a nonreceptor-mediated 
vasodilatory androgen effect.144 Sensitivity analyses revealed decreasing ORs with 
increasing confidence of diagnostic accuracy and of unbiased indication (i.e. in 
patients with a likely cardiovascular context and in patients without certain 
dermatologic co-diagnoses). However, although we accounted for such bias, some 
residual confounding by indication or chance cannot be ruled out. To our knowledge, 
this is the largest study on the association between spironolactone and rosacea. We 
are not aware of previous studies reporting a spironolactone effect on rosacea in 
women or a potential association between other diuretics and rosacea. As a certain 
efficacy in treating dermatologic diseases with topically applied spironolactone has 
been shown, local spironolactone application might be a promising approach for the 
treatment of rosacea.137, 145, 146 
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Table 3.3-1: Distribution of diuretic exposure stratified by timing and duration of drug use in rosacea cases and controls in the UK 
  
Rosacea cases,  
No (%) (n=53,927) 
Rosacea-free controls 
No (%) (n=53,927) 
OR 
crude (95% CI) OR adj.* (95% CI) 
No high-ceiling diuretics 50,817 (94.2) 50,990 (94.6) (1.0) (ref.) (1.0) (ref.) 
Use of high-ceiling diuretics 3,110 (5.8) 2,937 (5.5) 1.07 (1.01-1.13) 1.06 (0.99−1.13) 
Duration (Nr of prescriptions) 
  1-19 2,184 (4.1) 1,971 (3.7) 1.12 (1.05−1.19) 1.09 (1.02−1.17) 
  20-39 391 (0.7) 432 (0.8) 0.91 (0.79−1.05) 0.89 (0.77−1.03) 
  40+ 535 (1.0) 534 (1.0) 1.02 (0.90−1.15) 0.98 (0.85−1.11) 
Timing (180d) 
        
  Current 1,331 (2.5) 1,444 (2.7) 0.93 (0.86−1.01) 0.88 (0.81−0.96) 
  Past 1,779 (3.3) 1,493 (2.8) 1.20 (1.12−1.29) 1.18 (1.09−1.27) 
No low-ceiling diuretics 47,428 (88.0) 47,811 (88.7) (1.0) (ref.) (1.0) (ref.) 
Use of low-ceiling diuretics 6,499 (12.1) 6,116 (11.3) 1.09 (1.04−1.13) 1.07 (1.02−1.12) 
Duration (Nr of prescriptions) 
  1-19 3,877 (7.2) 3,417 (6.3) 1.15 (1.10−1.21) 1.13 (1.07−1.19) 
  20-39 1,241 (2.3) 1233 (2.3) 1.03 (0.95−1.11) 1.00 (0.92−1.09) 
  40+ 1,381 (2.6) 1466 (2.7) 0.96 (0.88−1.04) 0.93 (0.85−1.01) 
Timing (180d) 
        
  current 3,225 (6.0) 3,255 (6.0) 1.01 (0.96-1.07) 0.99 (0.94-1.05) 
  past 3,274 (6.1) 2,861 (5.3) 1.17 (1.11-1.23) 1.15 (1.09-1.22) 
No Amiloride/Triamterene 52,128 (96.7) 52,278 (96.9) (1.0) (ref.) (1.0) (ref.) 
Use of Amiloride/Triamterene 1,799 (3.3) 1,649 (3.1) 1.11 (1.03-1.19) 1.07 (0.99-1.16) 
Duration (Nr of prescriptions) 
  1-19 1,162 (2.2) 1,038 (1.9) 1.13 (1.04-1.23) 1.09 (0.99-1.20) 
  20-39 259 (0.5) 269 (0.5) 0.98 (0.82-1.17) 0.95 (0.79-1.14) 
  40+ 378 (0.7) 342 (0.6) 1.12 (0.96-1.30) 1.08 (0.93-1.27) 
Timing (180d) 
        
  current 552 (1.0) 529 (1.0) 1.06 (0.94-1.20) 1.01 (0.88-1.15) 
  past 1,247 (2.3) 1,120 (2.1) 1.13 (1.04-1.23) 1.10 (1.00-1.20) 
No Spironolactone 53,646 (99.5) 53,600 (99.4) (1.0) (ref.) (1.0) (ref.) 
Use of Spironolactone 281 (0.5) 327 (0.6) 0.86 (0.73-1.01) 0.83 (0.70-0.98) 
Duration (Nr of prescriptions) 
  1-19 232 (0.4) 244 (0.5) 0.95 (0.79-1.13) 0.93 (0.77-1.12) 
  20-39 30 (0.1) 51 (0.1) 0.59 (0.37-0.92) 0.54 (0.34-0.85) 
  40+ 19 (0.0) 32 (0.1) 0.59 (0.34-1.04) 0.57 (0.32-1.01) 
Timing (180d) 
        
  current 67 (0.1) 134 (0.3) 0.49 (0.37-0.66) 0.47 (0.35-0.63) 
  past 214 (0.4) 193 (0.4) 1.11 (0.91-1.36) 1.09 (0.89-1.33) 
Abbreviations: adj., adjusted; CI, confidence interval; OR, odds ratio. 
 
Percentages are rounded to the nearest tenth digit. 
*
 adjusted for smoking, BMI, alcohol consumption, complementary diuretic drug classes, drug classes contained in combined products. 
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Table 3.3-2: Use of Spironolactone in rosacea cases and controls, after controlling for confounding by indication  
 
Rosacea cases, No (%) 
(n=53,927) 
Rosacea-free controls 
No (%) (n=53,927) 
OR 
crude (95% CI) OR adj.* (95% CI) 
No Spironolactone 53,646 (99.5) 53,600 (99.4) 1.00 (ref.) 1.00 (ref.) 
Spironolactone with A/S/H/A 91 (0.2) 32 (0.1) 2.82 (1.89-4.22) 2.91 (1.94-4.37) 
Spironolactone without A/S/H/A 190 (0.4) 295 (0.6) 0.64 (0.53-0.77) 0.65 (0.54-0.78) 
Duration (Nr of prescriptions)  
  1-19 153 (0.3) 217 (0.4) 0.70 (0.57-0.86) 0.72 (0.59-0.90) 
  20+ 37 (0.1) 78 (0.1) 0.47 (0.32-0.70) 0.46 (0.31-0.68) 
Timing (180d) 
        
  current 47 (0.1) 123 (0.2) 0.38 (0.27-0.53) 0.39 (0.27-0.54) 
  past 143 (0.3) 172 (0.3) 0.83 (0.66-1.04) 0.85 (0.67-1.07) 
Current spironolactone with 
cardiovascular co-medication  52 (0.1) 112 (0.2) 0.46 (0.33-0.64) 0.46 (0.33-0.65) 
Duration (Nr of prescriptions) 
1-19 30 (0.1) 57 (0.1) 0.51 (0.33-0.80) 0.54 (0.34-0.85) 
20+ 22 (0.0) 55 (0.1) 0.40 (0.24-0.65) 0.39 (0.24-0.64) 
Current spironolactone without 
cardiovascular co-medication 15 (0.0) 22 (0.0) 0.68 (0.35-1.31) 0.68 (0.35-1.32) 
Abbreviations: adj., adjusted; A/S/H/A, acne/seborrhea/hirsutism/alopecia; CI, confidence interval. 
Percentages are rounded to the nearest tenth digit. 
*
 adjusted for smoking, BMI, alcohol consumption, complementary diuretic drug classes, drug classes contained in combined products 
 
 
Table 3.3-3: Use of Spironolactone in rosacea cases and controls, after controlling for confounding by indication  
Women 
Rosacea cases, 
No (%) (n=53,927) 
Rosacea-free controls, 
No (%) (n=53,927) 
OR 
crude (95% CI) 
OR 
adj.* (95% CI) 
No Spironolactone 53,646 (99.5) 53,600 (99.4) 1.00 (ref.) 1.00 (ref.) 
Spironolactone with A/S/H/A 79 (0.2) 27 (0.1) 2.91 (1.881-4.51) 2.97 (1.92-4.61) 
Spironolactone without A/S/H/A 142 (0.4) 202 (0.6) 0.70 (0.56-0.87) 0.70 (0.56-0.87) 
Duration 
        
  1-19 113 (0.3) 146 (0.4) 0.77 (0.60-0.98) 0.79 (0.62-1.02) 
  20+ 29 (0.1) 56 (0.2) 0.52 (0.33-0.81) 0.51 (0.33-0.80) 
Timing (180d) 
        
  current 31 (0.1) 83 (0.2) 0.37 (0.24-0.56) 0.38 (0.25-0.57) 
  past 111 (0.3) 119 (0.4) 0.93 (0.72-1.22) 0.95 (0.73-1.25) 
Men  
            
    
  Spironolactone with A/S/H/A 12 (0.1) 5 (0.0) 2.32 (0.82-6.60) 2.35 (0.81-6.78) 
  Spironolactone without 
A/S/H/A 48 (0.2) 93 (0.5) 0.51 (0.36-0.73) 0.53 (0.37-0.75) 
Duration 
        
  1-19 40 (0.2) 71 (0.4) 0.56 (0.38-0.83) 0.59 (0.40-0.87) 
  20+ 8 (0.0) 22 (0.1) 0.36 (0.16-0.80) 0.36 (0.15-0.76) 
Timing (180d) 
        
  current 16 (0.1) 40 (0.2) 0.41 (0.23-0.72) 0.41 (0.23-0.74) 
  past 32 (0.2) 53 (0.3) 0.60 (0.38-0.93) 0.61 (0.39-0.96) 
Abbreviations: adj., adjusted; A/S/H/A,  Acne/Seborrhea/Hirsutism/Alopecia; CI, confidence interval; OR, odds ratio  
*
 adjusted for smoking, BMI, alcohol consumption, complementary diuretic drug classes, drug classes contained in combined products 
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3.4.1 Abridged report 
Rosacea is a chronic facial skin disease with a presumed key vasodilatory 
component,1 whereas diabetes mellitus (DM) is associated with impaired 
vasodilation congruent with the degree of endothelial dysfunction. Insulin is a 
physiologic regulator of the vascular tone, but in the insulin-resistant state insulin 
increases vasoconstriction.21, 71, 117, 147-149 Using the UK-based General Practice 
Research Database,99  we conducted a large population-based case-control 
analysis, including patients with a first-time rosacea diagnosis (index date) between 
January 1995 and September 2009. We excluded patients with recorded alcoholism 
(explicit medical Read-code), cancer, or HIV, and patients with <3 years of recorded 
active history before the index date. Patients with diagnosed rhinophyma or ocular 
rosacea in the absence of another record of facial rosacea were excluded. We 
randomly matched one control to each case on age, sex, general practice, calendar 
time, and number of previous years of history in the database, and applied the same 
exclusion criteria to controls as to cases. The study protocol was approved by the 
Independent Scientific Advisory Committee (ISAC) for MHRA database research. 
Disease exposure was defined as a DM diagnosis (validity proven elsewhere99, 150) 
before the index date. Among DM patients, we captured the last HbA1c value before 
the index date, stratified into 4 categories (none, ≤7.5%, 7.6-10.9%, or ≥11%). DM 
duration was stratified into 6 categories by the number of years between the first 
recorded prescription of any antidiabetic drug and the index date (no treatment, <1, 
1-3, 3-5, 5-10, 10+ years), sub-stratified by HbA1c levels (≤7.5% or >7.5%). We 
analyzed antidiabetic drug use (insulin vs. other antidiabetic drugs) stratified by 
timing (≤ or > 180 days before the index date) and duration of use (number of 
prescriptions before the index date). Within a mutually exclusive drug use model 
among diagnosed diabetics we assessed insulin exposure (irrespective of any OAD 
use) and OAD exposure alone (no insulin exposure at any time), stratified by timing 
and duration of drug use and by HbA1c levels. We conducted multivariate conditional 
logistic regression analyses using SAS statistical software (version 9.3, SAS 
Institute, Inc., Cary, NC, US), and calculated ORs with 95% CIs. We adjusted all 
ORs for smoking (non, current, ex, unknown), alcohol consumption (0, 1-4, 5-9, 
10-14, 15-24, or 25+ units per week, unknown), and body mass index (<18.5, 18.5-
24.9, 25.0-29.9, or 30+ kg m-2, unknown). Because other potential confounders, i.e. 
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depression, cardiovascular diseases (hypertension, myocardial infarction, 
hyperlipidemia, heart failure, ischemic heart disease, ischemic stroke / transient 
ischemic attack), cardiovascular drugs (CCBS, BBs, ACE inhibitors, angiotensin 
receptor blockers, statins, acetylsalicylic acid (anticlotting dosage), vitamin K 
antagonists, and diuretics), systemic steroids, and NSAIDs did not alter the relative 
risk estimates for the association between DM or insulin and rosacea by ≥10%, we 
did not include them in the final model. 
The study population’s demographics and methodology including limitations have 
been described in detail elsewhere.46 Of 53,927 rosacea cases and the same 
number of controls, 1,686 (3.1%) cases and 2,042 (3.8%) controls had a recorded 
DM diagnosis revealing an OR of 0.80 (95% CI 0.74-0.85), which further decreased 
with increasing HbA1c values (OR 0.57, 95% CI 0.41-0.79, HbA1c ≥11%) and with 
increasing disease duration (OR 0.64, 95% CI 0.54-0.78, disease duration ≥10 
years, Table 3.4-1). At earlier disease stages, we observed decreased ORs in poorly 
controlled diabetics (HbA1c >7.5%), whereas a disease history of ≥5 years revealed 
decreased ORs irrespective of blood glucose control (Table 3.4-4, supplementary). 
Exposure to any antidiabetic drug was associated with a decreased OR of 0.76 (95% 
CI 0.71-0.83). The prevalence of insulin exposure was higher in controls (1.1%) than 
in cases (0.7%), yielding an OR of 0.75 (95% OR 0.65-0.85), unchanged across 
strata of timing and duration of insulin exposure. OAD exposure was also slightly 
more prevalent in controls (2.6%) than in cases (2.1%, OR 0.83, 95% CI 0.76-0.91), 
again independent of timing and duration of drug exposure (Table 3.4-3, 
supplementary). The mutually exclusive drug use model (Table 3.4-2) yielded 
significantly decreased ORs for insulin users, irrespective of HbA1c control. OAD use 
in the absence of insulin was associated with decreased ORs at HbA1c levels >7.5%, 
but non-significant results at HbA1c levels ≤7.5%. 
Our findings suggest a decreased rosacea risk in DM patients at an advanced 
disease state, i.e. in patients with high HbA1c levels and / or long disease duration. 
The underlying mechanism remains to be clarified; we hypothesize a reciprocal link 
of the two diseases via the degree of endothelial dysfunction and thus impaired 
vasodilation. Extrinsic insulin exposure revealed significantly decreased ORs, 
irrespective of HbA1c control, whereas OAD use yielded decreased ORs in poorly 
controlled diabetics only. This might reflect an additional insulin effect on the rosacea 
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risk, but it could also depict a proxy for disease duration and / or severity. As insulin 
is used in diabetic patients only, we cannot disentangle the role of insulin from the 
underlying disease within this observational study. Most diabetic patients were coded 
with a DM-subtype-unspecific code (66.6% cases, 68.3% controls), but as ORs were 
decreased in insulin users and in poorly controlled OAD users, a subtype 
independent effect seems likely, especially since endothelial damage and diabetic 
microvascular complications are presumably driven by shared mechanisms caused 
by hyperglycemia in both DM subtypes.118, 149, 151, 152 Our study provides evidence for 
a significantly reduced rosacea risk in diabetics at an advanced disease stage. This 
is, to our knowledge, a previously unreported finding, but some residual confounding 
or chance cannot entirely be ruled out. Whether insulin enhances this effect per se or 
whether it reflects a proxy for disease severity remains unclear. 
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Table 3.4-1: Distribution of diagnosed DM stratified by HbA1c values and disease duration  
  
Rosacea cases, 
No (%) (n=53,927) 
Rosacea-free controls, 
No (%) (n=53,927) OR crude (95%CI) OR adj.* (95% CI) 
No diagnosed DM 52,241 (96.9) 51,885 (96.2) 1.00 (ref.) 1.00 (ref.) 
Diagnosed DM 1,686 (3.1) 2,042 (3.8) 0.81 (0.76-0.87) 0.80 (0.74-0.85) 
Diagnosed DM by HbA1c (%) 
0-7.5 880 (1.6) 971 (1.8) 0.89 (0.81-0.98) 0.87 (0.79-0.96) 
7.6-10.9 519 (1.0) 684 (1.3) 0.75 (0.67-0.84) 0.73 (0.65-0.82) 
≥11 58 (0.1) 101 (0.2) 0.57 (0.41-0.78) 0.57 (0.41-0.79) 
NA 229 (0.4) 286 (0.5) 0.79 (0.66-0.94) 0.78 (0.65-0.94) 
Diagnosed DM by treatment duration (year) 
Untreated 444 (0.8) 439 (0.8) 1.00 (0.87-1.14) 0.96 (0.84-1.10) 
<1 135 (0.3) 170 (0.3) 0.79 (0.63-0.99) 0.78 (0.62-0.98) 
1-3 288 (0.5) 325 (0.6) 0.87 (0.74-1.02) 0.85 (0.72-1.00) 
3-5 252 (0.5) 312 (0.6) 0.79 (0.67-0.94) 0.80 (0.68-0.95) 
5-10 368 (0.7) 503 (0.9) 0.72 (0.63-0.82) 0.71 (0.62-0.81) 
≥10 199 (0.4) 293 (0.5) 0.67 (0.55-0.80) 0.64 (0.54-0.78) 
 
Abbreviations: CI, confidence interval; DM, diabetes mellitus; HbA1c, Hemoglobin A1c; NA, no answer; OR, odds ratio. 
Percentages are rounded to nearest decimal.  
*adjusted for smoking, body mass index, alcohol consumption.  
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Table 3.4-2: Mutually exclusive antidiabetic drugs use stratified by timing and duration of drug exposure and by HbA1c values  
  
Rosacea cases, 
No (%) (n=53,927) 
Rosacea-free controls, 
No (%) (n=53,927) OR crude (95%CI) OR adj.* (95% CI) 
No DM 52,241 (96.9) 51,885 (96.2) 1.00 (ref.) 1.00 (ref.) 
Diagnosed DM untreated 444 (0.8) 439 (0.8) 1.00 (0.88-1.14) 0.96 (0.84-1.10) 
Diagnosed DM - HbA1c≤7.5         
Current Insulin 1-39 (+/- OAD) 52 (0.1) 73 (0.1) 0.70 (0.49-1.00) 0.67 (0.47-0.96) 
Current Insulin 40+(+/- OAD)  37 (0.1) 54 (0.1) 0.68 (0.44-1.03) 0.69 (0.45-1.05) 
Past insulin use (+/- OAD) 9 (0.0) 16 (0.0) 0.56 (0.25-1.27) 0.55 (0.24-1.24) 
Current OAD only 1-19 154 (0.3) 175 (0.3) 0.87 (0.70-1.08) 0.84 (0.67-1.04) 
Current OAD only 20-39 125 (0.2) 143 (0.3) 0.86 (0.67-1.10) 0.85 (0.67-1.09) 
Current OAD only 40+ 184 (0.3) 195 (0.4) 0.92 (0.75-1.13) 0.92 (0.75-1.13) 
Past OAD use only 20 (0.0) 32 (0.1) 0.59 (0.34-1.04) 0.62 (0.35-1.09) 
Diagnosed DM - HbA1c>7.5         
Current Insulin 1-39(+/- OAD) 118 (0.2) 160 (0.3) 0.72 (0.57-0.92) 0.72 (0.57-0.92) 
Current Insulin 40+(+/- OAD) 119 (0.2) 160 (0.3) 0.73 (0.58-0.93) 0.69 (0.55-0.88) 
Past insulin use (+/- OAD) 7 (0.0) 14 (0.0) 0.48 (0.20-1.20) 0.43 (0.17-1.07) 
Current OAD only 1-19 103 (0.2) 138 (0.3) 0.74 (0.57-0.95) 0.72 (0.55-0.93) 
Current OAD only 20-39 76 (0.1) 83 (0.2) 0.91 (0.66-1.24) 0.90 (0.65-1.23) 
Current OAD only 40+ 118 (0.2) 159 (0.3) 0.73 (0.58-0.93) 0.73 (0.57-0.92) 
Past OAD use only 3 (0.0) 29 (0.1) 0.10 (0.03-0.33) 0.11 (0.03-0.36) 
Treated DM - HbA1c not recorded 117 (0.2) 172 (0.3) 0.67 (0.53-0.85) 0.67 (0.52-0.85) 
 
Abbreviations: CI, confidence interval; DM, diabetes mellitus; OR, odds ratio. 
Percentages are rounded to the nearest decimal.  
*adjusted for smoking, BMI, alcohol consumption.  
OAD = oral antidiabetic drugs: include biguanides, sulfonylureas, thiazolidinediones, glinides, α-glucosidase inhibitors, and incretin-mimetics 
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Table 3.4-3: Distribution of diagnosed DM stratified by HbA1c, sub-stratified by disease duration  
  
Abbreviations: CI, confidence interval; DM, diabetes mellitus; HbA1c, hemoglobin A1c; OR, odds ratio; y, years. 
Percentages are rounded to the nearest decimal. 
* adjusted for smoking, body mass index, and alcohol consumption. 
 
 
 
 
 
  
Rosacea cases, 
No (%) (n=53,927) 
Rosacea-free controls, 
No (%) (n=53,927) OR crude (95%CI) OR adj.* (95% CI) 
No diagnosed DM 52,241         (96.9) 51,885              (96.2) 1.00 (ref.) 1.00 (ref.) 
Diagnosed DM 1,686         (3.1) 2,042             (3.8) 0.81 (0.76-0.87) 0.80 (0.74-0.85) 
HbA1c≤7.5 by DM treatment duration (y) 
Untreated 299 (0.6) 283 (0.5)  1.04 (0.88-1.22) 0.99 (0.84-1.17) 
<1 60 (0.1)  68 (0.1)  0.87 (0.62-1.24) 0.87 (0.61-1.23) 
1-3 169 (0.3)  188 (0.4)  0.89 (0.72-1.09) 0.85 (0.69-1.05) 
3-5 124 (0.2)  127 (0.2) 0.96 (0.75-1.23) 0.96 (0.75-1.23) 
5-10 159 (0.3)  207 (0.4)  0.76 (0.62-0.93) 0.75 (0.61-0.92) 
≥10 69 (0.1)  98 (0.2)  0.69 (0.51-0.94) 0.69 (0.50-0.94) 
HbA1c>7.5 by DM treatment duration (y) 
Untreated 33 (0.1)  42 (0.1)  0.78 (0.50-1.23) 0.73 (0.46-1.16) 
<1 50 (0.1)  80 (0.2)  0.62 (0.44-0.88) 0.61 (0.43-0.87) 
1-3 91 (0.2) 104 (0.2)  0.86 (0.65-1.14) 0.86 (0.64-1.14) 
3-5 98 (0.2) 157 (0.3)  0.62 (0.48-0.79) 0.62 (0.48-0.81) 
5-10 182 (0.3) 221 (0.4)  0.81 (0.67-0.99) 0.79 (0.65-0.97) 
≥10 123 (0.2) 181 (0.3)  0.67 (0.53-0.84) 0.63 (0.50-0.80) 
No HbA1c record                      229          (0.4)                    286            (0.5)         0.79           (0.66-0.94) 0.78      (0.65-0.93) 
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Table 3.4-4: Distribution of antidiabetic drug use (insulin and OAD) stratified by timing and duration of drug exposure 
  
Rosacea cases, 
No (%) (n=53,927) 
Rosacea-free controls, 
No (%) (n=53,927) OR crude (95%CI) OR adj* (95% CI) 
No AD 52,595 (97.5) 52,235 (96.9) 1.00 (ref.) 1.00 (ref.) 
Any AD 1,332 (2.5) 1,692 (3.1) 0.78 (0.72-0.84) 0.76 (0.71-0.83) 
OADs  1,134 (2.1) 1,405 (2.6) 0.80 (0.74-0.86) 0.83 (0.76-0.91) 
Duration (Nr of p) 
1-19 439 (0.8) 558 (1.0) 0.78 (0.69-0.89) 0.80 (0.70-0.91) 
20-39 268 (0.5) 309 (0.6) 0.86 (0.73-1.01) 0.89 (0.75-1.06) 
40+ 427 (0.8) 538 (1.0) 0.78 (0.68-0.89) 0.83 (0.73-0.96) 
Timing (180d) 
current 971 (1.8) 1167 (2.2) 0.82 (0.75-0.90) 0.84 (0.77-0.92) 
past 163 (0.3) 238 (0.4) 0.68 (0.55-0.83) 0.78 (0.63-0.97) 
Insulin  399 (0.7) 564 (1.1) 0.70 (0.62-0.80) 0.75 (0.65-0.85) 
Duration (Nr of p) 
1-39 230 (0.4) 319 (0.6) 0.72 (0.60-0.85) 0.77 (0.64-0.92) 
40+ 169 (0.3) 245 (0.5) 0.69 (0.57-0.84) 0.71 (0.58-0.87) 
Timing (180d) 
current 373 (0.7) 513 (1.0) 0.72 (0.63-0.83) 0.78 (0.67-0.90) 
past 26 (0.1) 51 (0.1) 0.51 (0.32-0.81) 0.54 (0.33-0.87) 
 
Abbreviations: AD, antidiabetic drug; CI, confidence interval; d, day; OAD, oral antidiabetic drug; OR, odds ratio; p, prescription. 
Percentages are rounded to the nearest decimal. 
*adjusted for smoking, body mass index (BMI), and alcohol consumption. OAD use additionally adjusted for insulin use. Insulin use additionally adjusted for OAD use. 
OADs include biguanides, sulfonylureas, thiazolidinediones, glinides, α-glucosidase inhibitors, and incretin-mimetics. 
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3.5.1 Abstract 
Background: Psychological conditions, such as traumatic events or stress, have been 
discussed controversially as aetiologic factors for rosacea. 
Objectives: To assess the association between diagnosed depression, other affective 
disorders, and schizophrenia and subsequent incident rosacea. We further aimed at 
evaluating a possible role of different psychotropic drugs within this association.  
Methods: We conducted a matched case-control study of psychiatric diseases and 
incident rosacea, stratified by exposure to various psychotropic drugs, using the UK-
based General Practice Research Database (GPRD). Cases had a first diagnosis of 
rosacea recorded between 1995 and 2009. Each case was matched to one control 
on age, sex general practice, and years of history on the database.  
Results: We observed a decreased rosacea risk (OR 0.71, 95% CI 0.60-0.91) for 
patients with diagnosed schizophrenia independent of lithium use, but not for patients 
with depression or other affective disorders. After stratification of these psychiatric 
diseases according to psychotropic drug treatment, lithium was the only drug that 
significantly affected the risk estimate. A sub-analysis of lithium users yielded a 
decreased OR of 0.58 (95% CI 0.38-0.88) for current long-term lithium use among 
people with no schizophrenia diagnosis (with or without affective disorders) 
compared to people not exposed to lithium.  
Conclusions: Depression or other affective disorders did not affect the risk estimate 
of developing rosacea, whereas patients with schizophrenia were at a decreased risk 
of this skin disease in our study population. We observed a materially decreased risk 
of rosacea among people with chronic lithium exposure.  
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3.5.2 Introduction 
Rosacea is a common facial skin disease encompassing four different clinical 
subtypes, i.e. ‘erythematotelangiectatic’, ‘papulopustular’, ‘phymatous’, and ‘ocular’ 
rosacea. The skin disease is characterized by vascular dysfunction (persistent 
erythema, flushing episodes, telangiectasia), inflammation (papules / pustules), and 
neuronal components (burning / stinging), but its pathology remains largely unclear. 
Fibrotic changes, such as the rhinophyma, or inflammatory ocular symptoms can be 
additional manifestations.47, 48 Evidence points towards a pathogenic key role of 
neurovascular dysregulation and neurogenic inflammation.1, 55, 56, 70 Despite scarce 
evidence, psychogenic factors have been discussed as aetiologic factors for rosacea, 
a notion that originated in a small and rather outdated body of anecdotal evidence 
that linked the onset of rosacea to emotional stress or traumatic events. The skin 
disease has even been associated with a specific personality structure that includes 
increased feelings of anxiety, guilt, and shame,52-54, 65, 153-157 but more recent results 
do not support a general psychogenic aetiology of rosacea.64 In 2011, a new rosacea 
subtype (neurogenic rosacea) was suggested for a small sub-group of therapy 
refractory rosacea patients, with a high degree of neurologic and neuropsychiatric 
conditions including depression.158 Previous studies assessed rosacea with regard to 
depression mainly aimed at evaluating the psychological impact of facial 
disfigurement, but did not account for the chronological appearance of the two 
diseases.156, 159 We are not aware of any studies that have assessed the association 
between rosacea and schizophrenia. 
We are not aware of any evidence on a potential association between psychotropic 
drugs and the skin disease. We conducted a large population-based case-control 
analysis to explore the association between depression, other affective disorders, 
schizophrenia, and use of antidepressant and antipsychotic drugs, and the risk of 
developing rosacea. 
 
3.5.3 Materials and Methods 
Study Design and Data Source 
We conducted a matched case-control analysis using data from the UK-based GPRD 
(General Practice Research Database, now known as the CPRD – the Clinical 
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Practice Research Datalink). This database is a large source of anonymous primary-
care data comprised of approximately 7 million active patients who are enrolled with 
selected general practitioners (GPs). The GPs have been trained to provide clinical 
data in a standardised format. Participating practices provide information on patient 
demographics and characteristics (e.g. age, sex, height, weight, smoking status), 
symptoms or medical diagnoses, lab test results, and referrals to secondary care. 
Drug prescriptions are generated electronically via computer, ensuring a virtually 
complete drug history. The Medicines and Healthcare Products Regulatory Agency 
(MHRA) checks the raw data before release, and performs quality control checks. 
The patients enrolled in the GPRD are representative of the UK population with 
regards to age, sex, geographic distribution, and annual turnover rate. Extensive 
validation of the GPRD has documented its high validity, especially for chronic 
conditions.99, 121 The database has been the source for numerous 
pharmacoepidemiological studies and for public health and disease epidemiology 
studies.101, 121 The study protocol was approved by the Independent Scientific 
Advisory Committee (ISAC) for MHRA database research. 
Study Population  
The study population consisted of all patients in the GPRD with a first-time recorded 
Read code for rosacea99 between January 1995 and September 2009. We excluded 
patients with <3 years of recorded active history in the database prior to the date of 
their first rosacea diagnosis (‘index date’) to increase the likelihood of only including 
incident cases. Patients with a diagnosis of rhinophyma or ocular rosacea only, in the 
absence of another code for facial rosacea, were not included. We also excluded 
patients with a recorded Read code for alcoholism / alcohol abuse, cancer (except 
non-melanoma skin cancer), or HIV / AIDS prior to the index date. The validity of 
rosacea diagnoses in the GPRD is high and has been reported in a previous study of 
our group.46 We randomly identified one control patient for each case matched on 
age (year of birth), sex, general practice, calendar time (index date), and number of 
years of recorded history in the database prior to the index date. We applied the 
same exclusion criteria to controls as to cases. Controls were not eligible if they had 
rhinophyma (without facial rosacea) or flushing symptoms recorded at any time.  
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Case-Control Analysis 
Exposure was defined as a Read code diagnosis of depression (ICD-10 F32-33), 
other affective disorders (ICD-10 F30,31,34,38,39) or schizophrenia (ICD-10 F20-
29)99, 160 at any time prior to the index date. Drug exposure was defined as a 
minimum of one prescription for a certain drug class prior to the index date, using 
single agent preparations only. We stratified antidepressants according to the WHO 
ATC drug index161 into serotonin reuptake inhibitors (SSRI), tricyclic antidepressants 
(TCA), lithium, or other antidepressants. Antipsychotics were also stratified by WHO 
ATC drug-classes into phenothiazines, diazepines / oxazepines/ thiazepines, or other 
antipsychotics.162  
We compared patients with diagnosed depression and/or other affective disorders to 
patients with neither of the two diagnoses, stratified by current drug exposure. 
Patients with diagnosed schizophrenia were compared to patients without a recorded 
schizophrenia diagnosis, divided into those with or without current drug treatment (≤ 
or > 180 days).  
Statistical Analysis 
We conducted multivariate conditional logistic regression analyses to evaluate the 
association of the various exposures in relation to rosacea using SAS statistical 
software (version 9.3, SAS Institute, Inc., Cary, NC, US). Relative risk estimates were 
calculated as odds ratios (ORs) with 95% confidence intervals (CIs). We established 
a mutually exclusive model, where we stratified patients with diagnosed depression 
and/or other affective disorders according to their psychotropic drug treatment into 
currently (≤ 180 days from last prescription to index date) untreated patients and into 
those currently treated either with SSRIs only, TCAs only, lithium only, another 
antidepressant only, or a combination of > 1 antidepressant drug class, and 
compared them to patients without any diagnosed affective disorder. Use of SSRIs, 
TCAs, and lithium was further sub-stratified according to timing (last prescription 
recorded ≤ or > 180 days before the index date) and duration of use (by assessing 
the number of prescriptions prior to the index date). Patients with diagnosed 
schizophrenia on current drug treatment were sub-stratified by pharmacologic drug 
classes. The small sample size did not allow stratification by timing and duration of 
antipsychotic drug therapy. In a sensitivity analysis we divided all lithium users into 
patients with a previous diagnosis for schizophrenia, irrespective of any co-
ROSACEA PROJECT    STUDY 3.5   
80 
 
diagnoses, and into patients without a recorded schizophrenia diagnosis, sub-
stratified by timing and duration of lithium use, and compared them to patients 
without lithium use at any time prior to the index date. We adjusted all ORs for 
smoking (non, current, ex, unknown), alcohol consumption (0, 1-4, 5-9, 10-14, 15-24, 
or 25+ units per week, or unknown), and body mass index (BMI, <18.5, 18.5-24.9, 
25.0-29.9, 30+ kg/m2, or unknown). We further adjusted the analyses on depression 
and/or other affective disorders for concomitantly recorded schizophrenia diagnoses 
and vice versa. Lithium use was additionally adjusted for the presence of 
seborrhea/seborrheic dermatitis. We separately tested for confounding by asthma, 
chronic obstructive pulmonary disease, diabetes mellitus, hypertension, ischemic 
heart disease, heart failure, myocardial infarction, stroke / transient ischemic attack, 
epilepsy, hyperthyroidism, hypothyroidism, rheumatoid arthritis, as well as for use of 
benzodiazepines or for other hypnotic agents. Since none of these variables 
individually altered the relative risk estimates for the association between the 
exposure variable and rosacea by ≥ 10%, we did not include them in the final 
multivariate model. 
 
3.5.4 Results 
Among 53,927 rosacea cases and the same number of controls, 62.8% were female, 
and 54.4% were diagnosed between 30 and 59 years of age. Table 3.5-1 provides 
demographics characteristics, and smoking and BMI for cases and controls; these 
have been reported in detail elsewhere.46 Of all rosacea patients, 3086 (5.7%) cases 
and 2770 (5.1%) controls had a recorded referral to a psychiatrist / psychologist at 
some time before or after the index date, of which 637 (1.2%) cases and 594 (1.1%) 
controls were referred within 1 year before or after the index date.  
We identified 9521 (17.7%) cases and 8528 (15.8%) controls with a diagnosis of an 
affective disorder (i.e. depression and/or other affective disorder) at any time before 
the index date, yielding an OR of 1.21 (95% CI 1.16-1.25) compared to patients 
without any recorded affective disorder. Of those, 93.3% of cases and 92.7% of 
controls were diagnosed with depression (OR 1.20, 95% CI 1.16-1.24 for depression 
compared to no recorded depression), and 17.1% of cases and 16.7% of controls 
had a record for other affective disorders (OR 1.13, 95% CI 1.05-1.22 for other 
affective disorders compared to no recorded other affective disorder). Stratification of 
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all patients with affective disorders according to their current treatment (stratified by 
exposure timing and duration) did not affect the relative risk estimates, revealing ORs 
around 1.0 for currently untreated patients as well as for patients treated with either 
antidepressant drug class. By contrast, patients with affective disorders currently 
treated with long term lithium had a decreased rosacea risk compared to patients 
without diagnosed affective disorders, with an OR of 0.59 (95% CI 0.34-1.02) for 
those who received ≥20 prescriptions, but the sample size was small (Table 3.5-2).  
Recorded schizophrenia at any time before the index date (225, 0.4% cases and 
318, 0.6% controls) yielded a statistically significantly decreased OR when compared 
to patients without a recorded schizophrenia diagnosis of 0.71 (95% CI 0.60-0.85). Of 
those, 101 cases and 143 controls were currently not under antipsychotic drug 
treatment (OR 0.70, 95% 0.54-0.91), whereas 124 cases and 175 controls received 
some antipsychotic therapy (OR 0.72, 95% CI 0.57-0.91). Although statistical power 
was low, a trend toward decreased ORs was present across all strata of 
antipsychotic drug classes (Table 3.5-3). The small sample size did not allow 
stratification by timing and duration of drug exposure. 
Of all lithium users within our study population (125 cases, 194 controls), only 21% of 
cases and 20% of controls were diagnosed with schizophrenia before the index date 
(Table 3.5-4). We observed a significantly decreased OR of 0.58 (95% CI 0.38-0.88, 
≥20 prescriptions) for current long-term lithium users without diagnosed 
schizophrenia (35 cases and 64 controls) compared to patients without lithium 
exposure at any time prior to the index date. Additional adjustment for 
seborrhea/seborrheic dermatitis did not substantially change the relative risk estimate 
(OR 0.54, 95% CI 0.35-0.82, for current long-term users without schizophrenia). 
Within the schizophrenic sub-group, the sample size was too small to yield 
meaningful results.  
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Table 3.5-1: Distribution of demographics, life-style factors, comorbidities, and comedications in rosacea cases and controls in the UK GPRD 
  
Rosacea cases,  
No (%) (n=53,927) 
Rosacea-free controls, 
No (%) (n=53,927) 
OR  
crude  (95% CI) 
Sex  
 
    
male 20,048 (37.2) 20,048 (37.2)   
female 33,879 (62.8) 33,879 (62.8)   
Age (years)       
<20 6,630 (12.3) 6,626 (12.3)   
20-29 5,202 (9.7) 5,213 (9.7)   
30-39 8,586 (15.9) 8,576 (15.9)   
40-49 11,338 (21.0) 11,343 (21.0)   
50-59 9,410 (17.5) 9,403 (17.5)   
60-69 6,955 (12.9) 6,960 (12.9)   
70+ 5,806 (10.8) 5,806 (10.8)   
Smoking Status 
      
Non 27,475 (51.0) 25,031 (46.4) 1.00 (ref.) 
Current 7,635 (14.2) 10,660 (19.8) 0.64 (0.62-0.66) 
Ex 9,981 (18.5) 8,277 (15.4) 1.13 (1.09-1.17) 
Unknown 8,836 (16.4) 9,959 (18.5) 0.69 (0.66-0.72) 
BMI (kg/m2) 
      
12.0-18.5 905 (1.7) 953 (1.8) 0.88 (0.80-0.97) 
18.5-24.9 18,839 (34.9) 17,808 (33.0) 1.00 (ref.) 
25.0-29.9 13,146 (24.4) 12,291 (22.8) 1.01 (0.98-1.05) 
30.0-60.0 6,942 (12.9) 7,184 (13.3) 0.92 (0.88-0.95) 
Unknown 14,095 (26.1) 15,691 (29.1) 0.76 (0.73-0.79) 
Referrals to psychiatrist 
      
No referral  50,841 (94.3) 51,157 (94.9)   
Referral to psychiatrist 
overall 3,086 (5.7) 2,770 (5.1)   
≤1 year prior to or after  ID 637 (1.2) 594 (1.1)   
 
Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio. 
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Table 3.5-2: Distribution of diagnosed affective disorders stratified by exposure to antidepressant drugs (by timing and duration of drug use) in rosacea cases and controls  
  
Rosacea cases,  
No (%) (n=53,927) 
Rosacea-free controls, 
No (%) (n=53,927) 
OR  
crude  (95% CI) OR adj.* (95% CI) 
No depression with or without other affective 
disorders 45,044 (83.5) 46,020 (85.3) 1.00 (ref.) 1.00 (ref.) 
Diagnosed depression 8,883 (16.5) 7,907 (14.7) 1.16 (1.12-1.20) 1.20 (1.16-1.24) 
No other affective disorders with or without 
depression 52,303 (97.0) 52,503 (97.4) 1.00 (ref.) 1.00 (ref.) 
Diagnosed other affective disorders 1,624 (3.0) 1424 (2.6) 1.15 (1.07-1.24) 1.13 (1.05-1.22) 
No depression or other affective disorder 44,406 (82.3) 45,399 (84.2) 1.00 (ref.) 1.00 (ref.) 
Diagnosed depression and / or other affective 
disorder 9,521 (17.7) 8,528 (15.8) 1.16 (1.12-1.20) 1.21 (1.16-1.25) 
Currently untreated 6,342 (11.8) 5,663 (10.5) 1.16 (1.12-1.21) 1.20 (1.15-1.25) 
Current SSRI only 1,642 (3.0) 1,481 (2.8) 1.15 (1.07-1.24) 1.21 (1.13-1.31) 
1-19 945 (1.8) 831 (1.5) 1.18 (1.07-1.30) 1.24 (1.13-1.37) 
20-39 410 (0.8) 353 (0.7) 1.20 (1.04-1.38) 1.26 (1.09-1.46) 
≥40 287 (0.5) 297 (0.6) 1.01 (0.85-1.19) 1.08 (0.91-1.27) 
TCA only 876 (1.6) 746 (1.4) 1.22 (1.10-1.34) 1.26 (1.14-1.40) 
Current 1-19 413 (0.8) 345 (0.6) 1.24 (1.07-1.43) 1.26 (1.09-1.46) 
Current 20-39 192 (0.4) 143 (0.3) 1.39 (1.11-1.72) 1.45 (1.17-1.81) 
Current ≥40 271 (0.5) 258 (0.5) 1.09 (0.92-1.29) 1.15 (0.97-1.37) 
Lithium only 27 (0.1) 44 (0.1) 0.64 (0.40-1.03) 0.77 (0.47-1.25) 
Current 1-19 7 (0.0) 2 (0.0) 3.62 (0.75-17.42) 4.43 (0.83-21.89) 
Current ≥20 20 (0.0) 42 (0.1) 0.49 (0.29-0.84) 0.59 (0.34-1.02) 
Other antidepressant only 291 (0.5) 314 (0.6) 0.95 (0.81-1.12) 1.04 (0.88-1.22) 
Combination > antidepressant 343 (0.6) 280 (0.5) 1.27 (1.08-1.48) 1.39 (1.18-1.63) 
 
Abbrevations: CI, confidence interval; OR, odds ratio; SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressant.     
* adjusted for smoking, BMI, alcohol consumption, disease additionally adjusted for complementary assessed diseases. 
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Table 3.5-3: Distribution of exposure to antiosychotic drugs stratified by timing and duration of drug use in rosacea cases and controls 
  
Rosacea cases,  
No (%) (n=53,927) 
Rosacea-free controls, 
No (%) (n=53,927) 
OR  
crude  (95% CI) OR adj.* (95% CI) 
No schizophrenia 53,702 (99.6) 53,609 (99.4) 1.00 (ref.) 1.00 (ref.) 
Diagnosed schizophrenia 225 (0.4) 318 (0.6) 0.70 (0.59-0.83) 0.71 (0.60-0.85) 
Currently untreated 101 (0.2) 143 (0.3) 0.70 (0.54-0.91) 0.70 (0.54-0.91) 
Currently treated 124 (0.2) 175 (0.3) 0.70 (0.56-0.89) 0.72 (0.57-0.91) 
Phenothiazines only 37 (0.1) 42 (0.1) 0.88 (0.57-1.37) 0.90 (0.57-1.41) 
Diazepine, oxazepine, thiazepine only 19 (0.0) 45 (0.1) 0.42 (0.25-0.72) 0.41 (0.24-0.72) 
Other antipsychotic only 44 (0.1) 61 (0.1) 0.72 (0.49-1.06) 0.76 (0.51-1.12) 
Combination >1 antipsychotic 24 (0.0) 27 (0.1) 0.88 (0.50-1.54) 0.88 (0.50-1.56) 
 
Abbreviatoins: CI, confidence interval; OR, odds ratio.      
* adjusted for smoking, BMI, alcohol consumption, depression, other affective disorders.   
 
 
Table 3.5-4: Distribution of exposure to oral lithium stratified by underlying indication, sub-stratified by timing and duration of drug use in rosacea cases and controls 
  
Rosacea cases,  
No (%) (n=53,927) 
Rosacea-free controls, 
No (%) (n=53,927) OR crude (95% CI) OR adj*. (95% CI) 
No Lithium 53,802 (99.8) 53,733 (99.6) 1.00 (ref.) 1.00 (ref.) 
Lithium with schizophrenia 26 (0.1) 39 (0.1) 0.64 (0.39-1.07) 0.73 (0.43-1.21) 
By number of prescriptions 
      
  
current 1-19 presc. 3 (0.0) 3 (0.0) 0.90 (0.18-4.53) 0.94 (0.18-4.81) 
current 20+ presc. 14 (0.0) 16 (0.0) 0.86 (0.41-1.80) 1.02 (0.48-2.17) 
past use 9 (0.0) 20 (0.0) 0.44 (0.20-0.97) 0.48 (0.21-1.06) 
Lithium with no schizophrenia (with or without other 
affective disorder) 
99 (0.2) 155 (0.3) 0.64 (0.49-0.82) 0.69 (0.54-0.89) 
By number of prescrtions 
        
current 1-19 presc. 14 (0.0) 18 (0.0) 0.78 (0.39-1.56) 0.80 (0.39-1.62) 
current 20+ presc. 35 (0.0) 64 (0.1) 0.54 (0.36-0.82) 0.58 (0.38-0.88) 
past use 50 (0.1) 73 (0.1) 0.68 (0.48-0.98) 0.76 (0.53-1.10) 
 
Abbreviatoins: CI, confidence interval; OR, odds ratio.   
*adjusted for smoking, BMI, alcohol consumption 
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3.5.5 Discussion 
The findings of this large observational case-control study do not suggest a major 
association between diagnosed depression or other affective disorders and the risk 
of developing rosacea. Patients with diagnosed schizophrenia were at a substantially 
decreased risk of incident rosacea, but potential diagnostic bias cannot entirely be 
ruled out. Oral lithium was the only drug, among all psychotropic medications, that 
was materially associated with the risk of rosacea, yielding significantly decreased 
odds ratios in patients with long-term lithium exposure, irrespective of the underlying 
diagnosis (OR = 0.58, 95% CI 0.38-0.88 for ≥20 prescriptions) 
Our results do not suggest an aetiologic association between pre-existing depression 
or other affective disorders and incident rosacea in general, though we cannot 
exclude the possibility of an association for a small subset of rosacea patients, as 
hypothesised for the neurogenic rosacea subtype.158 It seems that the persistent 
belief in a potential psychogenic aetiology of rosacea is rooted in a rather outdated 
and small body of anecdotal evidence linking acute stressful life events, or other 
rather mild psychological conditions to the onset of the skin disease,54, 153, 155 while 
more recent evidence does not support this hypothesis.64 Since variables such as 
general stress or other mild psychological conditions are not reliably recorded in the 
GPRD, we did not assess these diagnoses in this study. To date, there is no specific 
evidence of an aetiologic effect of depression or other affective disorders on rosacea. 
One previous retrospective observational study assessed the concomitant 
manifestation of rosacea and depression based on the notion of a potential 
psychogenic origin of rosacea; the authors reported a relative over-representation of 
depression diagnoses in rosacea patients as compared to other psychiatric 
diagnoses. However, the overall rate of psychiatric comorbidities was very low 
(1.04%), and the question of the temporal sequence of the manifestation of the two 
diseases was not addressed.97 Other studies on the association between depression 
and rosacea aimed to assess the impact of the facial disfigurement on the 
development of depressive symptoms.156, 159  
We observed a significantly decreased risk of rosacea in patients with diagnosed 
schizophrenia, irrespective of drug treatment, a so far unreported association. While 
this is an interesting observation the association may not be causal and may rather 
reflect an under-diagnosis of the skin disease in patients with schizophrenia, due to 
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an altered disease perception of the patient or an altered diagnostic behavior on 
behalf of the GP.  
We observed a decreased risk of rosacea with systemic long term lithium therapy, an 
effect which has also not been shown before. Oral lithium is indicated for the 
treatement of affective disorders, but may also be used as an add-on medication for 
schizophrenia.163 However, as schizophrenia was only diagnosed in a minority of 
lithium users, and as ORs were significantly decreased in lithiums users without 
schizophrenia, confounding by underlying schizophrenia seems an unlikely 
explanantion for the result. Thus, our results are intriguing and suggest that lithium 
reduces the risk of rosacea. Although systemic lithium exposure might not be a 
desirable treatment approach for rosacea due to its toxicity and narrow therapeutic 
window,164, 165 this finding might lead to new insights on the pathophysiology of the 
skin disease and should be followed up in further research.  
This large observational study is based on a high quality, extensively validated and 
large primary-care database, but several limitations have to be considered when 
interpreting our findings. Firstly, we may be missing some rosacea patients since 
mild rosacea may not result in a visit to a doctor, especially in the case of 
erythematotelangiectatic rosacea.159 Coding in the GPRD does not differentiate 
between erythematotelangiectatic and papulopustular rosacea, and our study 
population is likely to comprise an over-representation of more severe papulopustular 
rosacea patients.159 Despite this potential for under-diagnosis and some degree of 
potential disease misclassification, a 74% concordance of rosacea diagnoses 
between dermatologists and the referring GPs has been shown in a cross-sectional 
study from South-East Scotland,111 providing reassurance that the validity of rosacea 
diagnoses in the GPRD is sufficiently good. Second, the likelihood of being 
diagnosed with rosacea may increase with increasing medical attention, which is the 
case for patients with diagnosed psychiatric illnesses. We previously reported that 
rosacea patients tended to see the GP more often prior to the diagnosis than 
controls.46 Thus, a certain degree of diagnostic bias cannot be ruled out, as it has 
been reported that patients with depressive symptoms have a stronger perception of 
mild skin symptoms.159 Finally, we cannot rule out a certain degree of residual 
confounding and chance, since we could not control for ethnical background, skin 
pigmentation, socioeconomic status, or life-style factors such as sun exposure, 
profession, or nutrition, as these parameters are not recorded in the GPRD. Despite 
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these limitations, this is, to our knowledge, the largest study to assess the 
association between psychogenic factors and incident rosacea. It is also the first to 
analyze the impact of psychotropic drugs on the risk of rosacea. 
In summary, this observational study suggests a potentially decreased risk of incident 
rosacea in patients with diagnosed schizophrenia, but we cannot rule out some 
diagnostic bias. Neither diagnosed depression nor other affective disorders were 
associated with an altered relative risk of developing rosacea in the current study 
population. Interestingly, we observed a materially decreased risk of rosacea in 
association with chronic oral lithium exposure independent of schizophrenia, which 
has not to our knowledge been reported before. His finding will have to be followed 
up in further research.  
 
 88 
 
ROSACEA PROJECT    STUDY 3.6   
89 
 
 
 
 
3.6 Antihypertensive drugs and the risk of incident rosacea (Study 3.6) 
 
 
 
Julia Spoendlin1,2, Johannes J. Voegel3, Susan S. Jick4, and Christoph R. Meier1,2,4 
 
 
 
 
 
 
1Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, 
University of Basel, Switzerland 
2Hospital Pharmacy, University Hospital Basel, Switzerland 
3Galderma Research & Development, Sophia Antipolis, France 
4Boston Collaborative Drug Surveillance Program, Boston University, Lexington, MA, USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
Submitted to the British Journal of Dermatology 
 
 
 
 
ROSACEA PROJECT    STUDY 3.6   
90 
 
 
 
3.6.1 Abstract 
Background: Despite scarce evidence, use of calcium channel blockers is 
discouraged in rosacea patients, whereas beta-blockers are recommended as an off-
label treatment for erythematotelangiectatic rosacea. 
Objectives: To study the association between use of calcium channel blockers, beta-
blockers, and other antihypertensive drugs and incident rosacea. 
Methods: We conducted a matched case-control study of antihiypertensive drugs and 
incident rosacea, using the UK-based General Practice Research Database. Cases 
had a first diagnosis of rosacea recorded between 1995 and 2009. Each case was 
matched to one control on age, sex, general practice, and years of history on the 
database before the index date. Drug use was stratified by timing (≤ or > 180 days 
before the index date) and duration (number of prescriptions) of drug exposure, in a 
multivariate conditional logisitic regression model.  
Results: Among 53,927 cases and 53,927 controls, we observed ORs around unity 
for calcium channel blockers across all strata, with a slightly decreased ORs of 0.77 
(95% CI 0.69-0.86) for current users of dihydropyridine calcium channel blockers with 
≥40 prescriptions. Among beta-blockers, atenolol and bisoprolol yielded slightly 
decreased ORs across all exposure strata, whereas propranolol revealed ORs 
around 1.0, irrespective of timing and duration of exposure. Neither ACE-inhibitors 
nor angiotensin receptor blockers altered the relative rosacea risk.  
Conclusions: Our data contradict the prevailing notion that calcium channel blockers 
increase the risk of rosacea. Beta-blocker use was associated with a slightly 
decreased risk of rosacea, but the effect may be somewhat stronger in patients with 
erythematotelangiectatic rosacea. 
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3.6.2 Introduction 
Rosacea is a common facial skin disease that has been categorised into four clinical 
subtypes, i.e. ‘erythematotelangiectatic’, ‘papulopustular’, ‘phymatous’, or ‘ocular’ 
rosacea. The skin disease is characterised by vascular dysfunction (persistent 
erythema, flushing episodes, telangiectasia), inflammation (papules / pustules), and 
neuronal components (burning / stinging), but its pathology remains largely unclear. 
Fibrotic changes, such as the rhinophyma, or inflammatory ocular symptoms can be 
further manifestations.48 Besides various other suggested mechanisms, evidence 
points toward a key role of neurovascular dysregulation and neurogenic inflammation 
in the vasodilative pathomechanism of rosacea.1, 55, 56, 70  
Beta-blockers (BBs, sub-type unspecified) are recommended as off-label treatment 
for erythematotelangiectatic rosacea.2, 47, 59, 87 The evidence is, however, confined to 
a few small studies and case series showing limited effects.68, 69, 166, 167 Use of 
calcium channel blockers (CCBs, again sub-type unspecified), on the other hand, is 
commonly discouraged in rosacea patients,47, 168 as they supposedly trigger or 
exacerbate rosacea. Again, evidence to support this widespread belief seems to 
consist of one single small retrospective study from Italy.54 As CCBs, BBs, ACE-
inhibitors (ACEIs), and angiotensin receptor blockers (ARBs) are among the 
mainstays in the treatment of essential hypertension,169-172 a more robust and valid 
risk-benefit assessment for these frequently used drugs in association with rosacea 
is required. We are not aware of any previous studies assessing a potential 
association of use of ACEIs or ARBs on the risk of developing rosacea. We therefore 
conducted a large population-based case-control analysis to explore the association 
between BBs, CCBs, ACEIs, and ARBs and the risk of developing a first-time 
rosacea diagnosis.  
 
3.6.3 Materials and Methods 
Study Design and Data Source 
We conducted a matched case-control analysis using data from the UK-based GPRD 
(General Practice Research Database), now known as the CPRD (General Practice 
Research Datalink). This database is a large source of anonymous primary-care data 
comprised of approximately 7 million active patients who are enrolled with selected 
general practitioners (GPs). The GPs have been trained to provide clinical data in a 
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standardised format. Participating practices provide information on patient 
demographics and characteristics (e.g. age, sex, height, weight, smoking status), 
symptoms or medical diagnoses, lab test results, and referrals to secondary care. 
Drug prescriptions are generated electronically via computer, ensuring a virtually 
complete drug history. The Medicines and Healthcare Products Regulatory Agency 
(MHRA) checks the raw data before release and performs quality-control checks. 
The patients enrolled in the GPRD are representative of the UK population with 
regard to age, sex, geographic distribution, and annual turnover rate. Extensive 
validation of the GPRD has documented its high validity, especially for chronic 
conditions.99, 121 The database has been the source for numerous 
pharmacoepidemiological studies and for public health and disease epidemiology 
studies.101, 121 The study protocol was approved by the Independent Scientific 
Advisory Committee (ISAC) for MHRA database research. 
Study Population 
The study population consisted of all patients in the GPRD with a first-time recorded 
Read-code for rosacea99 between January 1995 and September 2009. We excluded 
patients with <3 years of recorded active history in the database prior to the date of 
their first rosacea diagnosis (index date) to increase the likelihood of restricting the 
study to incident cases. Patients with a diagnosis of rhinophyma or ocular rosacea, in 
the absence of another code for facial rosacea, were not included. We also excluded 
all patients with a recorded Read-code for alcoholism / alcohol abuse, cancer (except 
non-melanoma skin cancer), or HIV / AIDS prior to the index date. Validity of rosacea 
diagnoses on the GPRD is discussed elsewhere.46 We randomly identified one 
control for each case matched on age (year of birth), sex, general practice, calendar 
time (index date), and number of years of recorded history in the database prior to 
the index date. We applied the same exclusion criteria to controls as to cases. In 
addition, controls were not eligible if they had rhinophyma (without facial rosacea) or 
flushing symptoms recorded at any time. 
Case-Control Analysis 
Exposure to cardiovascular drugs was assessed irrespective of the underlying 
diagnosis, including single agents and combined products. Drug exposure was 
defined as a minimum of one prescription for a certain drug class prior to the index 
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date. We assessed all drug classes (i.e. ACEIs, ARBs, BBs, and CCBs) as separate 
groups, and compared patients with exposure to a certain drug class to patients 
without recorded use of the respective drugs at any time prior to the index date, 
stratified according to timing (last prescription recorded ≤ or > 180 days before the 
index date) and duration (number of prescriptions prior to the index date) of drug use. 
In addition, we stratified CCB use according to their pharmacodynamic properties 
into dihydropyridines (mainly vascular effects) or non-dihydropyridines (mainly 
cardiac effects), according to the WHO ATC index,173, 174 and compared those 
patients to patients without CCB exposure at any time prior to the index date. Among 
BBs, we performed a sensitivity analysis for the three most frequently prescribed 
compounds (i.e. atenolol, propranolol, and bisoprolol, mutually exclusive by capturing 
the last recorded prescription before the index date), compared to non-use of BBs at 
any time prior to the index date.  
Statistical Analysis 
We conducted multivariate conditional logistic regression analyses to evaluate the 
association of different antihypertensive drugs in relation to rosacea using SAS 
statistical software (version 9.3, SAS Institute, Inc., Cary, NC, US). Relative risk 
estimates were calculated as odds ratios (ORs) with 95% confidence intervals (CIs). 
We adjusted all ORs for smoking (non, current, ex, unknown), alcohol consumption 
(0, 1-4, 5-9, 10-14, 15-24, or 25+ units per week, or unknown), and body mass index 
(BMI, <18.5, 18.5-24.9, 25.0-29.9, 30+ kg/m2, or unknown). We further adjusted each 
analysis for use of statins and any of the other assessed cardiovascular drugs, 
including drugs contained in combination products. We separately tested the 
association between exposure to each assessed cardiovascular drug class and 
rosacea for confounding by diuretics (namely high-ceiling and low-ceiling diuretics, 
spironolactone, or other potassium sparing diuretics), as well as by hypertension, 
myocardial infarction, heart failure, ischemic stroke / transient ischemic attack, 
ischemic heart disease, diabetes mellitus, and hyperlipidemia. Since none of these 
variables individually altered the relative risk estimates for the association between 
the exposure variable and rosacea by ≥10%, we did not include them in the final 
multivariate model. 
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3.6.4 Results 
Among 53,927 included rosacea cases and the same number of controls, 62.8% 
were female, and 54.4% were diagnosed between 30 and 59 years of age. The 
demographics of the study population, life-style factors (smoking, BMI), 
comorbidities, and comedication are displayed in Table 3.6-1, and are discussed in 
detail elsewhere.46 
We identified 8977 (16.7%) cases and 8319 (15.4%) controls with one or more 
recorded BB prescription, revealing ORs around 1.0 in most strata, with a marginal 
trend toward decreased ORs in current users (OR 0.91, 95% CI 0.86-0.96) and in 
long-term users of 40+ prescriptions (OR 0.89, 95% CI 0.83-0.96, Table 3.6-2). This 
trend remained in a combined analysis of timing and duration of drug use, with 
slightly decreased ORs in current long-term users of BB, compared to non-users at 
any time prior to the index date (data not displayed). After stratification into the three 
predominantly prescribed BBs within the UK, we observed slightly decreased ORs 
during current use of atenolol across all strata of exposure duration (OR 0.83, 95% 
CI 0.74-0.94, 1-19 prescriptions], OR 0.80, 95% CI 0.70-0.90 [20-39 prescriptions], 
OR 0.82, 95% CI 0.74-0.91 [40+ prescriptions]), as well as for current long-term use 
of bisoprolol (OR 0.76, 95% CI 0.60-0.96), whereby strata of less than 40 
prescriptions showed the same trend but did not reach statistical significance. 
Propranolol yielded ORs around unity across all strata of timing and duration of drug 
exposure, compared to non-users of any BB at any time before the index date (Table 
3.6-3). 
Among 4421 (8.2%) cases and 4441 (8.2%) controls with ever use of CCBs, we did 
not observe any statistically significantly altered ORs for current exposure across any 
strata of timing and duration of CCB use. ORs were marginally decreased in current 
users (OR 0.86, 95% CI 0.81-0.92) and in long-term users (OR 0.84, 95% CI 0.76-
0.92, 40+ prescriptions, Table 2) when compared to non-users before the index date. 
After stratification by pharmacodynamic properties the same trend was present in 
patients with exposure to CCBs of the dihydropyridine type, with a slightly decreased 
OR of 0.77 (95% CI 0.69-0.86) in current users with 40+ prescriptions as compared 
to patients not using CCBs before the index date. Current short-term use of 
dihydropyridine CCB as well as use of non-dihydropyridine CCBs across all strata of 
timing and duration revealed ORs around unity (Table 3.6-4).  
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ACEIs as well as ARBs yielded ORs around 1.0 across all strata of timing and 
duration of drug exposure (Table 3.6-2).  
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Table 3.6-1: Distribution of demographics, life-style factors, co-morbidities, and co-medications in diagnosed rosacea cases and controls 
Rosacea cases, 
No (%) (n=53,927) 
Rosacea-free controls,  
No (%) (n=53,927) 
OR 
crude (95% CI) 
Sex  
 
    
male 20,048 (37.2) 20,048 (37.2)   
female 33,879 (62.8) 33,879 (62.8)   
Age (years)       
<20 6,630 (12.3) 6,626 (12.3)   
20-29 5,202 (9.7) 5,213 (9.7)   
30-39 8,586 (15.9) 8,576 (15.9)   
40-49 11,338 (21.0) 11,343 (21.0)   
50-59 9,410 (17.5) 9,403 (17.5)   
60-69 6,955 (12.9) 6,960 (12.9)   
70+ 5,806 (10.8) 5,806 (10.8)   
Smoking Status 
      
Non 27,475 (51.0) 25,031 (46.4) 1.00 (ref.) 
Current 7,635 (14.2) 10,660 (19.8) 0.64 (0.62-0.66) 
Ex 9,981 (18.5) 8,277 (15.4) 1.13 (1.09-1.17) 
Unknown 8,836 (16.4) 9,959 (18.5) 0.69 (0.66-0.72) 
BMI (kg/m2) 
      
12.0-18.5 905 (1.7) 953 (1.8) 0.88 (0.80-0.97) 
18.5-24.9 18,839 (34.9) 17,808 (33.0) 1.00 (ref.) 
25.0-29.9 13,146 (24.4) 12,291 (22.8) 1.01 (0.98-1.05) 
30.0-60.0 6,942 (12.9) 7,184 (13.3) 0.92 (0.88-0.95) 
Unknown 14,095 (26.1) 15,691 (29.1) 0.76 (0.73-0.79) 
Comorbidities 
      
Hypertension 7,235 (13.4) 7,411 (13.7) 0.97 (0.93-1.00) 
Hyperlipidemia 2795 (5.2) 2,822 (5.2) 0.99 (0.93-1.05) 
Myocardial infarction 824 (1.5) 923 (1.7) 0.88 (0.80-0.97) 
Ischemic stroke / TIA 897 (1.7) 973 (1.8) 0.92 (0.83-1.01) 
Ischemic heart disease 2,462 (4.6) 2,405 (4.5) 1.03 (0.97-1.09) 
Heart failure 518 (1.0) 552 (1.0) 0.93 (0.82-1.06) 
Diabetes Mellitus 1,686 (3.1) 2,042 (3.8) 0.81 (0.76-0.87) 
Co-medication 
      
Diuretic 8372 (15.5) 7926 (14.7) 1.08 (1.05-1.13) 
OAD  1134 (2.1) 1405 (2.6) 0.80 (0.74-0.86) 
Insulin 399 (0.7) 564 (1.1) 0.70 (0.62-0.80) 
Statin 3718 (6.9) 3852 (7.1) 0.95 (0.90-1.00) 
 
Abbreviations: BMI, body mass index; CI, confidence interval; OAD, oral antidiabetic drug; OR, odds ratio; TIA = Transient ischemic 
attack.  
 
Percentages are rounded to the nearest decimal.  
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Table 3.6-2: Distribution of ACEI, ARB, BB, and CCB exposure, stratified by timing and duration of drug use in rosacea cases and controls 
  
  
Rosacea cases,  
No (%) (n=53,927) 
Rosacea-free controls, 
No (%) (n=53,927) OR crude (95% CI) OR adj.* (95% CI) 
No BB 44,950 (83.4) 45,608 (84.6) 1.00 (ref.) 1.00 (ref.) 
Use of BB 8,977 (16.7) 8,319 (15.4) 1.11 (1.07-1.15) 1.11 (1.07-1.15) 
Duration 
        
  1-19 6,170 (11.4) 5,273 (9.8) 1.20 (1.15-1.24) 1.19 (1.14-1.24) 
  20-39 1,166 (2.2) 1,187 (2.2) 1.00 (0.92-1.09) 0.98 (0.90-1.07) 
  40+ 1,641 (3.0) 1,859 (3.5) 0.90 (0.84-0.96) 0.89 (0.83-0.96) 
Timing (180d) 
        
  current 3,238 (6.0) 3603 (6.7) 0.92 (0.87-0.96) 0.91 (0.86-0.96) 
  past 5,739 (10.6) 4,716 (8.8) 1.25 (1.20-1.30) 1.25 (1.19-1.30) 
No CCB 49,506 (91.8) 49486 (91.8) 1.00 (ref.) 1.00 (ref.) 
Use of CCB 4,421 (8.2) 4,441 (8.2) 0.99 (0.95-1.04) 0.95 (0.90-1.00) 
Duration 
        
  1-19 2,542 (4.7) 2,344 (4.4) 1.08 (1.02-1.15) 1.03 (0.96-1.10) 
  20-39 811 (1.5) 878 (1.6) 0.92 (0.83-1.01) 0.87 (0.79-0.97) 
  40+ 1,068 (2.0) 1,219 (2.3) 0.87 (0.79-0.95) 0.84 (0.76-0.92) 
Timing (180d) 
        
  current 2,534 (4.7) 2,780 (5.2) 0.91 (0.86-0.96) 0.86 (0.81-0.92) 
  past 1,887 (3.5) 1,661 (3.1) 1.13 (1.06-1.22) 1.09 (1.01-1.17) 
No ACEI 49,629 (92.0) 49,622 (92.0) 1.00 (ref.) 1.00 (ref.) 
Use of ACEI 4,298 (8.0) 4,305 (8.0) 1.00 (0.95-1.05) 0.93 (0.89-0.99) 
Duration 
        
  1-19 2,345 (4.4) 2,205 (4.1) 1.06 (1.00-1.31) 0.99 (0.93-1.07) 
  20-39 897 (1.7) 968 (1.8) 0.93 (0.84-1.02) 0.88 (0.79-0.97) 
  40+ 1,056 (2.0) 1,132 (2.1) 0.93 (0.85-1.02) 0.91 (0.83-1.01) 
Timing (180d) 
        
  current 2,965 (5.5) 3,023 (5.6) 0.98 (0.93-1.04) 0.94 (0.88-1.00) 
  past 1,333 (2.5) 1,282 (2.4) 1.04 (0.96-1.13) 0.95 (0.86-1.04) 
No ARB 52,716 (97.8) 52,822 (98.0) 1.00 (ref.) 1.00 (ref.) 
Use of ARB 1,211 (2.3) 1105 (2.1) 1.115 (1.02-1.21) 1.08 (0.99-1.18) 
Duration 
        
  1-19 681 (1.3) 632 (1.2) 1.09 (0.97-1.22) 1.03 (0.92-1.16) 
  20-39 299 (0.6) 267 (0.5) 1.13 (0.96-1.34) 1.07 (0.90-1.27) 
  40+ 231 (0.4) 206 (0.4) 1.14 (0.94-1.38) 1.13 (0.92-1.37) 
Timing (180d) 
        
  current 983 (1.8) 869 (1.6) 1.14 (1.04-1.26) 1.10 (0.99-1.23) 
  past 228 (0.4) 236 (0.4) 0.98 (0.81-1.17) 0.92 (0.76-1.12) 
 
Abbreviations: ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; BB = β-blocker; CCB, calcium channel blocker; CI, confidence interval; OR = odds ratio. 
Percentages are rounded to the nearest decimal. 
* adjusted for smoking, body mass index, alcohol consumption, other analyzed antihypertensives, drug classes in combined products. 
 
 
 
ROSACEA PROJECT    STUDY 3.6   
98 
 
 
 
 
 
Table 3.6-3: Exposure to the most frequently prescribed BBs within the UK stratified by timing and duration of use in rosacea cases and controls 
 
    Rosacea cases, 
No (%) (n=53,927) 
      Rosacea-free controls, 
No (%) (n=53,927) 
OR 
crude (95% CI) 
OR 
adj.* (95% CI) 
No BB 44,950 (83.4) 45,608 (84.6) 1.00 (ref.) 1.00 (ref.) 
Use of propranolol  3,968 (7.4) 3,200 (5.9) 1.27 (1.21-1.34) 1.28 (1.22-1.35) 
current 1-19 396 (0.7) 298 (0.6) 1.35 (1.16-1.58) 1.36 (1.17-1.59) 
current 20-39 91 (0.2) 105 (0.2) 0.88 (0.66-1.17) 0.90 (0.67-1.19) 
current 40+ 171 (0.3) 170 (0.3) 1.01 (0.82-1.25) 1.02 (0.82-1.27) 
past 3,310 (6.1) 2,627 (4.9) 1.30 (1.23-1.37) 1.30 (1.23-1.38) 
Use of atenolol 3,803 (7.1) 3,898 (7.2) 0.99 (0.94-1.04) 0.95 (0.90-1.01) 
current 1-19 572 (1.1) 672 (1.3) 0.86 (0.77-0.96) 0.83 (0.74-0.94) 
current 20-39 475 (0.9) 573 (1.1) 0.84 (0.74-0.95) 0.80 (0.70-0.90) 
current 40+ 853 (1.6) 1010 (1.9) 0.85 (0.78-0.94) 0.82 (0.74-0.91) 
past 1,903 (3.5) 1,643 (3.1) 1.18 (1.10-1.26) 1.14 (1.06-1.23) 
Use of bisoprolol 510 (1.0) 539 (1.0) 0.96 (0.85-1.09) 0.94 (0.83-1.07) 
current 1-19 113 (0.2) 133 (0.3) 0.85 (0.67-1.10) 0.85 (0.66-1.10) 
current 20-39 79 (0.2) 90 (0.2) 0.88 (0.65-1.20) 0.88 (0.64-1.20) 
current 40+ 133 (0.3) 170 (0.3) 0.79 (0.62-0.99) 0.76 (0.60-0.96) 
past 185 (0.3) 146 (0.3) 1.29 (1.04-1.61) 1.27 (1.01-1.58) 
Use of other BB 696 (1.3) 682 (1.3) 1.04 (0.93-1.15) 1.00 (0.90-1.12) 
Abbreviations: BB, β-blocker; CI, confidence interval; OR, odds ratio. 
Percentages are rounded to the nearest decimal. 
* adjusted for smoking, body mass index, alcohol consumption, other analyzed antihypertensives, drug classes in combined products 
 
 
 
Table 3.6-4: Exposure to DH and non-DH CCBs stratified by timing and duration of drug exposure in rosacea cases and controls. 
 
Rosacea cases, 
No (%) (n=53,927) 
   Rosacea-free controls, 
No (%) (n=53,927) OR crude (95% CI) OR adj.* (95% CI) 
No CCB 49,511 (91.8) 49,487 (91.8) 1.00 (ref.) 1.00 (ref.) 
Use of DH 3,598 (6.7) 3,623 (6.7) 0.99 (0.94-1.04) 0.94 (0.89-1.00) 
current 1-19 844 (1.6) 865 (1.6) 0.97 (0.88-1.07) 0.92 (0.82-1.01) 
current 20-39 526 (1.0) 583 (1.1) 0.90 (0.80-1.01) 0.85 (0.75-0.96) 
current 40+ 693 (1.3) 847 (1.6) 0.81 (0.73-0.90) 0.77 (0.69-0.86) 
past 1,535 (2.9) 1,328 (2.5) 1.15 (1.07-1.25) 1.11 (1.02-1.20) 
Use of non-DH 818 (1.5) 817 (1.5) 1.00 (0.91-1.10) 0.97 (0.88-1.00) 
current 1-19 140 (0.3) 143 (0.3) 0.98 (0.77-1.23) 0.97 (0.76-1.23) 
current 20-39 108 (0.2) 130 (0.2) 0.82 (0.64-1.06) 0.77 (0.60-1.00) 
current 40+ 223 (0.4) 211 (0.4) 1.05 (0.87-1.27) 1.04 (0.86-1.27) 
past 347 (0.6) 333 (0.6) 1.04 (0.89-1.21) 1.01 (0.86-1.17) 
Abbreviations: CCB, calcium channel blocker; CI, confidence interval; DH, dihydropyridine; non-DH, non-dihydropyridine; OR, odds ratio. 
Percentages are rounded to the nearest decimal. 
* adjusted for smoking, body mass index, alcohol consumption, other analyzed antihypertensives, drug classes in combined products. 
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3.6.5 Discussion 
The findings of this large observational case-control study do not support the current 
perception that CCBs trigger rosacea, a hypothesis which is based on a weak body 
of evidence mainly based on the fact that CCBs can trigger flushing reactions.47 
There was no material class effect of BBs, which are suggested as off-label 
treatment for erythematotelangiectatic rosacea.2, 47, 59 Interestingly, atenolol and 
bisoprolol, for which no previous data were available, were associated with slightly 
decreased ORs, whereas propranolol, for which a beneficial effect on rosacea has 
been postulated,68 was not associated with a decreased risk. Nor was there an 
association between either  ACEIs nor ARBs and the risk of rosacea. 
Natale et al.67 previously reported a rosacea or pre-rosacea diagnosis in more than 
half of 62 patients following cessation of antihypertensive CCB treatment due to 
flushing side effects. In contrast to these results, we observed ORs of around 1.0 in 
current users of dihydropyridine CCBs, and even a slightly but statistically 
significantly decreased OR in current long-term users. Natale et al. did not provide 
their diagnostic criteria for either rosacea or pre-rosacea, and the proportion of 
diagnosed pre-rosacea vs. rosacea is not known. The adverse effects leading to 
CCB treatment cessation - i.e. flushing, peripheral edema, and tachycardia - suggest 
that most patients received their diagnosis based on flushing reactions and were thus 
likely diagnosed with pre-rosacea, which is not a well-defined diagnosis.2, 48 It has 
previously been reported that many patients with flushing symptoms alone actually 
never develop rosacea.47 These factors make a comparison between the previous 
study and ours difficult. A certain degree of confounding by indication cannot be ruled 
out within our study, as patients with a rosacea diagnosis might have had facial 
symptoms before the actual date of the first-time diagnosis, preventing GPs from 
prescribing CCBs to these patients. However, such confounding by indication would 
likely be strongest in short-term CCB users, as a time lag of several years between a 
first diagnostic suspicion and an actual rosacea diagnosis is rare. However, the fact 
that we observed the lowest OR in patients with long-term CCB exposure makes 
substantial confounding by indication unlikely. Thus, our results, which are based on 
a large study population from a well validated database, do not suggest a material 
association between use of dihydropyridine CCBs or non-dihydropyridine CCBs and 
the risk of developing rosacea. Based on these data we cannot determine whether 
the slightly decreased OR in current long-term users of dihydropyridine CCBs 
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represents a true effect, as the effect size is small and residual confounding and 
chance cannot be ruled out. We were not able to assess whether use of CCBs 
aggravates pre-existing rosacea with this study design.  
Although BBs as a drug class have been recommended as an off-label treatment for 
erythematotelangiectatic rosacea,2, 47, 59 we observed only marginally decreased ORs 
for current use of atenolol and bisoprolol. Propranolol, for which a beneficial effect on 
rosacea-associated flushing symptoms has been proposed,68 yielded ORs of around 
unity across all strata. Two further small studies postulated a beneficial effect of 
carvedilol and nadolol on rosacea,69, 166, 167 but no evidence was found on the effect 
of atenolol or bisoprolol. Interestingly, all previously reported allegedly beneficial 
effects of BBs involved non-cardio-selective BBs, whereas the only non-selective 
BBs within our study population (i.e. propranolol) yielded a null-result across all 
strata, while atenolol and bisoprolol, both cardio-selective BBs, revealed slightly 
decreased ORs.176 We cannot rule out a certain degree of confounding by 
heterogeneity of BB subgroups, as propranolol holds a wider range of indications 
than each of the other substances (i.e. migraine prophylaxis, prophylaxis of variceal 
bleeding in portal hypertension, anxiety symptoms177), which has to be considered 
when interpreting our findings. The observed effect for current use of atenolol or 
bisoprolol was only small, but this effect might be somewhat diluted by the presence 
of papulopustular rosacea patients within our study population. The GPRD’s Read 
codes do not allow a differentiation between papulopustular and 
erythematotelangiectatic rosacea, but previous results showed that papulopustular 
rosacea is overrepresented among diagnosed rosacea patients when compared to 
rosacea patients not seeking medical help.159 Since the proposed beneficial effect of 
BBs has been hypothesised for the erythematotelangiectatic rosacea subtype 
exclusively, the effect found in this study may be stronger in an analysis restricted to 
this sub-group of patients. As in the case of CCBs, we cannot evaluate the potential 
effect of BBs on the course of pre-existing rosacea as this lies beyond the scope of 
our case-control study design. Thus, our results may partially support the 
recommendation of BBs as a possible rosacea treatment, but it remains to be 
clarified whether this effect differs between BB-substances. ACEIs and ARBs were 
not associated with the risk of incident rosacea. 
This observational study is by far the largest of its kind and is based on a high 
quality, extensively validated, large primary-care database, which ensures a virtually 
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complete drug prescription history.99 Nevertheless, several limitations have to be 
considered when interpreting our findings. First, we may have missed some rosacea 
patients, as patients with mild rosacea may not seek medical help.159 Despite this 
potential under-diagnosing a 74% concordance of rosacea diagnoses between 
dermatologists and the referring GPs has been shown in a cross-sectional study from 
South-East Scotland,111 providing reassurance that the validity of rosacea diagnoses 
in the GPRD is sufficient. Second, the likelihood of being diagnosed with rosacea 
may increase with increasing medical attention, which is the case for patients with 
cardiovascular medication. We previously showed that rosacea patients tended to 
see the GP more often prior to the diagnosis than controls.46 Thus, a certain degree 
of diagnostic bias, masking a beneficial effect of a drug by skewing an OR toward 
1.0, cannot be ruled out. Finally, we could not control for ethnical background, skin 
pigmentation, socioeconomic status (e.g. income, education), or life-style factors 
such as sun exposure, profession, or nutrition, as these parameters are not recorded 
in the GPRD. Despite these limitations, this is, to our knowledge, by far the largest 
study to assess the impact of various antihypertensive drugs on rosacea, an issue 
that has been discussed over decades based on a weak body of evidence.  
In summary, our data contradict the prevailing impression that CCB use increases 
the risk of rosacea, a hypothesis that arose based on the fact that CCBs can induce 
flushing reactions.47, 168 BBs, which are recommended as an off-label treatment for 
erythematotelangiectatic rosacea, were associated with slightly reduced risks, but 
only for atenolol and bisoprolol and not for propranolol. This effect might be stronger 
in patients with erythematotelangiectatic rosacea, as papulopustular rosacea is over-
represented among diagnosed rosacea patients, possibly diluting an effect of unclear 
size of BBs in our study population.159 
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4 Discussion and outlook 
4.1 Discussion 
Although the understanding of rosacea has advanced over the past years, the skin 
disease remains a neglected area of research, haunted by an abundance of 
equivocal etiologic and pathomechanistic hypotheses.48, 52, 53 Furthermore, 
epidemiologic research in the field of dermatology is scarce.36 Therefore, this thesis 
aimed at contributing to the general understanding of rosacea by means of a 
comprehensive observational case-control study, using data from the GPRD,b a large 
and well-established physician-based primary care database from the UK.  
Although pharmacoepidemiologic research originally focused on the field of post-
marketing drug surveillance of rare ADEs, increasingly complex drug safety 
requirements augmented its importance across all stages of drug development. 
Pharmacoepidemiologic studies are applied in the assessment of disease burden 
(incidence, prevalence data), in the evaluation of previously undiscovered drug 
effects, in the analysis of drug utilization in clinical practice, and also to some degree 
in comparative effectiveness research.3, 4, 6, 19 This rosacea project exemplifies the 
versatile applicability of pharmacoepidemiologic research covering three areas of 
focus; 1) the first part of the project (Study 3.1) describes demographics and 
characteristics of patients with rosacea in the UK, including first-ever IRs of rosacea. 
2) Another part of the work brings the area of drugs as potential risk or protective 
factors for rosacea into focus, an area of rosacea research that has not received 
much attention in the past. 3) A further part of the study is concerned with the 
association of certain pre-existing co-morbidities and incident rosacea; again a 
largely unexplored field. 
While some of the addressed research questions depict revisited hypotheses, others 
were newly raised. Table 4.1-1 schematically displays the six thematically ordered 
studies of this project with their objectives, main findings, research area, and the 
degree of novelty of the hypothesis.  
                                                 
b
 Although the GPRD has been transferred into the CPRD in April 2012, the database is referred to as the GPRD throughout this thesis, as data 
collection was completed before the transfer. 
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Table 4.1-1: Schematic description and classification of the six observational studies on rosacea presented within this thesis 
Objectives Main findings Research area 
Hypothesis 
Revisited New 
Study 3.1 
• To describe demographics and characteristics of 
the study population, including ocular rosacea 
• To calculate first-ever IRs of rosacea. 
• To evaluate the impact of lifestyle factors on 
incident rosacea. 
• Overall IR of diagnosed rosacea in the UK: 1.65/1,000 py. Disease burden  x 
• Significantly reduced rosacea risk in current smokers. Lifestyle risk factor x  
• Marginal risk increase with alcohol consumption. Lifestyle risk factor x  
• 20.8% of patients with pre-existing ocular symptoms at rosacea diagnosis. Disease burden x  
Study 3.2 
• To assess the association of migraine and incident 
rosacea. 
• To evaluate the impact of triptan use on the risk of 
developing rosacea. 
• No overall association of migraine and incident rosacea. Associated disease x  
• Postmenopausal female migraine patients may be at a slightly increased rosacea risk. Associated disease x  
• No impact of triptans on the risk of incident rosacea. Non-established drug effect  x 
Study 3.3 
• To analyze a potential protective effect of 
spironolactone on incident rosacea. 
• To analyze the effect of other diuretics on rosacea 
• Significantly reduced odds ratios under spironolactone. Non-established drug effect x  
• Other diuretics were not associated with an altered rosacea risk. Non-established drug effect  x 
Study 3.4 
• To assess a potential association between DM 
and antidiabetic drugs (insulin or OADs) and 
incident rosacea. 
• Significantly reduced rosacea risk in diabetics at an advanced disease stage. Associated disease  x 
• Unclear whether insulin enhances this effect. Non-established drug effect  x 
• No effect of OADs on incident rosacea. Non-established drug effect  x 
Study 3.5 
• To evaluate the risk of developing rosacea in 
patients with depression, other affective disorders, 
or schizophrenia. 
• To analyze the role of psychotropic drugs in the 
risk of being diagnosed with rosacea. 
• No association between depression / other affective disorders and incident rosacea. Associated disease  x 
• Decreased rosacea risk in patients with diagnosed schizophrenia? Associated disease  x 
• Significantly decreased risk for rosacea during lithium exposure. Non-established drug effect  x 
Study 3.6 
• To analyze the role of antihypertensive drugs 
(BBs, CCBs, ACEIs, ARBs) in the risk of 
developing rosacea. 
• Rosacea risk not increased during CCB exposure. Non-established drug effect x  
• Slightly decreased rosacea risk during BB use. Non-established drug effect x  
• No association between ACEIs / ARBs and incident rosacea. Non-established drug effect  x 
 
Abbreviations: ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; BB, β-blocker; CCB, calcium channel blocker; DM, diabetes mellitus; IR, incidence rate; OAD, oral antidiabetic drug; py, person-year.  
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The main findings, as well as a detailed evaluation of the results of the individual 
studies, are presented in the discussion section of the respective studies. In the 
following, the most intriguing findings and some general aspects are highlighted and 
discussed. 
 
4.1.1 Study 3.1  
A study on the epidemiology of rosacea in the UK.46 
 
• The first-ever overall IR of rosacea was 1.65 / 1,000 py within the UK. This IR 
is confined to diagnosed rosacea patients, and cannot be arbitrarily 
extrapolated across geographic regions. 
• Ocular symptoms were recorded in 20.8% of rosacea patients at the time of 
their first-time facial rosacea diagnosis.  
• Current smokers revealed a significantly reduced rosacea risk (OR 0.64, 
95% CI 0.62-0.67). This effect might be due to vasoconstricting and/or 
immunosuppressive effects of cigarette smoke and needs further investigation.  
• The age-old misconception that rosacea was associated with an excessive 
drinking behavior was not supported; alcohol consumption was only 
associated with a marginal risk increase.  
 
Study 3.1 is the basis of this rosacea project, describing the study population in terms 
of demographics and characteristics, including ocular symptoms that presented 
before the actual diagnosis of facial rosacea. Results are discussed in detail in the 
discussion section of Study 3.1. It is in the nature of the disease that epidemiologic 
results for rosacea cannot be extrapolated onto any other given population, as 
disease susceptibility varies across geographic regions, i.e. with the degree of skin 
pigmentation as well as with the degree of sun exposure.44, 47 Thus, this study has to 
be regarded as an important entity within this project, conveying important 
information about the disease burden of rosacea within the UK. However, caution has 
to be applied when results are applied to other populations.  
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4.1.2 Study 3.2 
Migraine, triptans, and the risk of developing rosacea.178 
 
• In contrast to previous literature, incident rosacea was not overall associated 
with pre-existing migraine. However, the data do not allow inferences on 
rosacea as a triggering factor for migraine. 
• Female migraine patients aged 50 years or older revealed slightly increased 
ORs, which is in line with one previous observational study from the 1980’s.  
• Although mechanistically conceivable, triptans did not exert an effect on the 
risk of developing rosacea. However, they might depict a proxy for migraine 
severity, suggesting a slightly increasing rosacea risk with increasing migraine 
severity. 
 
Over the last decades, several studies reported an increased prevalence of migraine 
in patients with rosacea, albeit with inconsistent findings ranging from an overall 
association of the two diseases to an association confined to postmenopausal 
women.41, 62, 63, 115 All of them applied a cross-sectional study design, which does not 
account for the chronologic manifestation of the variables of interest (i.e. migraine 
and rosacea), and is thus mainly useful in raising new hypotheses.17 Study 3.2 aimed 
at assessing the association between pre-existing migraine and incident rosacea in a 
case-control analysis using the largest study population ever to address the 
association of the two diseases. Results do not indicate an increased risk of incident 
rosacea in migraine patients overall, but a slightly increased rosacea risk in 
postmenopausal females may exist.185 Data do not allow an inference on whether or 
not pre-existing rosacea changes susceptibility to migraine. Thus, it remains to be 
clarified, whether the previously reported general association between migraine and 
rosacea was a spurious finding or whether rosacea favors the development of 
migraine. 
One of the main drawbacks of large electronic health databases in the use of 
pharmacoepidemiologic research came into effect within this study, which is the 
failure to adequately capture time-varying factors such as disease progress or 
disease severity.4 In this case of migraine. Triptans have been suggested as a proxy 
for disease severity in previous studies,130 and are likely to be a good compromise to 
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infer upon migraine severity. However, as we were not able to entirely disentangle 
the drug effect from the disease effect by the given means, a final conclusion on this 
question will have to be achieved using another research approach. 
 
4.1.3 Study 3.3 
Spironolactone may reduce the risk of incident rosacea.186 
 
• Current spironolactone exposure seemed to protect patients from developing 
rosacea across genders (OR 0.38, 95% CI 0.25-0.57, women / OR 0.41, 95 % 
CI 0.23-0.74, men). Although preventive effects were assessed in this study, 
this result justifies therapeutic off-label use of spironolactone in rosacea to 
some degree, as current drug use yielded the greatest effects.  
• No other diuretic drug class had an impact on the risk of developing rosacea. 
 
Bias and confounding can be a bottleneck in observational database research. If the 
drug under study has been associated with the outcome of interest beforehand, case 
patients might actually have received the drug to treat the disease under study before 
the diagnosis was recorded, causing ORs to be artificially increased.3, 13, 17 In a 
sensitivity analysis, we accounted for confounding by indication in patients with 
previously recorded differential diagnoses, for which spironolactone is also used (i.e. 
acne, hirsutism, alopecia, seborrhea). However, we could not account for the fact that 
spironolactone has been suggested as an off-label rosacea treatment over several 
years. The significantly decreased ORs in current spironolactone users are thus all 
the more remarkable;47, 59 If such bias was to play a role in these results, the rosacea 
risk would be even lower in the general population.  
The common gender-unspecific recommendation for the use of spironolactone in the 
treatment of rosacea is attributed to its anti-androgenic properties, although a role of 
sex hormones in the skin disease could never be established.47, 58 In contrast, the 
only study showing a beneficial effect of spironolactone on rosacea included male 
patients only, and hypothesized a cytochrome-inhibition confined to male skin.66  Our 
study revealed a highly likely strong effect of spironolactone on incident rosacea in 
women and men, and a similar therapeutic effect of the drug on pre-existing rosacea 
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is likely, since patients with current drug exposure yielded the most prominent 
effects.179 Thus, after the use of spironolactone in rosacea had found its way into 
clinical practice despite inexistent evidence to back it up, our study provides evidence 
that supports clinicians in their daily decisions. Such evidence is required more than 
ever, since spironolactone may cause severe side-effects, such as hyperkalemia or 
endocrine disorders, and should not be arbitrarily used in the treatment of a rather 
benign skin disorder.180 Experimental research is now needed for a concluding 
efficacy and safety assessment of oral spironolactone in the treatment of rosacea, or 
to follow up on a potential topical application of the drug.  
Today, rosacea is regarded as a mainly inflammatory skin disease. Most drugs that 
are used for rosacea therapy, such as metronidazole or tetracyclines, were originally 
used with a different intention (i.e. based on their antimicrobial effect), but are now 
known to be effective due to anti-inflammatory properties.2 Recent evidence also 
indicates anti-inflammatory properties for spironolactone via blockage of the 
mineralocorticoid receptor.142, 143 Another study observed that spironolactone 
stimulates the elastogenic effect, based on an as yet unclear mechanism.181 It is thus 
thinkable that spironolactone joins other existing drugs in the group of anti-
inflammatory drugs that were originally thought to act on the skin disease via a 
different mechanism. However, the conclusion on the underlying mechanism of the 
observed effect lies beyond the scope of an observational study, and will require 
further research. 
 
4.1.4 Study 3.4 
The risk of rosacea in patients with diabetes using insulin or oral antidiabetic drugs.182 
 
• A decreased rosacea risk for patients with advanced DM was described for the 
first time.  
• Poorly controlled hemoglobin A1c (HbA1c) levels and the approximate disease 
duration correlated with the disease risk, yielding ORs around 0.6 in patients 
with a diabetes history of ≥10 years and / or HbA1c levels of ≥11%.  
• Use of insulin might additionally decrease the rosacea risk, but it might also 
depict a proxy for DM severity. OADs did not affect the risk estimate. 
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Study 3.4 introduces an entirely novel aspect to the field of rosacea research, 
demonstrating that observational research merits acknowledgment in the field of 
exploratory research. The hypothesis behind this study is based on the idea that a 
recently highlighted vasodilatory key component in the pathomechanism of rosacea1, 
56, 70
 may be prevented by the increased microvascular vasoconstriction inherent to 
DM, especially upon insulin exposure at an advanced stage of the disease.71, 118 
Admittedly, this is a rather vague hypothesis that does not fathom the 
pathomechanism of the two diseases on a molecular level. However, it is not 
uncommon that the exact biologic rationale behind an observation in epidemiology 
can only be explained many years later. In JP Vandenbroucke’s17 ‘hierarchy of study 
designs that give the best chances of discovery and of studying new explanations’, 
observational study designs using pre-recorded data are described among the most 
desirable approaches to investigate new exploratory hypotheses in terms of cost and 
timeliness, which is clearly exemplified here. Thus, we were able to go about the 
evaluation of this question because the data was there, ready to be analyzed, and 
although such an observational study does not allow causal inference on the 
association of rosacea and diabetes, our study retrieved intriguing results, which will 
hopefully spark further research leading to future insights into the molecular 
mechanism of the observed association. In the case of insulin, it was impossible to 
entirely disentangle a potential drug effect from the effect of the underlying disease, 
but a hint towards an additional insulin effect on the risk of incident rosacea should 
be followed up in further research. Furthermore, it would be interesting to investigate 
a potential insulin effect on rosacea skin of non-diabetic patients, but to find an 
ethically acceptable study design for this might be challenging.  
 
4.1.5 Study 3.5 
The association between psychiatric diseases, psychotropic drugs, and the risk of 
incident rosacea. 
 
• In answer to the prevailing controversy on a psychogenic origin of rosacea, 
depression and other affective disorders were found not to be associated with 
an increased risk of developing rosacea.  
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• On the other hand, patients with schizophrenia were at a decreased rosacea 
risk (OR 0.78, 95% CI 0.65-0.92), independent of underlying lithium use. This 
is an intriguing, previously unreported finding, which requires further 
investigation.   
• Among all psychotropic drugs, chronic lithium exposure yielded a materially 
decreased risk of rosacea (OR 0.58, 95% CI 0.38-0.88), irrespective of the 
underlying diagnosis.  
 
Precedent studies, such as the study conducted by the BCDSP in 1974183, 184 about 
the effect of regular aspirin intake on the risk of myocardial infarction, taught us 
about the value of epidemiologic studies in the identification of new drug indications. 
Not only do we learn about a potential new treatment option for a certain disease, but 
such newly discovered associations can also reveal insights into potential pathologic 
mechanisms.185 
Study 3.5 revealed intriguing results suggesting a significantly reduced rosacea risk 
during oral lithium exposure. Although the number of lithium users was proportionally 
small, the study was equipped with enough statistical power to detect these results, 
owing to the large size of the study population. The risk for confounding by indication 
is one of the most frequently denounced feature of pharmacoepidemiologic studies, 
since it is hard to control for if an association between a drug and an outcome has 
previously been described.13, 19 In the case of lithium, such bias can be assumed to 
be minimal, since rosacea and oral lithium have never been associated.17 Thus our 
study delivers highly relevant results, which could not have been achieved in 
experimental research, as exposure to a drug with such a narrow therapeutic window 
in an attempt to cure a rather benign skin disease would simply be unethical.148 
Although this study assessed the preventive effect of lithium on rosacea, a 
therapeutic effect of lithium on pre-existing rosacea seems likely, as the effect was 
most prominent during current exposure to the drug. However, due to the mentioned 
hazardous profile of oral lithium, this drug is an unfavorable approach for rosacea 
therapy. Nevertheless, follow-up projects on this finding may provide important 
insight in the pathomechanism of the skin disease, or may lead the way into new 
therapeutic options for rosacea.   
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4.1.6 Study 3.6 
Antihypertensive drugs and the risk of incident rosacea. 
 
• Results contradict the prevailing notion of an increased rosacea risk during 
CCB treatment, but they do not allow inference upon whether or not CCBs 
aggravate pre-existing rosacea.  
• BBs, which have been suggested as an off-label treatment for ETR, were 
associated with a slightly decreased rosacea risk. The real effect is likely to be 
stronger in ETR patients only, as PPR is probably overrepresented in the 
GPRD. 
• Neither ACEIs nor ARBs blockers affected the risk of rosacea.  
 
The prevailing literature on rosacea consistently advises to abstain from CCBs in 
rosacea patients,47, 59 whereas BBs are suggested as an off-label rosacea 
treatment,2, 47, 59 both based on very scarce evidence.67, 68, 184 Within Study 3.6, we 
could not confirm the postulated increased rosacea risk during CCB exposure, and 
even observed slightly decreased ORs in long-term users of dihydropyridine CCBs. 
This emphasizes the need for re-evaluation of insufficiently backed up hypotheses, 
even if they have already found their way into clinical practice. On the other hand, 
BBs revealed a slightly decreased rosacea risk, which would likely have been 
stronger had we been able to distinguish between PPR and ETR.   
Considering the entire rosacea project, the inability to distinguish between ETR and 
PPR is most unfavorable in the case of this study (3.6). The association between BBs 
as well as CCBs and rosacea refers to a link via an altered flushing susceptibility 
upon drug intake. Per definition, flushing is mainly associated with ETR,47, 59 whereas 
an overrepresentation of PPR of unknown proportion can be assumed among 
diagnosed rosacea patients, and thus on the GPRD.159 However, a recent cross-
sectional study showed that although more frequent in ETR, flushing was also 
present in 56% of PPR patients.45 In the case of CCBs, it is unlikely that distortion of 
findings alone accounts for the results, since missing information would skew the OR 
towards 1.0 but would not cause decreased ORs in long-term users of 
dihydropyridine CCBs. However, for BBs we can only conclude a trend towards a 
beneficial effect of the drug class on the risk of developing rosacea, which will 
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hopefully trigger further investigation in this area of research. An actual reliable effect 
of BBs in ETR patients, which would be most valuable to clinicians in daily practice, 
could unfortunately not be displayed. This is a classical limitation of a database study 
employing pre-collected electronic data.4 However, in consideration of the existing 
situation, in which clinicians are more or less left alone to manage refractory rosacea 
using trial and error, evidence to support clinicians’ decisions on the use or non-use 
of important drugs, such as antihypertensives, is of great importance. Thus, the 
results of this study remain highly relevant.59  
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4.2 Limitations of the rosacea project 
4.2.1 Incident rosacea and validation of the diagnosis 
Rosacea has not been studied on the GPRD before, and validity of recorded rosacea 
diagnoses has thus never been assessed. Disease misclassification can be an issue 
in observational research, and the optimal measures to validate a recorded diagnosis 
on a database have to be defined individually based on a profound understanding of 
the database as well as of the disease under study. The validation of rosacea 
diagnoses on the GPRD, including challenges faced along the way, is discussed in 
detail in Study 3.1.46 Rosacea is mainly diagnosed by the GP (7.3% referred to a 
dermatologist), based on its clinical picture alone.  Therefore, most usual options to 
validate a recorded disease on the GPRD did not apply (i.e. sending for referral 
letters, hospital discharge letters, or questionnaires to GPs). However, a more or less 
contemporary cross-sectional study from South-East Scotland revealed a 
concordance of rosacea diagnoses of dermatologists and the referring GPs of 74%, 
implicating a rather high overall recording validity of rosacea on the GPRD.111 
Needless to say, an algorhythm including diagnostic and laboratory data would 
improve the confidence in the validity of rosacea diagnoses on the database, 
however this was not an option. The results from the cross-sectional study 
mentioned, combined with a demographic distribution of the study population that is 
congruent with previous studies, allowed us to assume a sufficient validity of rosacea 
diagnoses on the GPRD. After all, epidemiology is an approximate science by nature, 
and intractable uncertainties have to be discussed when interpreting study findings, 
such as a certain overlap of acne and rosacea diagnoses in the case of this project.46  
 
The study population of this rosacea project consists of patients with an incident 
diagnosis for facial rosacea (i.e. ETR or PPR, not those with rhinophyma or ocular 
rosacea only), with at least three years of rosacea-free active history prior to their first 
rosacea diagnosis. However, as rosacea develops over years, presenting with 
usually mild (flushing)-symptoms at early stages, which might not prompt patients to 
seek medical help,47, 76 we cannot entirely rule out that the disease has not actually 
existed in a mild stage before the date of the first diagnosis in some cases. In 
general, chronic diseases are gaining importance in pharmacoepidemiologic 
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research, and defining the onset of such chronic states imposes a general challenge 
in database studies, which has to be addressed when discussing the study findings.  
 
4.2.2 Rosacea sub-type and disease severity 
A major limitation of this rosacea project is the fact that the GPRD Read-coding 
system does not allow distinguishing between ETR and PPR. The two rosacea sub-
types differ with regard to their symptoms and morphologic characteristics of skin 
lesions and thus, also in their treatment options and differential diagnoses.47 A 
developmental march from one sub-type to another may be possible but has not 
been confirmed to date, and much has been speculated about potential differences in 
the basic pathology of the individual sub-types.45, 48, 53 Recent gene profiling of 
rosacea sub-types revealed an overlap of the genetic structure between sub-types, 
but also suggested potential variations with regard to molecular pathways.1 ETR is 
probably the most frequent rosacea sub-type in the general population,41, 45, 47 but 
there is reason to assume an altered frequency distribution among diagnosed 
rosacea patients, probably resulting in an overrepresentation of PPR of an unknown 
proportion on the GPRD.159 While PPR has a prominent inflammatory component, 
flushing and erythema are the prominent features in ETR.2, 47 Most drugs on the 
market (e.g. metronidazole, tetracyclines) act on the inflammatory part of rosacea, 
and are mainly effective in PPR. It is possible, although not proven, that 
spironolactone and lithium act on the inflammatory part of rosacea and that the 
strong effect for these drugs shown in Studies 3.3 and 3.6 is due to a majority of PPR 
patients within our study population.179 On the other hand, the use of BBs in rosacea 
patients is mainly attributed to their flushing-preventive action, and CCBs have been 
contraindicated in patients with rosacea as they may trigger flushing. The potential 
underrepresentation of ETR patients on the GPRD could have diminished the effect 
of these drugs on the skin disease.2 The inability to account for such differences 
leaves somewhat of a grey area within the interpretation of the results of this project, 
and clearly demonstrates a typical limitation in observational studies using pre-
collected data. This issue of missing information is discussed extensively in the 
respective studies, whenever it is assumed to play a role.  
Furthermore, the GPRD coding system does not adequately capture time-trends, 
such as disease severity, which can introduce channeling bias into a study. At times, 
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disease severity can be accounted for by means of recorded treatment or diagnostic 
results, but lacking treatment or diagnostic guidelines for rosacea combined with 
inexistent confirmatory histologic or laboratory tests made this impossible within this 
study.48 However, standardized grading of the skin disease does not seem to be 
routinely performed in daily clinical practice (inexistent official grading system), which 
is why an analysis on arbitrary severity levels of the skin disease using GPRD data 
would be of little value either way.49 Capturing patients at the time when the disease 
is first brought to medical attention is a good and practical approximation in capturing  
patients with rosacea at a similar stage of disease; i.e. when it first prompted patients 
to seek medical help.   
After taking into account the discussed limitations, the achieved results remain 
meaningful, providing strong evidence on a yet neglected field of research, using 
data from one of the largest health databases in use.  
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4.3 Strengths and limitations of database research 
In database research, a profound understanding of the database in use is of utmost 
importance in order to adequately decide upon a study’s feasibility and limitations.  
Electronic health databases generally allow analyzing of hypotheses within large 
populations over a long period of time, in an efficient manner. Owing to the large size 
of the GPRDc (approx. 8% of UK population, seven million active patients) rare 
exposures, such as spironolactone (Study 3.3) or oral lithium (Study 3.6) were able to 
be studied with enough statistical power within this rosacea project. Furthermore, the 
results achieved within this rosacea project by means of GPRD data may be referred 
to as population-based, since the database is generally representative of the 
underlying UK-population. This is not possible in the case where a database holds an 
overrepresentation of a certain social class in terms of socioeconomic status, race, or 
education. This is the case for most existing claims databases. Additionally, the 
GPRD offers the opportunity to obtain anonymous photocopies of patients’ paper 
medical records, or to send out questionnaires to the GPs asking them for additional 
patient information,187 which, however, was not applicable within this project, as 
rosacea is a GP-diagnosed disease lacking confirmatory laboratory or histologic 
parameters; needless to say,  it is also not usually a reason for hospitalization or 
death.4 
 
The lack of randomization makes observational studies prone to bias and 
confounding; while some types of bias are more pronounced in database research, 
others are negligible. Observation bias, which results from systematic differences in 
data collection between study groups, as well as recall bias (i.e. a patients’ recall 
upon exposure) or interviewer bias (i.e. systematically different data recording on 
behalf of the interviewer) are minimized in database research, since data is captured 
as a by-product of daily clinical or administrative practice, irrespective of any study 
question.4 Other types of bias, such as selection bias (differing enrolment criteria 
between cases and controls), misclassification bias, or confounding (especially 
residual confounding) can be of concern. In GPRD studies, however, selection bias 
                                                 
c
 Although the GPRD has been transferred into the CPRD in April 2012, the database is referred to as the GPRD throughout this thesis, as data 
collection was completed before the transfer. 
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can mostly be averted, as the database allows withdrawing of cases and controls 
from the same defined source population.  
Missing data imposes another limitation upon database research. Data on important 
confounders such as dietary or exercise habits, socioeconomic status, race, or 
profession are incompletely captured on most electronic databases. In the case of 
rosacea, more comprehensive information on nutrition, sun exposure, skin 
pigmentation, or socioeconomic factors could have minimized residual confounding. 
Patients whose occupation or lifestyle involves extensive sun exposure may 
experience chronic actinic damage, which may be misdiagnosed as rosacea on the 
GPRD.51, 85 Furthermore, fair-skinned people of Celtic origin are generally more 
susceptible to the skin disease than darker pigmented people.44, 47, 48 Patients’ race 
may be recorded on the GPRD, but until now the coverage of such information on the 
database is low. Also, certain foodstuff or beverages are commonly known as 
exacerbating factors of rosacea, and it would have been interesting to assess 
whether such aliments also increase the risk of actually developing the skin disease. 
Other lifestyle factors, such as smoking, BMI, or alcohol consumption are not 
recorded for all patients, and results of strata with missing data have to be interpreted 
cautiously.4, 187 With regard to medication, information on over-the-counter (OTC) 
drugs, as well as on patients’ compliance is lacking. Furthermore, in case of the 
GPRD, the tedious and time-consuming manual entry of information from specialists, 
in-hospital events, and laboratory tests may cause practices to only enter information 
that will affect the future care of the patient, such as abnormal test results. This 
however, does not affect GPRD-research on rosacea, as laboratory parameters or 
hospitalization data rarely apply to rosacea patients. For studies 3.1-3.6 different 
types of bias and confounding are discussed in the discussion sections of the 
respective manuscripts. 
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4.4 Outlook 
In rosacea research, few questions have been sufficiently answered, while many 
more remain uninvestigated. This comprehensive rosacea project contributes to the 
general understanding of this under-investigated disease, revealing some intriguing 
and partly unreported findings.  However, at the same time it has raised various new 
hypotheses that require further research and reproduction in studies using different 
study populations. Options using GPRD data have, for the most part, been 
exhausted within this project. Observational screening studies inquiring about 
previous drug use would allow follow-up investigations on the association of BBs or 
CCBs and the skin disease including a differentiation between PPR and ETR. Such a 
study design to assess different sub-types within the clinical picture of rosacea has 
recently been published, however drug exposure was not captured.45 An RCT would 
be the optimal means to assess the efficacy of oral or topical spironolactone in the 
treatment of rosacea. Although RCTs are expensive, in this case it has the potential 
to lead to a new treatment for the skin disease, which is a declared need in clinical 
practice.2 An observational cohort study could assess whether rosacea patients 
develop more migraine, whereas further observational studies of different designs 
should aim to reproduce the association between rosacea and schizophrenia, DM, 
and cigarette smoking, since these associations are insufficiently documented in 
previous literature.17 Moreover, the observed reduced rosacea risk in current 
smokers and in patients with DM will hopefully trigger some basic investigations on 
the pathomechanistic aspects of these findings. 
In April 2012 the GPRD was transferred into the Clinical Practice Research Datalink 
(CPRD), the new English National Health Service (NHS) observational data and 
interventional research service, jointly funded by the NHS National Institute for Health 
Research (NIHR) and the Medicines and Healthcare products Regulatory Agency 
(MHRA). This new research service is designed to maximize the population coverage 
as well as the data linkage to several datasets, such as disease registries, full 
mortality data, in-hospital and daycare drugs, mother-child linkage and many more.188 
Although this is a favorable development, it does not provide additional opportunities 
with regards to rosacea research, as rosacea is mostly neither a reason for referral to 
secondary care nor death. As an exception, Hospital Episode Statistics (HES) are 
available for patients who have been hospitalized within the UK, providing more 
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accurate and complete information about a patient’s ethnic background. This could 
be interesting for observational rosacea research on the CPRD in the future, as 
disease susceptibility is greater in fair-skinned people.188   
The research on the genetic background of rosacea is still in its infancy.1 Endeavors 
are being made, also within the CPRD, to link pharmacoepidemiologic data to the 
latest genetic techniques.188 However, it remains to be explored to what extent 
database studies may be used to include such molecular investigations. It is 
conceivable that in the near or distant future, CPRD data could be used to study drug 
effects at the level of a patients’ genetic profile.4 
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“And then I thought that I had to be like Sherlock Holmes and I had to 
detach my mind at will to a remarkable degree so that I did not notice 
how much it was hurting inside my head.”  
Mark Haddon, The Curious Incident of the Dog in the Night-Time 
